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Preface
More than seven years ago, while I was working as a biostatistician at the Nepal
Health Research Council, I got a call from Naveen Shrestha from the Institute of
Medicine at the Tribhuvan University, where I was also teaching part time. He
asked me to visit him with my biodata the same day – I thought it was for some sort
of research proposal. I was completely unaware of what was coming – something
that completely changed my future. At the meeting I found Naveen Shrestha and
Guus ten Asbroek waiting for me, where they offered me the opportunity to work on
a PhD in The Netherlands. It took me by surprise; however, I immediately agreed to
take it. At that time, I did have the desire to pursue further studies abroad, but had
not thought that the opportunity would come in such a package. With the support
from Prof. Bimala Shrestha, Head of the Department of Community Medicine, and
the honest advice from Prof. Ramesh Adhikari, Dean of the Institute of Medicine,
I travelled to Groningen at the end of August 2001 to start the new journey which
culminated in this book.
In Groningen, I spent the first year (August 2001–July 2002) mostly attending
the Master’s courses at the Population Research Center (PRC) along with Vanessa,
Jan Willem, and others. I had a hard time with the first course on demographic the-
ories, which was coordinated by Inge Hutter, as I was not used to studying social
science theories. At the end of three months I was quite relieved, as I completed
the course satisfactorily. In the later courses I learned a lot about technical de-
mography. Frans Willekens’ courses on multi-state demography and event-history
analysis were fundamental to this thesis. I met Sergei Scherbov during his course
on computing in demographics where I learned to do programming, which was
very useful for me in this analysis and also in my other work.
The social life in Groningen was mostly spent with Vanessa, Tomas, and Rob.
For almost 11 months of my stay in Groningen, I lived in a guest house next to
a very big and well maintained garden of the Dekker family, and I thank them for
their hospitality, and introducing me to the culture and ways of European life. Frans
and Maria were always there to support me in all matters. I am indebted forever to
all my friends and colleagues with whom I had a very wonderful time. I was lucky
to have Karen as my office mate and I praise her for her patience while listening
to my sometime strange chatting and answering my weird questions. I thank Stiny
for making sure that all the administrative matters were perfect during my stay in
Groningen, as well as during the preparation of my PhD defense. I share a lot of
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memories with all my colleagues and friends at Groningen including Jan Willem,
Sarbani, Mamun, Mauri, and Maaike.
All through the year, I was working on specifying a multi-state model for the
PAL project and was waiting for the day to get back to Nepal and get involved in the
data collection process, which was initially planned for six months, and would start
while I was still in Groningen, being undertaken by Naveen Shrestha and Guus ten
Asbroek in Nawalparasi, Nepal. I was supposed to take over the last two months of
the data collection and then continue with the data-entry. However, due to various
reasons, the data-collection started only after I got back to Nepal and I spent almost
17 months in Nepal before the final set of data was prepared, of which about 12
months were spent on data collection alone, as the expected number of samples
was not achieved during the initially-planned six months.
When I came back to Kathmandu from Groningen, I had to travel to Nawal-
parasi four days later (at the beginning of August 2002) to get involved in the
selection and training of around 50 field assistants. I met Pralhad Bhattarai and
Sagar Ghimire who were field research officers responsible for the day-to-day field
operation. The PAL-Nepal project had rented an apartment which was used as both
the office for PAL-Nepal and a residence for the four of us. The biggest room was
partitioned halfway by a thin board – one side was the office for PAL-Nepal and the
other side was a bedroom for all of us. Each of us had a small bed with a mosquito
net, and two ceiling fans were running all the time. I will never forget the first
night; around 1am the electricity went off and I found myself drowning in my own
sweat as all the windows were closed. I realized that the rest of my roommates
were also awake and the heat was unbearable. It took some hours before we got the
light back. This became a routine and it was exactly the reverse during winter; it
was so cold that I was wearing layers and layers of clothes all the time 24–7. After
a few days, Naveen Shrestha left for the Erasmus University in Rotterdam to study
for his Master’s degree, following the training of the field assistants.
During the data collection phase, field assistants were stationed in each of the
selected health centers spread all across the district. All the health centers were
accessible either by bitumen or dirt road. In order to supervise the field assistants,
we bought two 100cc Indian motorcycles and rode them all day, sometimes into the
evening, often travelling more than a hundred kilometers to visit the health centers
and the patients’ homes. At one point, we had to pull out of one of the sub-health
posts for security reasons as the Maoist insurgency was at its peak during the period.
I am highly grateful, and express my sincere appreciation, to all my colleagues,
starting with Naveen Shrestha and Guus ten Asbroek, who paved my way in the ini-
tial steps of the data collection. I thank Pralhad, Sagar and Prem Bhusal for their ef-
forts in managing and supervising the entire data collection process in Nawalparasi,
and I extend my thanks to Jogendra and Sarbatiya for their continuous support in
helping with local logistics and issues. I acknowledge the work done by Binjwala
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Shrestha, Bimala Shrestha, and Ram Prasad Pathak as external supervisors of the
whole process of data collection. Most importantly, I am grateful to the field as-
sistants who were doing the actual data collection at the health centers, as well as
visiting the respondents’ residences, in spite of all the difficulties associated with
working in rural Nepal at that time. I am highly indebted to the health workers in
the medical facilities, as well as the patients, who willingly and patiently provided
their time and responses to our questions. I also extend my gratitude to the students
BPH from IOM who helped us collect data related to facilities on two occasions.
Finally, I would like to thank all those who helped me during the data-entry process;
Hitesh, Madhusudan, Deepak, Archana, Sushma, and Jeevana.
In January 2004, I returned to Rotterdam, instead of Groningen, for two rea-
sons. Firstly, the PAL project was coordinated by Louis Niessen who was at the
Erasmus University and, secondly, Frans Willekens has moved to Den Haag as a
Director of NIDI. At the first meeting with Frans and Louis we planned to finish
everything in one year. I had the data, but was still not sure about the model to
be used. I struggled quite a lot in defining appropriate multi-state models for eval-
uation purposes and, with the advice and support from colleagues at the Erasmus
University, Naveen Shrestha, Louis, Rob Baltussen, and Frans, I managed to come
out with the two multi-state models presented in this book. At the end of that year
(2004) the drafts of all the chapters were ready and I thought that it would be few
more months before I could apply for the defense, as I was leaving for Vienna
to work at IIASA staring in May 2005. However, things were not as simple as I
thought, as it took me another three and half years to finally get the thesis ready.
It was a difficult time for me to work on all the comments that I was receiving
from Frans and Louis while simultaneously undertaking my usual research work
at IIASA, where I was mostly working with population projection by age, sex and
educational level for many countries of the world – the two jobs having nothing in
common. However, I believe that this manuscript got better in terms of the addi-
tional analysis, as well as the insights, that I started developing while working at
IIASA. I can see a big difference between the first draft that I prepared before I left
Rotterdam in late February 2005 and the one that is in this book.
While living in Rotterdam, unlike Groningen where I was like a ‘regular stu-
dent’, I made fewer friends. I was mostly with Naveen Shrestha and Pralhad. I
started playing football with Arthur, and Louis also joined in a few games. Be-
cause of that I am still playing football in two hobby football teams in Vienna, and
I still remember cheering the Dutch team in the Eurocup 2004 at the Dutch bars, as
well as at Louis’s house. Bart and Merijn took good care of me whenever I visited
them in Amsterdam.
When I joined IIASA in May 2005, I moved to Vienna along with my wife
and daughter. I thought that it would be a few more months before I could finalize
the thesis. I thank all of my colleagues at IIASA and also friends at the Vienna
xInstitute of Demography who kept on encouraging me and pushing me to finish
the PhD, especially Wolfgang, Anne, and Tapas. It took a long time to get to this
position and I am very happy and relieved to present the book in its current form.
I am quite satisfied with the outcome and I hope it can be useful to others, partic-
ularly to people at the WHO. I would like to thank the Publication Committee at
IIASA for publishing the book and to thank my colleagues in the IIASA Communi-
cations Department, especially Iain for managing the publication procedure, Ingrid
for type-setting, Anka for cover designing, and others who worked for this book. I
extend my appreciation to Niki who did the English editing and I am very grateful
to Biswamitra Sahu for the last minute printing and binding of the dissertation and
submitting it to the University.
Finally, this work would not have been a possible without the constant sup-
port and encouragement from my family. While in Groningen and in Rotterdam, it
was sometimes very painful to be away from them. Also, during the data collec-
tion, I spent more than half of my time in Nawalparasi, which is a long way from
Kathmandu. I missed all of them during these periods; however, I was constantly
encouraging myself that one day this would pay off. I dedicate this work to my
parents, to my wife Binita, my daughter Aayu and to the rest of the K.C. family.
Samir K.C.
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Summary
Human beings are susceptible to many different diseases which may cause death.
However, many diseases can be prevented, mitigated, and cured. People suffer from
different diseases in different parts of the world. People living in poor countries
continue to suffer from diseases that no longer exist in high-income countries. The
transfer of knowledge and technology helps to narrow this health burden through
the training of health care providers, along with the necessary investments, for
example, in new medicines, equipment, and management strategies, etc. These
interventions need to be adapted and contextualized to local settings and evaluated
ex ante to determine the potential health effects in relation to cost.
This book presents the findings of a cost-effectiveness analysis of an integrated
lung health strategy i.e., the Practical Approach to Lung health (PAL) strategy,
developed by the World Health Organization (WHO) and implemented in a rural
pilot setting in Nepal. Lung diseases, such as pneumonia, tuberculosis, chronic
obstructive pulmonary disease (COPD), and asthma, pose major health problems
in Nepal, especially in rural areas where proper facilities and well-trained health
staff are lacking.
The PAL strategy for primary health care centers is specifically designed for
health care providers with limited health care training. The program in the pilot dis-
trict trained at least one health care provider in the PAL guidelines at twenty-two
randomly-chosen, rural primary health care facilities (out of forty-two). Twenty
facilities in the same district, where the standard health care procedures were fol-
lowed, were selected as control areas. Data were collected from patients with lung
disease-related symptoms, namely fever, cough or breathing difficulties, during vis-
its to both types of health facilities during a one year follow-up period. The book
presents the results of the economic evaluation of the PAL pilot in terms of costs,
health effects, and cost-effectiveness, as compared to existing standard care proce-
dures.
Our research shows, as expected, that the implementation of PAL increases the
government’s health expenditure, due to the increased costs associated with the
training and supervision of health care providers, by US$ 1.04 per disease episode.
Therefore, before PAL is adopted, the initial increase in budget has to be guaran-
teed, either from the national budget or through international support. However,
the cost per episode can be reduced significantly once the PAL strategy is adopted
nationwide and integrated into the basic training of health care providers.
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At the patient level, we demonstrated that implementing PAL reduces patients’
out-of-pocket expenses, mostly due to the lower average cost per drug prescription.
The PAL strategy is designed to enhance the rational use of drugs; it reduces multi-
drug prescriptions, the number of antibiotic prescriptions, and increases generic
drug prescriptions, as well as drug use from the essential drugs list. Overall, pa-
tients visiting PAL facilities, on average, spent less on health care related costs per
episode, including expenses for drugs, fees, and diagnostic tests (US$ 0.83 vs. US$
1.01), as well as on non-health care related costs (US$ 2.00 vs. US$ 2.20). This
is an important finding, as most people visiting government facilities are poor, and
saving a few Rupees makes a difference to them.
Next, we found greater effectiveness of the treatment provided at PAL facilities
in patients with breathing difficulties with a non-chronic cough (lasting less than
two weeks). Better health for patients visiting PAL facilities is also linked to the
improvement in the prescribing behavior of health care providers, thereby reduc-
ing costs, and increasing health benefits. These effects, though not all statistically
significant, may ultimately lead to the improved health status of patients. Mea-
suring the health effects in terms of standard disease-specific indicators was not
possible in the context of rural Nepal. The remoteness, as well as the lack of re-
sources at the facilities, restricted us from using appropriate equipment to measure
patients’ health status. Also, the PAL intervention is a symptom-based approach
and not diagnosis-based, hence, it was actually not designed to use diagnosis-based
techniques. Therefore, we used several different questionnaires, as well as own
researcher observations to measure patient health. We measured the general health
effects of patients by means of generic health-related quality-of-life measurements,
adapted and contextualized within the local setting, after validation. We demon-
strated that patients treated at PAL facilities had increased health-related quality-
of-life outcomes compared to patients who were treated at non-PAL facilities, al-
though this was only observed in patients with a chronic cough.
For evaluation purposes, it was essential to develop disease models to study the
evolution of disease over time. This study developed two multistate models, the
first being a multistate approach to modeling generic health-related quality of life
outcomes, and the second being an integrated lung disease multi-state model. The
development of these models is based on an extensive literature review on mod-
eling lung diseases. The review found that models exist for single diseases based
on disease-specific measures. However, the review of multistate models for lung
diseases lead to the selection of the appropriate number of states and an appropriate
time period for modeling each of the four lung diseases.
The multistate model based on health-related quality of life was used to study
the evolution of patients in different health states defined by their generic health-
related quality-of-life (EuroQOL) scores during the follow-up. This model will be
useful in contexts in which diagnoses, or disease-specific measurements, are not
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available or difficult to establish. Also, this model can be useful in studying and
comparing multiple diseases. The present model application showed that patients
with a non-chronic cough who visited PAL facilities benefited from and increased
health-related quality of life than those who visited the control facilities, which was
consistent with what we found in the empirical analysis.
The second multistate integrated lung disease model was developed to analyze
the cost-effectiveness of the PAL guidelines compared to the standard practice. Pa-
tient categories are healthy, diseased with acute symptoms, or diseased with chronic
stable symptoms. The time spent in each state by the population is calculated and
weighted through any health-related measurement. At the same time, cost can be
associated with the incidence of transition from one state to another, as well as
with the time spent in each state. The model outcomes revealed that the PAL im-
plementation pilot was cost-effective at various levels based on standard economic
benchmarks. Uncertainty analysis showed that the probability of PAL being effec-
tive was 54% in all patient groups together. As such, it is difficult to conclude that
PAL would be effective as a program as a whole.
Considering the results of this PAL pilot and the conditions associated with a
full-scale implementation of PAL – especially the limited dedication and potential
commitment of the national and international implementers – the PAL strategy de-
serves the benefit of doubt. The partially-positive results and the possibility for
further improvement at different levels of implementation should help keep the
next PAL implementation phase flexible, taking into account the lessons learnt and
allowing for future evaluation and monitoring.

1
Introduction
1.1 Introduction
Human beings are susceptible to different, sometimes fatal, diseases. However,
diseases can be prevented, controlled (i.e. less suffering), and cured. People are
affected differently by the same diseases in different parts of the world. Those who
live in poor countries are still suffering (or dying) from diseases that are virtually
non-existent in wealthier countries. The reasons are mainly technical, including
lack of knowledge, manpower, equipment, infrastructure, and other facilities re-
quired for the provision of efficient health care services. Secondly, from the soci-
etal and policy-related perspective, the general inability and lack of commitment
by society and government to plan and implement policies in a (self-) sustainable
way as a result of poverty, such as less-educated population, lack of knowledge,
poor governance, corruption, etc., plays a significant role as well.
In order to effectively deal with diseases existing knowledge and technology
can be introduced through ’interventions’ by individuals or institutions. However,
an adaptation process should precede the introduction of an intervention in a new
setting or context. The adaptation process contextualizes the intervention, thus
making it more effective during the implementation phase. Prior to full implemen-
tation it is important to assess the value of the new or additional health benefits
the intervention provides for individuals and society. The health benefits need to
be evaluated with respect to costs given that resources are always limited. Hence,
economic evaluations are often carried out to determine the costs and effectiveness
of new or former interventions within a new setting.
This publication is the outcome of an evaluation study on the implementation of
an international health intervention in a poor, rural setting in a developing country,
namely in the lowland district of Nawalparasi in Nepal. The intervention selected
for the evaluation study is the Practical Approach to Lung Health (PAL) [1, 2],
respiratory care guidelines developed by the World Health Organization (WHO).
Specifically, the study underlying this book assessed the effectiveness of the PAL
intervention’s implementation in relation to the costs involved at individual and
national levels.
1
21.1.1 Intervention Practical Approach to Lung Health
Lung disease is one of the leading causes of death in developing countries. Lower
respiratory infection (LRI), tuberculosis (TB), chronic obstructive pulmonary dis-
ease (COPD), and asthma amount to 15.4% of all disability-adjusted life years
(DALYs) lost in the South East Asia Region [3, 4]. Health interventions are contin-
uously being developed to improve individuals’ health. Interventions in the form
of health care guidelines are implemented by trained health care workers who base
the treatment of patients on these guidelines. Guidelines are developed to establish
consistency and specific standards in the treatment of diseases within a given health
care setting.
In light of the progress made in the Integrated Management of Childhood Ill-
ness (IMCI) [5] – an integrated case management strategy – the World Health Orga-
nization (WHO) together with several countries across the globe initiated the Practi-
cal Approach to Lung Health (PAL) [1, 2], developing guidelines for an integrated
case management of tuberculosis, COPD, asthma, pneumonia, and other respira-
tory diseases. The PAL guidelines aim to improve the quality and efficiency of res-
piratory health care services by providing standardized tools for primary health care
and district hospital workers to effectively manage respiratory infections, tubercu-
losis, asthma, and chronic obstructive lung diseases in adults. Trained health care
workers at primary health care facilities implement the PAL guidelines to evaluate
a patient’s condition using algorithms that follow a syndromic approach to disease.
Health care providers use the guidelines to carry out patient evaluations step-by-
step, arriving at a specification of the most suitable form of disease management
and, where required, of treatment [6]. This initiative aims to promote better lung
health care of adult patients at first level government health care facilities.
The PAL guidelines’ effects and costs had not yet been tested in a real life set-
ting. Only few countries participated in the first phase of the pilot implementation
and evaluation, Nepal being one of the countries. PAL-Nepal [4], a research strat-
egy by the Nepal Tuberculosis Center (NTC) under the Ministry of Health, Nepal
(MoH-N), and the WHO-Nepal as an implementing partner, alongside a team of
researchers from national and international institutions as evaluating partners, was
developed in the Netherlands in 2001.
1.1.2 Nepal
In 2003 Nepal’s population size was estimated at over 26 million [7]. According
to a 2001 census [8], the population’s growth rate was 2.25%, with 86% of the
population residing in rural areas. The country can be divided into three ecological
zones, namely mountains, hills, and Terai (lowlands), covering 35%, 42%, and 23%
of Nepal’s total area, respectively. The Terai region, which is flat and more fertile, is
3inhabited by 48.4% of the population, while 7.3% and 44.3% of the population live
in the mountainous and hills regions, respectively. Nepal’s population is relatively
young with a median age of 20.1 years (19.7 for males and 20.5 for females) (2001).
Life expectancy at birth is 62.2 years (2004); life expectancy of females (62.5
years) only recently surpassed that of males (61.8 years) due to the successful re-
duction in maternal deaths (from 539 per 100,000 births between 1989–1995, to
281 between 1999–2005) (DHS). In 2005 the infant mortality rate was 56 per 1000
live births (WHOSIS).
According to a 2001 census [8], 42.8% of women in Nepal are literate, com-
pared to 65.5% of men. Nepal is one of the poorest countries in the world with
a GDP per capita of US$240 (168th in the world) and GDP (PPP) of US$1,402
(153rd in the world) [9].
1.1.3 Health Expenditure in Nepal
According to Hotchkiss et al. (1998) [10], 75% of the total health care expendi-
ture in the fiscal year 1994/1995 was out-of-pocket, amounting to 3.9% of the total
GDP. Health care costs added up to 5.02% of the average household budget, the
percentage among the wealthiest rural quartile being highest at 8.72% and lowest
at 1.11% among the urban poorest quartile. Additionally, donors (13%), the gov-
ernment (10%), and private companies (2%) contributed to the total health expen-
diture. More recent figures reveal a similar distribution of health care costs. Total
expenditure on health per capita amounted to US$12 in 2002, of which US$3 (25%)
derived from public funds [11]. Some 6.2% of the total national budget was allo-
cated to health care [11]. This highlights the weight of out-of-pocket expenditure
on health care in Nepal. That is, policies targeting the reduction of medical costs
should focus on the reduction of out-of-pocket costs. These include travel (8%) and
consultation fees (92%). Consequently our evaluation of the cost-effectiveness of
implementing PAL in Nepal considers health expenditure from a public perspective,
as well as from the patient’s perspective.
1.1.4 Health in Nepal
According to the 2002 WHO Global Burden of Disease study [12], 49% of all
deaths in Nepal (233,000) are caused by diseases and conditions classified by the
WHO under Group I diseases (communicable, maternal, perinatal, and nutritional
conditions); in South Asia, only Pakistan (52.8%) has a higher mortality rate. This
measurement can be used as an indicator of the status of health care services, de-
noting a negative association between the percentage of deaths linked to Group I
causes which correlates negatively with development as indicated by the following
figures – EU-25 (5.7%), US/Canada (6.0%), Sri Lanka (13.4%), Southeast Asia
4(29.1%), South Asia (42.2 %), and Africa (72.3%). The primary reason for a high
mortality rate from Group I causes is directly linked to poverty and illiteracy, which
impact the general health of the population, while many of the diseases and condi-
tions classified in this group have been eradicated or are prevented and controlled
in more developed countries. Tuberculosis and respiratory infections, which are of
particular interest for our study, are classified in this group. In 2002 6,000 deaths in
Nepal were linked to tuberculosis (2.6% of the country’s total mortality rate) and
23,800 to lower respiratory infections (10.2%).
The second group (Group II) in the WHO’s burden of disease study comprises
non-communicable diseases. The diseases in this group do not spread from one
person to the other, but are generally chronic in nature. Approximately 42% of the
deaths in Nepal in 2002 were linked to diseases in this group. In developed coun-
tries more deaths are linked to diseases from this group than from communicable
diseases. Asthma and chronic obstructive pulmonary disease (COPD), which are
also of particular interest for us, are classified in this group and are the cause of
2.2 (0.9%) and 6.6 (2.8%) deaths in Nepal, respectively. Nine percent of deaths are
caused by injuries (Group III) and ‘unclassified’ causes.
In addition to mortality estimates, the WHO burden of disease study also pro-
vides data on disability-adjusted life years (DALYs), that account for lives lost due
to both morbidity and mortality. In Nepal the total number of DALYs lost in 2002
was estimated at 7.5 million years, of which approximately 36% were lost as a re-
sult of disability caused by disease (estimated by the number of incidents, disability
weight of the disease, and duration of the disease). About 64% of the total number
of DALYs lost is caused by premature death, which is estimated with reference to
the person’s remaining average life expectancy at the time of death [13]. The per-
centage of total DALYs lost due to tuberculosis, lower respiratory disease, asthma,
and COPD was 1.9, 7.6, 1.1, and 1.1, respectively.
The data clearly illustrate the impact of respiratory diseases in Nepal. A base-
line study conducted by the WHO and the Global Tuberculosis Initiative (GTB)
in Nepal revealed that 8.5% of patients aged five and older, who visited primary
health care facilities with no on-site physician, had symptomatic respiratory prob-
lems [14]. Nepal has an extensive network of primary health care facilities offering
basic medical services to the majority of Nepalese living in rural areas [15]. The
lowest level unit is known as the Sub-Health Post (SHP), and the staff providing
services at this level only have a few years of basic medical training. The staff
at the higher-level units, the Health Posts (HP) and Primary Health Care Centers
(PHC), have more advanced medical training and the facilities are equipped with
some basic laboratory services. A referral system exists; patients are referred to
higher level facilities when complications arise or when the nature of the patient’s
disease is complex. Hospitals represent the highest health care facility level and are
generally located in big cities or urban areas. This study evaluates the effectiveness
5of the PAL guidelines in primary health care facilities, namely sub-health posts,
health posts, and primary health care centers.
1.1.5 PAL-Nepal
Researchers in Nepal, The Netherlands, and the USA developed a research plan to
assess the health outcomes and costs of implementing PAL in Nepal [4]. The main
research question was how cost-effective the implementation of PAL in Nepal is.
Specifically, the objectives of the study were:
1. To weigh the costs of implementing the PAL guidelines in government fa-
cilities against the costs of retaining the existing range of medical services.
Costs were considered from a societal and health sector perspective.
2. To compare the outcome for patients treated at PAL facilities to that of pa-
tients treated at facilities employing standard medical services.
3. To compare the cost-effectiveness of the PAL guidelines strategy to other
possible national health schemes. Such a comparison must take the actual
prevalence of disease into account, as well as the existing quantity and quality
of services being provided.
The researchers selected the lowland district Nawalparasi in Nepal in coordi-
nation with the WHO and the Nepal Tuberculosis Center (NTC), since it met all
the required preconditions for the implementation of the PAL guidelines. The pre-
conditions include the implementation of other WHO programs and availability of
experienced health care workers [16] for TB and Integrated Management of Child-
hood Illnesses (IMCI) [17]. DOTS (Directly Observed Treatment Schedule) for
TB was first introduced in Nepal in 1996 by NTC, and IMCI in 1995. The DOTS
strategy is a combination of technical and managerial components which quickly
transforms infectious TB cases into non-infectious ones and interrupts the transmis-
sion of the disease [16]. Similarly, IMCI is a strategy to improve children’s health
and includes a number of complementary interventions for various childhood ill-
nesses, mainly pneumonia, diarrhea, malaria, measles, and malnutrition at the com-
munity, health care facility, and health system level [17]. The integrated strategy
refers to the treatment, or case management, in which the health care worker uses
a color-coded triage (algorithm) system to classify the child’s condition as urgently
requiring a referral to a more specialized facility that can evaluate the child’s con-
dition more accurately and provide the necessary care, or whether the child can be
treated on site, or whether the child can convalesce at home [17]. The availability
of health care workers with experience in using these two strategies (DOTS and
IMCI) is crucial for the effective implementation of the PAL strategy [4]. PAL’s
algorithmic approach has a similar format as IMCI’s [4].
6After it was agreed that a pilot implementation would be launched, a group of
health professionals and researchers at local, national, and international levels were
assigned to devise an implementation plan. A research group was established under
the umbrella of the Nepal Health Research Council (NHRC), an ethics committee
under the MoH-Nepal. The WHO’s PAL guidelines were reviewed and an adapta-
tion process initiated at the national level. The PAL guidelines were translated into
Nepali and tested by local health professionals. The processes implemented at this
level are well documented in a thesis by Ten Asbroek (2006) [18].
Parallel to the implementation process, another group of researchers (which
included the author) was involved in designing a research plan to evaluate PAL’s
cost-effectiveness in relation to the standard treatments available. Data were con-
tinuously collected at the facility level. Data on infrastructure, costs, time, etc. were
gathered before and after the implementation of the PAL guidelines. Forty-two of
67 health care facilities in Nawalparasi were selected for inclusion in our study on
cost-effectiveness based on their high patient turnout.
Once nationally adapted PAL guidelines had been prepared, health care work-
ers from 22 randomly selected governmental first-level health care facilities were
trained in June and July 2002. The training was conducted by trainers who had pre-
viously been trained by experts from the NTC and WHO. The training of trainers
and the training of health care providers by these trainers are the most important
steps in the implementation process. Twenty primary health care facilities were
randomly selected in the same district to function as control facilities, representing
standard practice facilities.
Two months after the last training took place, field assistants (FAs) were sent
to all 42 health care facilities to collect data from individual patients with lung
disease-related symptoms. We waited two months to determine the actual effect
of the knowledge generated by the PAL guidelines in a real setting, since we be-
lieved that the training’s immediate result would be misleading. Data from the two
primary health care facility types were collected at patient- and facility-level from
September 2002 to September 2003. Baseline data from the facilities had been col-
lected since 2001. Data analyses were carried out in The Netherlands throughout
2004, the results of which are reported here.
1.2 Structure of This Book
This book is about assessing the costs and effectiveness of implementing PAL
guidelines and, ultimately, to estimating the cost-effectiveness of the PAL guide-
lines in comparison to standard practice. The analysis of the intervention type
and context required tailor-made techniques. The first step involved conducting an
empirical assessment on which to build a model for long-term predictions or for
7better understanding the process and including additional factors from secondary
sources. The first part of the book focuses on empirical analyses of costs, effects,
and on cost-effectiveness analysis. The second part presents a multistate modeling
technique to describe and simulate the evolution of PAL diseases. The results of
the model are elucidated in terms of standard outcomes, as well as in terms of new
outcome measures in six chapters.
The first three chapters (Chapters 2 to 4) depict the empirical analysis. Chap-
ter 2 analyzes the divergence in the health effects experienced by patients with
respiratory problems who visited a PAL facility, and the health effects experienced
by those who were treated at a conventional health care facility (control group).
The analysis involved two groups of patients who were classified in accordance
with their initial condition prior to visiting a facility, namely determined by the du-
ration of their cough. Those who had a chronic cough – defined as a cough that
had already lasted more than two weeks by the time the patient visited the health
care facility – were believed to have TB or COPD. The recovery period for TB and
COPD is longer than for other respiratory diseases, and hence, a follow-up inter-
view with patients diagnosed with either of the two conditions was conducted two
months later, while patients without a chronic cough were interviewed again after
two weeks. The results were mixed, although the patients that had been treated at
facilities implementing the PAL guidelines showed slightly better results.
Chapter 3 describes the tool used in the data collection to measure individ-
ual patient’s Health-Related Quality of Life (HRQOL). Health-Related Quality of
Life is a recommended outcome variable in health economics and epidemiology to
measure individuals’ health status [19, 20]. The HRQOL data were collected using
two sets of standard HRQOL questionnaires addressing all patients at the time of
their first visit to a health care facility, and selected patients after two weeks or two
months, depending on the initial duration of their cough. As far as we know, we
are the first to use Health-Related Quality of Life questionnaires to assess patients’
health status. In this book we describe the process of adapting the questionnaires,
and present the results of the patients included in the PAL study. We found that
the questionnaires adequately measured the changes in the health status of the two
groups of patients with respiratory symptoms within a time period of two weeks,
as well as two months.
In Chapter 4 we compare the prescription behavior of health care providers in
the PAL facilities and in the standard practice facilities. One of the aims of the PAL
intervention is to enhance efficient prescription behavior to promote the rational use
of drugs for selected respiratory diseases. Patients often pay for their drugs out-of-
pocket, and we presume that PAL’s impact on the rational use of drugs will lower
patients’ out-of-pocket costs by lowering excess expenditure on drugs. We found
the PAL guidelines to be more suitable for promoting rational use of drugs in terms
8of improved prescription behavior, as well as reducing the average prescription
costs.
Subsequently, we developed multistate models for lung diseases and used these
models to perform a cost-effectiveness analysis. Multistate models are useful for
studying life histories in terms of incidents, such as disease occurrence, progres-
sion, and mortality. Multistate models are widely used in the field of medical
prognosis, as well as in the study of model-based economic evaluation and medi-
cal decision making. The section on models comprises three chapters (Chapters 5
to 7). Chapter 5 reviews existing multistate models for lung health (tuberculosis,
asthma, and COPD). We did not find any other study that applied multistate models
for lower respiratory infections.
We then present an in-depth review of lung disease models and draw inferences
to build PAL multistate models. The definition of state-space, assumptions in the
model, the measurement of transition rates/probabilities, and uncertainty analysis
were reviewed. These are important steps in the establishment of a PAL model,
however, exact state-space and the measurement of transition rates/probabilities
were difficult or impossible to replicate, since most of the lung models studied had
in fact been implemented in the developed world with its abundant resources. In the
context of PAL, the measurement of individual disease states is difficult because of
a lack of resources, and the distinct design of the PAL strategy. In the subsequent
two chapters we present the multistate models based on health-related quality of
life states as an alternative to the states of disease.
In Chapter 6, we propose a state-space for health-related quality of life using
the European Quality of Life Questionnaire (EuroQOL), commonly known as EQ-
5D (EuroQol with 5 Dimensions) [21]. Most research on the HRQOL assesses the
mean HRQOL or the mean change in HRQOL. That is, it is not possible to model
HRQOL directly in, for instance, a Markov model with states defined by HRQOL.
In fact, when HRQOL is an outcome of a modeling exercise, it is a value attributed
to the categorized prognostic variables of the diseases [22–25]. In that regard one
could say that HRQOL is always modeled indirectly. If HRQOL is genuinely con-
sidered an important feature of health, then direct modeling of HRQOL is indeed
useful and the classification of health states based on HRQOL should be explored.
We propose several methods of classification and use empirical data from PAL for
demonstration purposes. After HRQOL is classified into appropriate states (with
discriminative and evaluative values), the divergence in the transition probabilities
between HRQOL states as a result of different interventions can be considered an
effect in the cost-effectiveness evaluation.
Finally, in Chapter 7 we address the question whether PAL, as implemented
in Nawalparasi Nepal, by the WHO-Nepal and NTC, is cost-effective. The imple-
mentation of the PAL guidelines in general is considered a better alternative to the
standard health care available at primary health care levels. However, health care
9providers who actually apply the PAL guidelines to treat patients are either the key
to the intervention’s success or the key to its failure. Hence, the intervention’s im-
plementation is one of the most crucial aspects. Moreover, its success depends on
the patients who have to follow the treatment guidelines and the recommendations
of the health care workers. Failure to understand or comply with the prescrip-
tion and advice makes even the best intervention ineffective and sometimes even
costlier. Costs are estimated from a societal, as well as from an individual perspec-
tive. The expenses covered by the government and the community include training
the health care workers, investments in infrastructure, equipment acquisition, pay-
ment of salaries, provision of subsidies for drugs/services, etc.
At the same time, individual patients have to also pay out-of-pocket for vari-
ous health care-related and non-health care-related costs. We expect that the im-
plementation of PAL will also help lower patients’ out-of-pocket costs, while the
government will have to spend more on the training and supervision of health care
providers during the implementation phase of the PAL strategy. We have developed
a single integrated multistate model for four PAL diseases. Based on data from the
WHO on lung diseases, as well as on data of costs and effects derived from the PAL
survey, we assessed the long-term cost-effectiveness of the PAL implementation in
Nepal.
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Part I
PAL: EMPIRICAL ASSESSMENT

2
Effectiveness of Integrated Syndromic
Lung Health-Guidelines in Patients with
Breathing Difficulties in Rural Nepal
The health effects of an integrated symptom-based approach to lung health, the
Practical Approach to Lung Health (PAL) guidelines developed by the World
Health Organization, were unknown in real-life settings. The PAL guidelines were
adapted to the Nepalese setting and health care providers from randomly selected
facilities (referred to in this study as PAL facilities) in a Nepalese rural district were
trained in applying the guidelines. We compared the health effects in patients with
breathing difficulties who has been treated at a PAL facility with those in patients
who had visited a facility using the standard treatment schedule (i.e. STS facilities).
We identified two groups of patients with breathing difficulties when the first
interview was conducted, namely, those with a cough that had lasted over two
weeks by the time of the visit to the health care facility (i.e. ‘with a chronic cough’),
and those ‘without a chronic cough’. Data were collected during the first visit
(baseline) to a given facility and during a follow-up visit at the patient’s place of
residence. The follow-up interview of patients with a chronic cough (n = 296) and
of those without a chronic cough (n = 270) took place two months and two weeks
later, respectively. We used five symptom-based questions derived from Juniper’s
Asthma Control Questionnaire (ACQ) to obtain ACQ5 scores. T-tests and a linear
regression analysis compared the health effects in patients treated at PAL and at
STS facilities.
At baseline, the mean (± standard deviation) of the ACQ5 score was higher
for patients without a chronic cough than for patients with a chronic cough (1.95
± 1.05 vs. 2.41 ± 0.96, P < 0.001). Patients’ conditions generally improved
following a visit to a health care facility. After correcting for age, the change
in the health states of patients with a chronic cough, who had been treated at a
PAL facility, resulted in a reduction of the ACQ5 score by 0.166 (P-value = 0.505)
compared with visitors of a STS facility, and by 0.360 (P-value = 0.008) among
patients without a chronic cough.
The treatment patients, who did not have a chronic cough, received at PAL
facilities seemed to be more effective than the treatment provided at STS facilities.
Are PAL guidelines thus more effective than the STS? This may depend on various
factors, including training, use of the skills acquired, etc. Differences may also be
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explained by the way the chosen instruments were implemented. The project trained
one person per facility, i.e. a ‘trained person-effect’ may be evident. Since the
facilities were randomly divided into two groups – into PAL and STS – at the onset
of the study, the only difference between the health facilities and the patient groups
was the training of the health care providers on how to apply the PAL guidelines
in the intervention. Pooled data in each group and averages were computed in
the assumption that any additional effects were random. Other factors may also
explain the results. The intervention strategy presumes that the trained health care
worker disseminates his/her acquired knowledge to others. From a clinical point
of view, patients with both breathing difficulties and a chronic cough are less likely
to be asthma patients. The Asthma Control Questionnaire is therefore less suitable
for bringing about health improvements for this patient group than for patients who
only suffer from breathing difficulties. This might very well explain why patients
with a chronic cough and who were treated at PAL facilities, did not display any
additional health benefits compared to those who visited STS facilities.
2.1 Introduction
A baseline study conducted by the World Health Organization (WHO) and the
Global Tuberculosis Initiative (GTB) in Nepal indicated that 8.5% of all patients
aged five and up, who visited a primary health care facility without an on-site physi-
cian, were classified as symptomatic respiratory cases [1]. Among these symp-
tomatic respiratory cases, 22.5% were chronic respiratory cases, with 12.5% suf-
fering from asthma and 10% from a chronic cough [1]. With the exception of
tuberculosis case management, Nepal’s health system does not employ a standard
strategy to deal with the large number of patients with lung diseases. This is re-
flected in the low quality of health care delivery and leads to unnecessary financial
burdens for both the health care system and the individual patient [2].
To date only few studies measuring the health effect of patients with lung dis-
eases in Nepal have been conducted. A study carried out by Melsom et al. (2001)
analyzed the implication of indoor environmental factors on childhood asthma, but
the health effects as such were not assessed [3]. The health effects of an inte-
grated symptom-based approach to lung health, the Practical Approach to Lung
Health (PAL) guidelines developed by the WHO, which covers four lung diseases
(tuberculosis, asthma, chronic obstructive pulmonary diseases, and pneumonia)
were unknown [2, 4, 5]. Consequently, the PAL guidelines were adapted to the
Nepalese context and health care providers from randomly selected facilities in a
rural Nepalese district were trained in how to apply them.
This chapter focuses on the case management of patients with breathing dif-
ficulties. Specifically, the health effects in patients with breathing difficulties are
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measured within the context of the PAL guideline implementation in Nepal [2, 4,
5]. Hence, our first task was to define standard tools – be they generic, disease-
or condition-specific – to measure health effects. Below we will describe the tool
used to measure the condition-specific health effects in patients with breathing dif-
ficulties.
The general objective was to compare the health effects of patients with breath-
ing difficulties who sought treatment at facilities that used the PAL-guidelines with
those of patients who visited facilities using the current standard treatment sched-
ule (STS). We established the baseline measures for breathing difficulties during
the patients’ first visits to the health care facility, taking some important covariates
into account. Subsequently, in a follow-up interview, the health effects in patients
who had been treated at a PAL or STS facility were assessed with reference to the
covariates age and sex. In addition, we studied the correlation between the health
effects in patients and an objective measurement of lung function, namely peak
flow measurements.
2.2 Methods
2.2.1 Background on the Design of PAL’s Field Trial in Nepal
A trial of the PAL-Nepal program was tested between 2001–2003, during which 42
health care facilities were randomized into a control group of 20 facilities, whose
staff applied the standard treatment schedule (STS) for lung disease being used in
community practices, and into an intervention group of 22 facilities, whose staff re-
ceived six days of training by the Nepal Tuberculosis Center (NTC) on how to apply
the PAL guidelines. The health care facilities selected included Sub-Health Posts
(SHP), Health Posts (HP), and Primary Health Care Centers (PHCC). The patient
cases are classified in accordance with this hierarchical system, though patients are
free to choose which health care provider to turn to [6]. SHPs are the smallest of
the three health care units, with a staff of only three health care workers, of which
only one has completed a two year professional training program and is thus the
only one qualified to treat adults. The staff at HPs and PHCCs include higher level
medical personnel. PHCCs are the most advanced and also the largest health care
units included in our study with a medical officer (doctor) on site. The details of
the intervention, as well as the general context, is explained in more detail in Ten
Asbroek (2005) [6]. Between June and July 2002, at least one health care provider
from each of the 22 selected health care facilities was trained in how to apply the
PAL guidelines. From September 2002 to July 2003 (ten months), patients aged 15
years and older who visited one of the 42 health facilities and reported having at
least one of the following symptoms – fever, coughing, and/or breathing difficulties
– were included in our study and followed-up during their treatment period at the
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given health care facility. We obtained a clearance from Nepal’s national ethics
committee and a written consent from the patients who participated in the data
collection process. Follow-up interviews were not conducted with patients who
only had a fever or a cough that lasted less than 15 days, since the likelihood that
these patients had one of the target diseases was rather low. Patients with a chronic
cough that lasted 15 or more days were interviewed again two months later, while
the remainder were interviewed two weeks after the initial interview, usually at the
patient’s home. A maximum of three attempts were made to schedule a follow-up
interview at the patient’s home. Data were collected from 2243 patients visiting
one of the 42 selected facilities between September 2002 and September 2003 (ten
months for the baseline interviews and two months for the follow-ups).
2.2.2 Materials and Methods Used in This Study
One of the main assumptions of the PAL-Nepal strategy was that patients were
likely to be misdiagnosed, because of the health care providers’ (mostly nurses)
lack of knowledge, the insufficient equipment, and inadequate infrastructure. To
reiterate, the four diseases included in the PAL guidelines are pneumonia, tubercu-
losis, chronic obstructive pulmonary disease, and asthma. According to the guide-
lines, pneumonia can be diagnosed at the facility level, while most of the other
lung diseases’ symptoms are recognizable and can subsequently be treated on site,
or patient referrals made to higher level health care facilities for further testing [4].
Known cases of asthma or chronic obstructive pulmonary disease can be diagnosed
for obvious reasons. Hence, our study was designed independently of a patient’s
diagnosis. Patients who answered “yes” to having any of the three PAL entry symp-
toms (breathing difficulties, a cough, and fever) were included in our sample. This
approach was validated in advance [7–9].
The PAL guidelines’ effectiveness for patients with breathing difficulties was
analyzed using Juniper’s Asthma Control Questionnaire (ACQ) [10]. Juniper de-
veloped and validated the ACQ which comprises seven questions on all criteria
to determine whether a patient has asthma (symptoms, airway caliber, and rescue
beta-two-agonist use) [11]. Juniper concluded that the force expiratory volume in
one second (FEV1) and beta-two-agonist questions could be omitted from the ACQ
for large clinical and epidemiological trials, without modifying the instrument’s va-
lidity or measurement properties [11].
The unavailability and cost of beta-two-agonist in Nepal’s rural areas reduces
the likelihood that patients use a beta-two-agonist. The evaluation research con-
sisted of one follow-up visit to the patient’s home, which was sometimes inacces-
sible for all types of vehicles. Hence, it was not practical in terms of costs and
management to include spirometry to measure peak expiratory flow. We therefore
used a peak flow meter instead and verify this instrument’s validity in our study.
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We used questions on symptoms from the ACQ for the analysis. There are
five questions on symptoms, referred to as ACQ5. We calculated ACQ5 scores by
taking the mean of responses related to symptoms (the first five) as described by
Juniper et al. [10]. The score ranges from 0 to 5, with a lower score indicating
better control of the disease.
A literature review revealed that ACQ had not yet been used in lung health-
related research in Nepal. This chapter presents the distribution of ACQ scores and
their association with the covariates age and sex. Furthermore, ACQ5 scores were
used to assess PAL-Nepal’s effectiveness in controlling asthma among asthma pa-
tients. According to the PAL guidelines, breathing difficulties are one of the leading
symptoms of asthma, as well as of chronic obstructive pulmonary disease. We eval-
uated patients with breathing difficulties and defined those whom we followed-up
after two months or after two weeks as ‘difficulties breathing with chronic cough’
(DBWCC) and ‘difficulties breathing without chronic cough’ (DBWoCC), respec-
tively.
2.2.3 Analysis
Table 2.1 illustrates patient characteristics. We include the descriptive statistical
mean and standard deviation of ACQ5 scores for the different values of the co-
variates age, sex, and health care facility level (PHCC, HP, and SHP). We also
applied independent t-tests and chi-square tests to examine the effect of random-
ization using baseline data. At the baseline, a stepwise linear regression analysis
was performed to assess the relationship between the ACQ5 score and the variables
age and sex.
The PAL effect was first measured using a paired t-test of the ACQ5 scores
during the baseline and follow-up. A stepwise linear regression was performed
to assess the relationship between the ACQ5 score and each covariate. Huber &
White’s variance estimator was used to adjust the effect of patient clustering in a
given facility. The relationship between the ACQ5 score and the peak flow mea-
surement was explored using Pearson’s correlation coefficient. Separate analyses
were conducted for patients with DBWoCC and DBWCC. We used STATA 8.2,
STATACORP LP for all statistical analysis.
2.3 Results
In total we interviewed 2243 patients with PAL-related symptoms who visited one
of the select health care facilities for the first time during the disease episode. Six
hundred and sixty (29.2%) patients reported that breathing difficulties were one of
the reasons for visiting the facility. We first identified cases with complete data
for the ACQ5; for the baseline assessment, we compiled a total of 638 cases with
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complete ACQ5 data during their first visit to the health care facility. Among these,
566 cases with complete ACQ5 data were interviewed during a visit to their home,
which subsequently were used for the effectiveness analysis. We identified 270
patients with DBWoCC and 296 patients with DBWCC.
Table 2.1 shows the distribution of patients with respect to the covariates used in
our analysis, as well as the distribution of the symptoms of patients having breath-
ing difficulties. Patients with DBWCC were older than patients with DBWoCC: the
mean (SD) age in years was 51.2(17.8) vs. 46.7(18.8) with |t| = 3.16 and P-value =
0.0016. In patients with DBWCC, the mean age was higher among those visiting
STS facilities than among those being treated at PAL facilities (53.5 years vs. 49.3
years, |t| = 2.19, P-value = 0.029). The difference was not statistically significant
among patients with DBWoCC (P-value = 0.202). The distribution of the covariate
sex among patients with either DBWoCC or DBWCC who sought treatment at the
PAL or STS facilities was similar.
Overall, the mean baseline ACQ5 score was lower among patients with DB-
WoCC (Table 2.2). With regard to sex, we found that the mean baseline ACQ5
score was lower in women than men across all categories. However, a statistically
significant difference between the two sexes was only found among patients with
DBWoCC who visited PAL facilities (1.77 vs. 2.14: |t| = 2.37, P-value = 0.02). We
found no significant difference in the ACQ5 scores of men and women who sought
treatment at PAL and STS facilities. Patients visiting PAL facilities had a slightly
higher baseline ACQ5 score than patients visiting STS facilities in both symptom
categories (Table 2.2). However, the t-test revealed no significant difference. The
divergence in the ACQ5 scores is low (0.157), possibly due to an initially higher
ACQ5 score for patients visiting PAL facilities. The difference in the ‘Both Sexes’
column with regard to DBWoCC is 0.05 higher in the PAL facilities, but when
compared separately, we actually see mixed results. Among males, the score is
0.16 higher in PAL facilities; among females, the difference is 0.08 higher in STS
facilities. Moreover, the reduction in the ACQ5 score by 0.157 (not statistically
significant) is found among patients with a chronic cough.
We performed a linear regression on the baseline ACQ5 score, including age
as a covariate, and found that an increase in age by one year increases the score
by 0.013 (P-value < 0.001) and 0.007 (P-value = 0.014) in patients with DBWoCC
and with DBWCC, respectively.
The mean ± standard deviation of the change in the ACQ5 score was found to
be -1.047 and 1.24 among all patients with breathing difficulties. The results for
patients with DBWoCC and with DBWCC were –1.188 ± 1.34 and -0.901 ± 1.11.
Mean differences were significant, with a P-value < 0.001 and a low standard error
of 0.00504 in the DBWoCC group (= 1.27/1260.5). The result shows that these
patients’ conditions improved after they visited a health care facility in general.
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Table 2.1. Patients’ Attributes by Facility Type
Total DBWoCC DBWCC
PAL STS PAL STS PAL STS
Age 15–29 83 (21.7%) 41 (14.7%) 45 (23.6%) 24 (18.9%) 38 (19.9%) 17 (11.3%)
30–39 46 (12.0%) 35 (12.6%) 30 (15.7%) 15 (11.8%) 16 ( 8.4%) 20 (13.2%)
40–49 62 (16.2%) 33 (11.9%) 27 (14.1%) 22 (17.3%) 35 (18.3%) 11 (7.3%)
50–59 59 (15.4%) 48 (17.3%) 26 (13.6%) 20 (15.7%) 33 (17.3%) 28 (18.5%)
60–69 77 (20.2%) 67 (24.1%) 42 (22.0%) 26 (20.5%) 35 (18.3%) 41 (27.2%)
70+ 55 (14.4%) 54 (19.4%)’ 21 (11.0%) 20 (15.7%) 34 (17.8%) 34 (22.5%)
Sex Male 209 (54.7%) 150 (54.0%) 102 (53.4%) 68 (53.5%) 107 (56.0%) 82 (54.3%)
Female 173 (45.3%) 128 (46.0%) 89 (46.6%) 59 (46.5%) 84 (44.0%) 69 (45.7%)
Symptoms∗ DB Only 10 (2.6%) 11 (4.0%) 10 (5.2%) 11 (8.7%) – –
DB +Fever 4 (1.1%) 3 (1.1%) 4 (2.1%) 3 (2.4%) – –
DBWoCC 73 (19.1%) 43 (15.4%) 73 (38.2%) 43 (33.9%) – –
DBWoCC +Fever 104 (27.2%) 70 (25.2%) 104 (54.5%) 70 (55.1%) – –
DBWCC 106 (27.7%) 69 (24.8%) – – 106 (55.5%) 69 (45.7%)
DBWCC +Fever 85 (22.3%) 82 (29.5%) – – 85 (44.5%) 82 (54.3%)
Total 382 (100%) 278 (100%) 191 (100%) 127 (100%) 191 (100%) 151 (100%
∗DB = Difficulties Breathing
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Table 2.2. Mean baseline ACQ5 scores among patients with breathing difficulties,
with and without a chronic cough, visiting PAL and STS facilities
Mean ± Standard Deviation (size)
STS PAL
Both Sexes Total 2.19 ± 1.01 (266) 2.20 ± 1.05 (372)
DBWoCC 1.92 ± 1.05 (119) 1.97 ± 1.06 (185)
DBWCC 2.40 ± 0.92 (147) 2.42 ± 0.99 (187)
Male Total 2.23 ± 1.00 (142) 2.29 ± 1.01 (203)1
DBWoCC 1.98 ± 1.09 (62) 2.14 ± 1.14 (100) 2
DBWCC 2.43 ± 0.87 (80) 2.43 ± 1.00 (103)
Female Total 2.13 ± 1.02 (124) 2.09 ± 1.01 (169)
DBWoCC 1.85 ± 1.00 (57) 1.77 ± 0.93 (85) 1
DBWCC 2.37 ± 0.99 (67) 2.37 ± 0.99 (67) 2
T-test Male vs. Female: 1P-value < 0.10; 2P-value < 0.05
Table 2.3. Test of the significance of the difference in mean change in the ACQ5
score between PAL/STS, in patients with DBWoCC and DBWCC
Mean ± Standard Deviation (size) t-statistic (P-value)
STS PAL t (P-value)
Change in Total –0.88 ± 1.21 (230) –1.17 ± 1.25 (336) 0.296 (0.005)
ACQ5 Score DBWoCC –1.04 ± 1.27 (126) –1.29 ± 1.38 (170) 0.374 (0.007)
DBWCC –0.68 ± 1.12 (104) –1.05 ± 1.09 (166) 0.250 (0.112)
The mean difference of the change in the ACQ5 score between patients vis-
iting PAL and STS facilities was –0.25 (P-value = 0.112) and –0.37 (P-value =
0.007) in DBWCC and DBWoCC, respectively (see Table 2.3). The results indi-
cated a lower ACQ5 score following treatment at a PAL facility, consistent with
an improvement in respiratory health. However, the difference was statistically
significant only among patients who did not have a chronic cough.
Two sets of stepwise multiple regression analyses for patients with DBWoCC
and DBWCC were performed to explain the change in the ACQ5 score during the
follow-up, by testing independent variables including: facility-type (PAL/STS),
age, sex, baseline ACQ5 score, and facility-level (see Table 2.4).
The variables age, sex, baseline ACQ5 score, and facility-level (two dummy
variables) were introduced in the model as covariates, since they (could) affect the
change in the ACQ5 score and, hence, we separated the main effect, i.e. the effect
of facility type visited (PAL/STS) on the change in the ACQ5 score. We included
the baseline ACQ5 score in the model, since the baseline score among patients
visiting PAL facilities was higher (though statistically insignificant) (Table 2.2). In
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Table 2.4. Linear regression models of change in the ACQ5 score, based on different variables
Regression coefficients (P-values) of change in the ACQ5 score based on variables
DBWoCC Model 1 Model 2 Model 3 Model 4∗∗∗ Model 5
Constant –0.675 (0.000) –1.134 (0.000) –1.107 (0.000) –0.315 (0.070) –0.317 (0.072)
Group (PAL = 1) –0.374 (0.008) –0.344 (0.009) –0.341 (0.008) –0.360 (0.008) –0.361 (0.007)
Age 0.009 (0.008) 0.010 (0.007) 0.016 (0.000) 0.016 (0.000)
Sex (male = 1) –0.118 (0.358) – –
Baseline ACQ5 –0.583 (0.000) –0.579 (0.000)
PHCC –0.181 (0.197)
HP 0.015 (0.929)
DBWCC Model 1 Model 2 Model 3 Model 4 Model 5∗∗∗
Constant –1.044 (0.000) –1.849 (0.000) –1.792 (0.000) –0.526 (0.181) –0.345 (0.388)
Group (PAL = 1) –0.249 (0.354) –0.184 (0.481) –0.181 (0.483) –0.158 (0.566) –0.166 (0.505)
Age 0.015 (0.006) 0.015 (0.005) 0.02 (0.000) 0.019 (0.000)
Sex (male = 1) –0.13 (0.400) – –
Baseline ACQ5 –0.658 (0.000) –0.651 (0.000)
PHCC –0.462 (0.034)
HP –0.375 (0.218)
∗∗∗Final Model
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addition, patients with a lower ACQ5 score (i.e. whose health condition was better)
recovered sooner than patients with a higher ACQ5 score.
At the same time, the minimum value ACQ5 could have was 0, implying that no
problems were associated with breathing difficulties. It also means that the reduc-
tion of the ACQ5 score is limited, and for those with a lower ACQ5 score the limit
is smaller. In line with this argument, age and sex were included, since an increase
in age leads to a higher ACQ5 score at baseline, and females have lower ACQ5
scores (though statistically insignificant). Regarding the variables related to facil-
ity level, we expected that receiving treatment from higher level facilities would
have a positive effect on the patient’s health, considering that the medical compe-
tency and resources of higher level facilities are more advanced. We introduced two
dummy variables for facility level, with PHCC = 1 and HP = 0 indicating facility
visited as PHCC; with PHCC = 0 and HP = 1 indicating HP; and with PHCC = 0
and HP = 0 indicating SHP.
Our main hypothesis is that the reduction in the ACQ5 score is higher among
patients who seek treatment at PAL facilities than among those visiting non-PAL
facilities, correcting for other relevant characteristics, including baseline ACQ5
scores, as these may be effect modifiers. We considered several stepwise regression
models as illustrated in Table 2.4. Variables with a statistically insignificant effect
were excluded from the model at each step. That is, the final model only consists
of statistically significant dependent variables.
Table 2.4 represents the individual results of the regression analysis of change
in the ACQ5 scores with reference to the different (previously described) covariates
for the two groups of patients, DBWoCC and DBWCC. Our main independent
variable in Model 1 (Table 2.4) is ‘Group’, which either has a value of 0 for a
STS facility or a value of 1 for a PAL facility. A higher reduction in the ACQ5
score for patients visiting PAL facilities is evident with 0.374 (P-value = 0.008) for
patients with DBWoCC, and 0.249 (P-value = 0.354) for patients with DBWCC.
This implies that a PAL facility provides better health care than a STS facility,
which applies to patients with DBWoCC, but not to those with DBWCC.
To control for other covariates’ effects on the ACQ5 score, we included each
covariate separately, as demonstrated in Models 2 to 5 (Table 2.4). In Model 2,
we introduced the patient’s age, which has a significant positive effect (i.e. dete-
riorating health effect) on the ACQ5 score for both groups of patients, with each
additional year in age lowering the total reduction in the ACQ5 score by 0.009
(P-value = 0.008) among patients with DBWoCC, and by 0.015 (P-value = .006)
among patients with DBWCC.
Next we introduced the patients’ sex. Model 3 in Table 2.4 indicates that the
reduction of males’ ACQ5 score is higher than females’. The additional reduction
for male patients with DBWoCC is 0.118 (P-value = 0.358), and 0.13 (P-value =
0.400) for those with DBWCC. Based on the P-values, the sex of a patient had no
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statistically significant effect on the ACQ5 score, therefore, we excluded patients’
sex from the model. We also introduced patients’ baseline ACQ5 score in Model 4
(in addition to facility type and age), which reveals that the effect on the reduction
in ACQ5 is statistically significant in both groups of patients, with a reduction of
58.3% of the initial ACQ5 score. To further explain this result, let us assume two
patients, both aged 40, visited a PAL facility. The initial ACQ5 score was 2.5 for
Patient 1 and 1.5 for Patient 2. According to Model 4, the reduction in the ACQ5
score for patients with DBWoCC would, two weeks later, lie at 1.503 (–0.325 –
0.36 + 0.016 ∗ 40-0.583 ∗ 2.5) for Patient 1 (with a final ACQ5 score of 0.997),
and 0.920 (–0.325-0.36 + 0.016 ∗ 40 – 0.583 ∗ 1.5) for Patient 2 (with a final ACQ5
score of 0.581). This implies that the reduction in the ACQ5 score is higher if the
patient’s initial score was higher.
Lastly, in Model 5 we introduced a variable indicating the level of the health
care facility visited by the patient. As mentioned above, we included two dummy
variables, PHCC (1/0) and HP (1/0). The ACQ5 score of patients with DBWoCC
who visited a PHCC reduced by -0.181 (P-value = 0.197) and by -0.462 (P-value
= 0.034) for patients with DBWCC. That is, visiting a PHCC makes a difference,
which comes as no surprise, since PHCCs employ more competent health care
providers and, at the same time, are better equipped than the other facilities. How-
ever, the effect of facility level is only statistically significant among patients with
DBWCC, and not among patients with DBWoCC. The effect of visiting a HP is
statistically insignificant for both groups of patients.
Based on this regression analysis, Model 4 is the most appropriate model for
patients with DBWoCC in terms of change in the ACQ5 score within a two week
period (change in ACQ5 score = facility type + age + initial ACQ5 score). Sim-
ilarly, Model 5 is the best model for change in the ACQ5 score for patients with
DBWCC within two months (change in ACQ5 score = facility type + age + initial
ACQ5 score + level of facility). Controlling for age, sex, baseline ACQ5 score,
and facility level, our findings showed that the ACQ5 score of patients visiting a
PAL facility further reduced by 0.36 (P-value = 0.008) compared to those visiting
a STS facility. Among patients with DBWCC, the additional reduction was 0.166
(P-value = 0.505), which was not statistically significant.
To support the validity of the ACQ5’s use, we confirmed the scores against
those from the peak flow meter measurements and computed the Pearson correla-
tion. Along with the ACQ5 questionnaire, peak flow measurements were obtained
from the patients as an objective measurement of their lung function. A higher
value for the peak flow measurement indicates better lung function. A strong cor-
relation between the peak flow measurement and the ACQ5 score verified the “field
level” validity of the ACQ5 in the Nepalese context, considering that the peak flow
measurement is a valid and objective measurement of lung function. Hence, we
calculated Pearson’s correlation as being between the peak flow measurement and
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the ACQ5 score. We found a significant negative correlation coefficient, r = –0.21
(P-value < 0.001) between the baseline ACQ5 score and the peak flow measure-
ment; and r = -0.44 (P-value < 0.001) between the follow-up ACQ5 score and the
peak flow measurement. The correlation between the change in the ACQ5 score
and in the peak flow measurement was negative with r = -0.30 (P-value < 0.001).
The negative correlation seems to confirm that both the ACQ5 and the peak flow
measurement provide similar estimates: the ACQ5 decreases with improved lung
function, while the peak flow measurement increases. Earlier, we used the term
“rough” validity because the primary device for testing lung function is, in fact,
the spirometer; however, using a spirometer was not feasible in our case due to
limited resources, as well as the local terrains, which made it impossible to bring
a spirometer along when visiting patients at home. Concurrently, measurements
using a peak flow meter were made under comparable conditions to ensure that the
measurement was applicable either between individuals or to one individual at a
specific time. Hence, a weaker correlation in the expected direction is an indication
of the ACQ5 questionnaire’s validity within the Nepalese context. The ACQ5 is
a simple and easily understandable questionnaire that is used worldwide and does
not necessarily require further validation for use within the local Nepalese context.
2.4 Discussion and Conclusion
Symptoms related to breathing difficulties improved after patients visited a health
care facility, demonstrated by the difference between the ACQ5 baseline scores
and those of the follow-up among patients with and without a chronic cough (Ta-
ble 2.3). Health improvement was significantly higher among patients who did not
have a chronic cough and visited a PAL facility than for those who visited a STS fa-
cility. The higher degree of improvement may be attributable to the use of the PAL
guidelines by the health care providers, since one of the objectives of implementing
the PAL guidelines is to improve the quality of respiratory care management [5].
However, the degree of improvement was higher among patients without a cough
or with a non-chronic cough than among patients with a chronic cough. There are
three possible reasons that may explain this finding; the condition of patients with-
out a cough or with a non-chronic cough is acute or short-term, and these patients
are more likely to be healthier than patients with a chronic cough, even before any
symptoms have appeared. Appropriate treatment reduces the symptoms immedi-
ately and the patient’s former health condition is more easily restored.
The second reason could be related to the design of the survey. Patients with a
chronic cough were followed-up two months after the first interview, while patients
without a cough or with a non-chronic cough were followed-up after two weeks.
We already asserted that a patient’s condition improves after he/she visits a health
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care facility in general. Hence, the speed of recovery becomes the crucial factor.
When a patient is followed-up after a prolonged time lapse, it is more likely that
his/her health status is similar to other patients’, irrespective of which type of health
care facility was visited. This could explain why we found a statistically significant
difference in the average decline in ACQ5 scores between patients who had visited
a PAL facility (higher degree of improvement) and those who visited a STS facility,
though this applied only to patients with no cough or a non-chronic cough. Another
reason may be the selected measuring instrument, in our case the ACQ. Since the
ACQ was developed to measure the control of asthma but was used here for pa-
tients with a chronic cough who were more likely to have tuberculosis or chronic
obstructive pulmonary disease with or without an asthmatic component, the result
may not be valid. ACQ is not used to measure the change in the health status of
patients with a chronic obstructive pulmonary disease or tuberculosis, since it is
a valid instrument used for asthma patients. Unfortunately, other simple instru-
ments or questionnaires were not available. The ACQ was the most appropriate
tool we could find to measure the health effect among patients with breathing dif-
ficulties. We used the ACQ questionnaire to measure the health status of patients
with asthma – the main symptom being breathing difficulties – by interviewing
all the patients who reported having these symptoms (with the exception of those
patients who were previously diagnosed with chronic obstructive pulmonary dis-
ease, tuberculosis, or asthma),,since the PAL guidelines are based on a syndrome
approach.
At the baseline we found that the severity of symptoms measured by the ACQ5
increased with age, which can be explained by aging in general and secondly, by
the chronic nature of diseases. Severity was lower among women than men. The
reason for this could be age rather than sex since the women in our sample were
younger than the men. Severity is higher among patients with chronic conditions,
and due to the younger age of the women in our sample, there were fewer cases of
chronic conditions among the women included. Among patients with DBWoCC,
the sex difference in the baseline ACQ5 score was significant.
Some discussion points on the introduction of the WHO PAL program must
be raised here. Firstly, this is a symptoms-based study and not a diagnosis-based
study, as it involved primary health care facilities in real-life settings. At this level,
the health care providers in Nepal have one to two years of basic training and, in
addition, the lack of resources makes it difficult to correctly diagnose a disease.
Hence, diagnosis-confirmed studies cannot (and should not) be conducted at this
level, given the PAL program’s objectives. Consequently, the possibilities of com-
paring our results with those from other studies were limited, with the exception
of a comparison with other PAL evaluation studies [8, 9]. Our study is the first
symptom-based study on patients with breathing difficulties in Nepal, and in fact,
in all of South-East Asia.
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Secondly, the intervention in this study comprises the actual instruction and
training of health care providers about how to apply PAL guidelines, which is dif-
ferent from providing direct treatment to patients in typical intervention-control
trials. We can only presume that the quality and methodology of training, as well
as the background of the trainees would influence the results of the analysis on
the effectiveness of the guidelines. Also, this approach reflects real-life settings in
the actual practice of promoting and implementing primary care in the Nepalese
setting.
Thirdly, the research period of one year for assessing the effect of a one-time
training may have two different consequences. The limited number of PAL patients
required an extension of the study period to one year. With more practice, health
care providers may have gained a better understanding of the guidelines. In the ab-
sence of proper supervision, however, health care providers may have reduced the
level of adherence to the guidelines and returned to the standard treatment methods,
since the guidelines are more complex to follow and more time consuming. In both
cases, the effect of the guidelines may have varied throughout the one year period.
A shorter evaluation timeframe would probably provide better results among the
intervention groups. However, there is a wash-out of the training effect the more
time passes. Fourthly, patients in the sample do not necessarily represent the area’s
general population because many patients visit private medical facilities, utilize tra-
ditional medicine, and travel to India or other facilities in neighboring districts in
search of better care.
Finally, the use of the asthma control questionnaire to measure the severity of
symptoms in patients with breathing difficulties should be seriously reconsidered
given that not all patients with breathing difficulties are asthmatic. We recommend
that more research be conducted to explore and establish simple generic tools for
measuring chronic health effects in lung patients, suitable for symptom-based al-
gorithms and guidelines.
To conclude, tools for measuring the health effects of interventions using syn-
dromic approaches to lung health should be explored further in order to more accu-
rately describe (improvements in) patients with a chronic cough. The PAL guide-
lines were shown to be more effective than the Standard Treatment Schedules in
patients who had breathing difficulties without a chronic cough.
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3
Health-Related Quality of Life of Adults
in Nepal with Respiratory Symptoms,
Using WHOQOL and EQ-5D
Only few studies on health-related quality of life have been carried out in Nepal
using generic health-related quality of life (HRQOL) instruments. The aim of this
chapter is to determine the HRQOL of patients with respiratory symptoms in Nepal
with the use of the World Health Organization Quality of Life Questionnaire (WHO-
QOL) and the European Quality of Life Questionnaire (EQ-5D), and to establish
and compare their construct validity within the Nepalese context.
The English versions of the WHOQOL and EQ-5D were translated into
Nepalese and Bhojpuri (a local dialect) and translated back into English, following
the standard adaptation guidelines. Using WHOQOL and EQ-5D, we interviewed
2243 patients with respiratory symptoms (aged 15 years and older) who visited one
of the 42 primary health care facilities selected for our study within a ten month
period (September 2002–July 2003).
We found EQ-5D to be a valid instrument for measuring the Nepalese patients’
health-related quality of life. We established the validity of EQ-5D with reference to
different WHOQOL domains by comparing EQ-5D’s utility score with the median
scores of each WHOQOL domain. We found a higher degree of association between
the EQ-5D utility scores and the physical (r = 0.533) and psychological (r = 0.393)
domains of the WHOQL.
We also determined that breathing difficulties are among the most prevalent
respiratory problems that significantly reduce patients’ health-related quality of
life. Fever and chronic cough also contribute to the reduction of patients’ HRQOL,
but to a lesser degree. Younger patients have a better HRQOL; patients with a
higher level of educational attainment also have a better HRQOL; while patients
who are separated, divorced or widowed have lower HRQOL levels. Patients’ sex
was found to only have an insignificant effect on the level of HRQOL.
This publication is the first of its kind to describe the HRQOL of patients in
Nepal. More research on the validation of generic and disease-specific HRQOL
should be carried out to facilitate future economic evaluations.
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3.1 Introduction
Health-related quality of life (HRQOL) plays an important role in assessing the ef-
fectiveness of health care [1–3]. General health-related quality of life scales assess
the impact of illness and individuals’ experiences with health [4]. An individual’s
general health-related quality of life is often measured by using a set of questions
representing different dimensions. Demands for measuring health-related quality
of life is increasing worldwide [5]. Several questionnaires have been developed in
the past with many more to be developed in the future. The World Health Organi-
zation Quality of Life Questionnaire (WHOQOL) [6] and the European Quality of
Life Questionnaire (EuroQOL, but referred to here as EQ-5D) [7] are commonly
used instruments to determine the general population’s health-related quality of life
or that of a disease-specific group of patients. We used these two questionnaires to
measure the health-related quality of life of patients with respiratory symptoms
within the context of a study on the cost-effectiveness of an intervention in Nepal.
3.1.1 Intervention
The intervention is an integrated symptom-based approach to lung health, namely
the Practical Approach to Lung Health (PAL) guidelines developed by the World
Health Organization, targeting four lung diseases including tuberculosis, asthma,
chronic obstructive pulmonary diseases, and pneumonia [8-10]. The PAL guide-
lines were adapted to the Nepalese setting and health care providers at randomly
selected facilities in a rural Nepalese district were trained to apply them. We con-
ducted a one-year intervention-control prospective trial during which – along with
other patient-related data – we collected patients’ health-related quality of life us-
ing the translated and locally adapted WHOQOL and EQ-5D. The trial’s aim was
to assess the cost-effectiveness of the PAL guidelines’ implementation in Nepal
3.1.2 Quality Adjusted Life Years
The two key purposes of the HRQOL measurement are to either compare the level
of HRQOL between people as a discriminative instrument or as an evaluative in-
strument to compare the change in individuals’ HRQOL levels over time [11]. In
cost-effectiveness studies, effectiveness is often measured in terms of quality ad-
justed life years (QALYs) gained/lost for which an evaluative tool is needed. In-
dividuals’ QALYs for a certain period is estimated by multiplying that particular
time period by a specified weight (ranging from 0 to 1) that is associated with the
individual’s health-related quality of life during the given period of time. What we
need is an index, preferably between 0 and 1, that corresponds to an individual’s
health-related quality of life. In the PAL study, we included the EQ-5D as our eval-
uative instrument of choice, since it was developed to produce a single value that
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can be used to estimate QALYs. Numerous cost effectiveness studies have used
EQ-5D to estimate QALYs. The purpose of WHOQOL, on the other hand, is to
describe individual’s self-assessed health status in detail for the different domains
of health-related quality of life. Notably, the WHOQOL has already been adapted,
tested, and implemented in India [12], and since the conditions in Nepal are similar
to India’s, the use of the WHOQOL in Nepal did not have to be re-adapted to an en-
tirely new setting (which was actually a requisite by the developers of WHOQOL)
[13]. An algorithm has been developed to compute a single value for individuals’
health-related quality of life using the WHOQOL; however, the (implicit) assump-
tions in the summarization process preclude a single value from being used as a
weight to estimate the QALYs. This is discussed in detail later in the chapter.
3.1.3 Validity of HRQOL Instruments to Measure Patients’ HRQOL
within the Nepalese Context
An efficient measurement tool should generally have the following instrumental
properties: reproducibility, accuracy, validity, and interpretability [11]. Repro-
ducibility is measured by reliability and responsiveness when using discriminative
and evaluative instruments, respectively. The validity of an instrument must be
determined prior to using the measurements’ results. The validity of an already
established instrument should also be tested when measuring a property in a new
context. Measuring the validity of an instrument involves verifying whether or not
the instrument measures the targeted domain, which is also referred to as face va-
lidity [11]. An instrument’s face validity can easily be established either through
empirical evidence or by theoretical consideration (examining how the measure
was established and whether existing theories confirm that the indicators used for
the instrument are directly – or indirectly – associated with the domain), or both.
Once the instrument’s face validity has been established, the second question is
how accurately the instrument measures a given property. This can be determined
through construct validation, which is used to compare the different measures, and
to explore the logical relationship that ought to exist between a given measure and
the characteristics of a patient or a patient group [11]. The comparison is typically
carried out by estimating the correlation coefficient between the test instrument’s
measurements and the existing standard instrument. In this study, we describe and
present the results of the validation of the EQ-5D (test instrument) in relation to the
WHOQOL (standard instrument). Finally, a HRQOL measuring instrument should
be interpretable. For a given HRQOL score it should be possible to categorize indi-
viduals’ condition into “normal, mild, moderate or severe impairment of HRQOL”
[11] and, if the change in HRQOL level is being measured over time, it should be
possible to interpret the change as being “trivial, small but important, moderate, or
large improvement or deterioration”, an aspect we address in Chapter 6 [11].
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3.1.4 Objective
The main objectives of this chapter are to describe the variation in the health-related
quality of life of patients with respiratory symptoms with reference to precisely
these symptoms and to various other demographic and socio-economic variables.
We furthermore aim to analyze the change in the impairment of HRQOL over time.
To achieve these objectives, it is important to establish the validity of the measuring
instruments. Therefore, the second objective is to establish the validity of the EQ-
5D with reference to WHOQOL’s different domains. The validation of EQ-5D will
be the starting point for using the EQ-5D measurement as an evaluative instrument
in the analysis of the PAL intervention’s cost-effectiveness.
In the following section, we describe the two HRQOL instruments, WHOQOL
and EQ-5D, in detail. Next, in the methods section, we explain the PAL study de-
sign and describe the process of adapting the HRQOL instruments to the Nepalese
context. The methods section also describes the statistical analysis used to achieve
our objectives. The results and inferences are presented in the results section. Fi-
nally, the chapter concludes with a discussion and general conclusions.
3.2 HRQOL Instruments
3.2.1 WHOQOL
The developers of the WHOQOL defined the quality of life as an individual’s per-
ception of his/her position in life within the context of his/her culture and value
system, and in relation to the individual’s goals, expectations, standards, and con-
cerns [6, 13, 14]. It is viewed as a subjective, multidimensional concept [15, 16],
which places emphasis on the individual’s self-perception of his/her current health
state. WHOQOL was used in the trial to assess the health-related quality of life
of patients with respiratory symptoms. We chose the WHOQOL, since the Indian
version, WHOQOL-Hindi, was verified as a valid instrument for comprehensively
assessing the quality of life in health care settings in India [12]. Due to the geo-
graphical proximity and historical relationship between the two countries, people
from India and Nepal have a lot in common, including culture, religion, value sys-
tems, etc. It is therefore justifiable to infer that the WHOQOL is a valid instru-
ment for measuring the Nepalese population’s generic health-related quality of life.
We did not conduct a validation process of the Nepali and Bhojpuri (local dialect)
WHOQOL independently as recommended by the developers of WHOQOL, since
it was beyond the scope of the PAL evaluation study. We translated the WHOQOL-
Hindi into the local language and made context-specific adaptations following re-
peated field testing. We then used the translated and locally adapted WHOQOL
(WHOQOL-Nepali and WHOQOL-Bhojpuri; we did not distinguish between the
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two versions in our analysis and for simplification purposes, we will refer to both
as WHOQOL) as a valid instrument to measure health-related quality of life in the
study on cost-effectiveness, and also used it to test the validity of EQ-5D.
The WHOQOL questionnaire consists of 26 items [17]. The first two items
are global indicators for quality of life and satisfaction with general health. The
remaining 24 items are grouped into 4 domains: physical health (7 items), psycho-
logical health (6 items), social relationships (3 items), and environment (8 items).
Each item is rated on a 5-point Likert scale. Hence, one of the 6 x 1016 (524) states
of the WHOQOL’s overall states may be attributable to an individual, or one of the
78125, 15625, 125, and 390625 states of the WHOQOL’s domains physical health,
psychological health, social relationships, and environment, respectively. To nar-
row it down, the WHOQOL group proposes the calculation of the responses’ mean
(recoded as 1, 2, 3, 4 or 5 with a higher value indicating an improved status) in each
domain. The means were multiplied by 4 to obtain domain scores ranging from 5 to
20. Finally, the overall WHOQOL score was calculated as a sum of these domain
scores, resulting in a range of 20 (for worst health state) and 100 (for best health
state).
At the domain level, the use of the mean implicitly assumes that the responses
are summed in an interval scale, which, however, is not the case since they are
summed in an ordinal scale. We propose using the median as a more suitable al-
ternative for representing the HRQOL level in each of the WHOQOL’s domains,
considering that the median as a measure better represents central tendencies when
averaging values in an ordinal scale. Next, at the general level, the summing of
domain scores to obtain the overall WHOQOL score implicitly assumes equal
HRQOL weight for all domains, which is also erroneous because the perceived
value of these weights differs between individuals and communities. Therefore, the
current developmental status of the WHOQOL cannot be used to calculate QALYs
that require a single utility measure. In this study, for descriptive purposes, we cal-
culated the median response for each WHOQOL domain. Using the median scores
for each domain, 625 WHOQOL states were defined, and with some additional
modifications on weight estimation, the WHOQOL could be used in the study on
QALYs. For the purpose of validating EQ-5D using WHOQOL, we limited our
validation to the domain level.
3.2.2 EQ-5D
The EQ-5D questionnaire [18] is a commonly used tool to measure health-related
quality of life. It contains five dimensions for health (mobility, self-care, usual
activities, pain/discomfort, anxiety/depression) with three levels of response (1 for
“no problem”; 2 for “some problem”; 3 for “severe problem”), which represent
243 (35) health states. We included EQ-5D in the cost-effectiveness analysis to
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estimate the QALYs of patients. The original version of the EQ-5D was translated
and locally adapted for this purpose, and the validation of EQ-5D performed by
using WHOQOL as a valid standard measurement of health-related quality of life
in Nepalese patients.
A unique feature of the EQ-5D is that former validation research facilitates the
measuring of severity of the 243 health states [19]. This measure of severity in
HRQOL impairment is often expressed in terms of utility as perceived by patients
with a decline in utility, signifying a more serious HRQOL impairment. It has a
value of 1.00 when the individual is healthy (11111) and 0.00 when the person
is deceased. Very severe health states, e.g. 33333, have negative values (–0.59).
The utilities were calculated using a reference set of preference weights derived
from a representative sample of the UK’s general population, known as the UK
weights [5]. We used the UK weights since no such weights exist for Nepal’s
population. The possibility to attribute a measure of severity to the EQ-5D health
states eliminates the problem of multiple outcomes, which is inextricably linked
to the use of multidimensional HRQOL measures (e.g. the WHOQOL). For this
reason, the utility score of the EQ-5D provides an especially suitable result for
modeling purposes, when the burden of disease or the effectiveness of a health care
intervention is evaluated in terms of health-related quality of life [19]. The utility
score, which corresponds to the specific condition a patient is in, can be understood
as the amount of ideal quality time a patient is ready to trade for one unit of (less)
quality time.
Additionally, the EQ-5D consists of a single rating scale of health impairment,
a vertical calibrated 20 cm Visual Analogue Scale (VAS) with ratings of ’worst
imaginable health state’ (0) at one end, and ’best imaginable health state’ (100) on
the other [18]. The objective when using the VAS in valuation studies is to attach
values (or utilities) to all EQ-5D statuses according to the protocol described on
EuroQol’s official Web site (http://www.euroqol.org). Even though the PAL study
is not a valuation study of the EQ-5D, local versions of EQ-VAS were developed
through repeated field testing. Later, we collected the responses to the modified
EQ-VAS (Figure 3.1) along with the EQ-5D questionnaire (this is mentioned here
for information purposes for future EQ-5D users in Nepal). The respondents were
asked to mark the point on the scale that they felt best described their current state.
The rating scale in this study differs from the EQ-VAS, since we added three pic-
tures to indicate ‘best’ (100), ’worst’ (0), and ’average’ (50) health states. These
were repeatedly field tested among health professionals, students, patients, and the
general population in the area under investigation. Interviews based on an early
version of the survey indicated some confusion between the verbally presented
concept of “full health” and material or monetary well-being. After the pictures
were introduced, this confusion no longer emerged (see Figure 3.1). We used VAS
results as an additional instrument to measure health status.
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Your own health state today
Figure 3.1. Modified visual analogue scale.
To help people say how good or bad a health state is, we have drawn a scale (rather like
a thermometer). On this scale the best health state you can imagine is marked 100 (Field
assistant: point now with your finger to figure 100) and the worst state you can imagine is
marked 9 (point now with your finger to figure 0).
We would like you to indicate on this scale how good or bad your own health is today, in
your opinion. Please do this by drawing a line from the box below to whichever point on
the scale indicates how good or bad your health state is today.
3.3 Methods
3.3.1 Study Design
The stratified intervention-control cluster randomized trial was conducted in the
rural lowland district of Nawalparasi in Nepal between 2002 and 2003. The details
of the trial are described in Chapter 2. To recapitulate, two primary health care
centers, eight health posts, and 32 sub-health posts were randomly selected and
grouped into intervention facilities (PAL) and standard practice facilities (STS) at
which health care providers followed standard treatment schedules, with a total of
22 and 20, respectively. At least one health care provider per PAL facility partici-
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pated in a five-day training program on how to apply the PAL guidelines. After the
intervention, data were collected from patients aged 15 and above, who visited a
PAL or STS facility and reported having one or more of the following respiratory
symptoms: fever, a cough (duration less than, equal to, or more than two weeks),
and breathing difficulties. Patient-level data were collected directly at the facility
from all patients included in the trial and later from patients with specific symp-
toms at their home. Along with other data, facts on patients’ health-related quality
of life were collected using locally translated and adapted WHOQOL and EQ-5D
questionnaires. A total of 2243 patients were interviewed during this period.
3.3.2 Translation and Validation of the Questionnaire
WHOQOL
We used the WHOQOL-Bref-Hindi questionnaire to measure general health sta-
tus [12]. This instrument had already been tested in Delhi, India [12] and was
translated into Nepalese and Bhojpuri following the standard methods described
below.
EQ-5D
The EQ-5D questionnaire has been tested worldwide and the standard question-
naires are available in different languages. The English version of the questionnaire
was translated into Nepalese and Bhojpuri following the standard guidelines.
Translation
Both questionnaires were first translated from English into Nepali and Bhojpuri
by two qualified translators who were native speakers of these two languages. The
translated questionnaires were then independently translated back into English (2nd
English version). The second English version was then compared with the original
version and the divergences taken into consideration to produce a second Nepali
and Bhojpuri version of the questionnaire. This version was then piloted by con-
ducting interviews with a few people. Based on the pilot test, a third version of the
questionnaire was prepared and used for data collection. The score of the EQ-5D
ranges from –0.59 to 1, while the range is 1 to 5 for the domains included in the
WHOQOL.
Validation
To test construct validity, we estimated that Spearman’s correlation coefficients
were situated between the EQ-5D score and each dimension of the WHOQOL. A
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stronger correlation indicates a higher level of EQ-5D validity with regard to the
WHOQOL. The quantitative significance of the correlation coefficient is based on
the recommendation by Burnand et al. [20]. According to Burnand et al., a corre-
lation coefficient’s value, r, that is less than 0.30 indicates an insignificant associ-
ation; a range of 0.30–0.45 signifies a moderate degree of association; a range of
0.45–0.60 indicates a substantial level of association, and a correlation coefficient
value that is greater than 0.60 denotes a high level of association. In our analysis,
we expected to at least detect a moderate level of association between the EQ-5D
and similar domains of the WHOQOL.
As explained earlier, the dimensions of the EQ-5D include mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression; the domains of the WHO-
QOL are physical, psychological, social, and environmental. We used a single score
for the EQ-5D, and the correlation coefficients were calculated as being situated be-
tween the EQ-5D’s single score and the individual domain scores of the WHOQOL.
When comparing the dimensions of the EQ-5D with the WHOQOL’s domains, we
noticed that the first four EQ-5D dimensions matched the WHOQOL’s physical
domain, and the EQ-5D’s fifth dimension (anxiety/depression) matched the WHO-
QOL’s psychological dimension. Therefore, we expected the EQ-5D score to reveal
a higher degree of positive association with physical attributes, and a lower degree
with psychological attributes. We did not expect the EQ-5D’s dimensions to be
associated with the WHOQOL’s social and environmental domains.
3.3.3 Statistical Analysis
After the validation exercise, for descriptive purposes, we estimated the mean and
standard deviation of the HRQOL score for the EQ-5D and the domains of the
WHOQOL for the patients in general, as well as for sub-groups of patients by sex,
age group, marital status, level of educational attainment, and, most importantly,
by the patients’ respiratory symptoms. We expected patients with a chronic cough
and breathing difficulties to have a lower HRQOL compared to those with a shorter
cough duration or with only a fever. At the same time, we expected younger pa-
tients, as well as more educated patients to have a higher HRQOL level. We also
included marital status in our model. We assumed that patients who were sepa-
rated, divorced or widowed would have a lower HRQOL level. The majority of
the population in Nepal marries at a relatively young age and the rate of separation
and divorce is very low. To test these hypotheses, we used a t-test for sex (two
sub-groups) and for the rest, with more than two sub-groups, we used a one-way
ANOVA.
Finally, to analyze the variation in HRQOL with respect to the above-stated ex-
planatory variables, we performed two linear regression analyses of health-related
quality of life scores – one for the EQ-5D dimensions and one for the domains
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of the WHOQOL – on respiratory symptoms and various socio-demographic vari-
ables. The results from the regression analyses were used to test the hypotheses
stated earlier.
3.4 Results
A total of 2243 patients aged 15 or older were included in the PAL study. The
response rate to the four domains of the WHOQOL, namely physical, psycholog-
ical, social, and environmental, were very high with 98%, 97%, 97%, and 97% of
the total respondents (2243) rating them, respectively. According to the WHOQOL
protocol, if the number of questions answered for each domain is less than 80%, the
response to the domain is considered incomplete. The response rate to the overall
WHOQOL was 90.5%, which is quite low in relation to the response rate for each
domain. This indicates that non-response at the individual level was limited mostly
to one domain, since the response rate at the general domain level was quite high.
Similarly, the EQ-5D demonstrated a higher response rate (95.5%). The higher
response rate for the EQ-5D is attributable to the fact that the EQ-5D consists of
fewer (five) questions that are easier to answer than those posed by the WHOQOL
(26 questions). Table 3.1 presents the distribution of patients who responded in full
to the EQ-5D and to each of the WHOQOL’s different domains by age, sex, marital
status, level of educational attainment, and symptoms.
A similar proportion of male and female patients responded to the WHOQOL’s
different domains in full (51% males) and to the EQ-5D (51% males) (see Ta-
ble 3.1). The second to last block in Table 3.1 represents the distribution of re-
spondents by respiratory symptom at the time of their visit to a health care facility.
Around 40% of the patients either had a cough that lasted less than 2 weeks or
fever. These patients were not included in the follow-up stage, since – in accor-
dance with the PAL guidelines – they were less likely to have a PAL target dis-
ease, namely tuberculosis, chronic obstructive pulmonary disease, pneumonia, or
asthma. Some 30% of the patients had breathing difficulties as an individual or one
of several symptoms, and for these patients, a separate questionnaire (a modified
Asthma Control Questionnaire) was administered. Some 21% of the patients had
a chronic cough as an individual or one of several symptoms, and these patients
were followed-up two months later. The remaining patients (39%) were followed-
up after two weeks. A higher proportion of patients (around 44%) belonged to
the younger age groups (15–34 year olds). Around 79% of the patients were mar-
ried, while approximately 9% were either separated, divorced, or widowed. The
majority of patients had a low level of education (76%) (see Table 3.1).
In the EQ-5D, the majority of patients reported having no problem at all in
the dimensions mobility (59.4%) and self-care (75.1%), whereas the majority of
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Table 3.1. Distribution of patients by age, sex, marital status, level of educational
attainment, and symptoms of patients who responded to the different domains of
the WHOQOL and the EQ-5D in full (total patients = 2243)
WHOQOL - number (%) EQ-5D
Physical Psychological Social Environmental Number (%)
All patients 2189 (100%) 2185 (100%) 2170 (100%) 2181 (100%) 2164 (100%)
Sex
Male 1115 (51%) 1113 (51%) 1111 (51%) 1114 (51%) 1104 (51%)
Female 1074 (49%) 1072 (49%) 1059 (49%) 1067 (49%) 1060 (49%)
Age Group
15–24 536 (24%) 536 (25%) 534 (25%) 536 (25%) 527 (24%)
25–34 442 (20%) 442 (20%) 436 (20%) 441 (20%) 437 (20%)
35–44 370 (17%) 369 (17%) 367 (17%) 368 (17%) 360 (17%)
45–54 293 (13%) 293 (13%) 292 (13%) 292 (13%) 294 (14%)
55–64 274 (13%) 273 (12%) 271 (12%) 272 (12%) 273 (13%)
65–74 199 (9%) 197 (9%) 195 (9%) 197 (9%) 200 (9%)
75+ 74 (3%) 74 (3%) 74 (3%) 74 (3%) 72 (3%)
Marital Status∗
Single 255 (12%) 255 (12%) 255 (12%) 255 (12%) 251 (12%)
Other 197 (9%) 196 (9%) 192 (9%) 193 (9%) 196 (9%)
Married 1732 (79%) 1729 (79%) 1718 (79%) 1728 (79%) 1712 (79%)
Symptoms
Fever or Cough 882 (40%) 881 (40%) 875 (40%) 879 (40%) 871 (40%)
Fever and Cough 429 (20%) 429 (20%) 427 (20%) 429 (20%) 423 (20%)
Breathing Difficulties 20 (1%) 20 (1%) 20 (1%) 20 (1%) 20 (1%)
DiB and Fever/Cough 121 (6%) 121 (6%) 117 (5%) 119 (5%) 117 (5%)
DiB, Fever and Cough 170 (8%) 170 (8%) 169 (8%) 169 (8%) 168 (8%)
Chronic Cough 105 (5%) 105 (5%) 105 (5%) 105 (5%) 103 (5%)
C-Cough and Fever 129 (6%) 128 (6%) 127 (6%) 129 (6%) 128 (6%)
C-Cough and DiB 170 (8%) 169 (8%) 169 (8%) 169 (8%) 173 (8%)
C-Cough, DiB,
and Fever 163 (7%) 162 (7%) 161 (7%) 162 (7%) 161 (7%)
Level of Education
No education 1669 (76%) 1665 (76%) 1653 (76%) 1661 (76%) 1654 (76%)
Primary 266 (12%) 266 (12%) 265 (12%) 266 (12%) 261 (12%)
Secondary 215 (10%) 215 (10%) 213 (10%) 215 (10%) 211 (10%)
Tertiary 39 (2%) 39 (2%) 39 (2%) 39 (2%) 38 (2%)
∗Total does not add up due to missing information
patients reported having some problem in the dimensions pain/discomfort (63.3%)
and anxiety/depression (57.3%). Some 16% of the patients reported having severe
problems with pain/discomfort, while less than 3% of the patients indicated having
severe problems in the dimension mobility, and less than 2% reported having severe
problems in the dimension self-care.
Table 3.2 demonstrates the results of the average scores and their standard de-
viation for the different domains of the WHOQOL and EQ-5D by sex, age, marital
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Table 3.2. Mean and standard deviation of the WHOQOL domain scores and the
EQ-5D utility score
Mean ± Standard Deviation
Physical Psychological Social Environmental EQ-5D
All patients 3.12 ± 0.7 3.22 ± 0.6 3.50 ± 0.7 2.95 ± 0.6 0.55 ± 0.3
Sex
Male 3.16 ± 0.7 3.28 ± 0.7 3.55 ± 0.6 3.02 ± 0.6 0.56 ± 0.3
Female 3.08 ± 0.7 3.15 ± 0.6 3.46 ± 0.7 2.88 ± 0.6 0.53 ± 0.3
Age Group
15–24 3.34 ± 0.7 3.44 ± 0.6 3.56 ± 0.7 3.11 ± 0.6 0.63 ± 0.3
25–34 3.22 ± 0.7 3.31 ± 0.6 3.57 ± 0.6 2.95 ± 0.6 0.58 ± 0.3
35–44 3.15 ± 0.7 3.22 ± 0.6 3.54 ± 0.6 2.87 ± 0.6 0.56 ± 0.3
45–54 3.11 ± 0.7 3.12 ± 0.6 3.48 ± 0.7 2.90 ± 0.6 0.54 ± 0.3
55–64 2.94 ± 0.7 3.02 ± 0.7 3.45 ± 0.6 2.90 ± 0.7 0.53 ± 0.3
65–74 2.71 ± 0.7 2.91 ± 0.6 3.28 ± 0.7 2.87 ± 0.6 0.32 ± 0.4
75+ 2.62 ± 0.7 2.95 ± 0.7 3.43 ± 0.6 2.87 ± 0.6 0.37 ± 0.4
Marital Status
Single 3.47 ± 0.6 3.48 ± 0.6 3.50 ± 0.7 3.18 ± 0.6 0.66 ± 0.2
Other 2.70 ± 0.8 2.81 ± 0.7 3.05 ± 0.7 2.77 ± 0.6 0.34 ± 0.4
Married 3.12 ± 0.7 3.23 ± 0.6 3.56 ± 0.6 2.94 ± 0.6 0.55 ± 0.3
Symptoms
Fever or Cough 3.30 ± 0.7 3.40 ± 0.6 3.55 ± 0.6 3.00 ± 0.6 0.62 ± 0.3
Fever and Cough 3.19 ± 0.7 3.25 ± 0.6 3.56 ± 0.7 3.01 ± 0.6 0.55 ± 0.3
Breathing Difficulties 2.90 ± 0.8 3.18 ± 0.6 3.48 ± 0.8 3.08 ± 0.7 0.50 ± 0.4
DiB and Fever/Cough 3.04 ± 0.7 3.11 ± 0.7 3.41 ± 0.7 2.96 ± 0.6 0.54 ± 0.3
DiB, Fever, and Cough 2.90 ± 0.7 2.99 ± 0.7 3.49 ± 0.7 2.86 ± 0.6 0.40 ± 0.4
Chronic Cough 3.32 ± 0.7 3.35 ± 0.6 3.53 ± 0.7 3.00 ± 0.6 0.70 ± 0.2
C-Cough and Fever 3.02 ± 0.8 3.13 ± 0.7 3.44 ± 0.6 2.95 ± 0.6 0.52 ± 0.3
C-Cough and DiB 2.67 ± 0.7 2.86 ± 0.7 3.39 ± 0.7 2.76 ± 0.6 0.41 ± 0.3
C-Cough, DiB,
and Fever 2.71 ± 0.7 2.85 ± 0.6 3.35 ± 0.7 2.80 ± 0.6 0.33 ± 0.4
Level of Education
No education 3.02 ± 0.7 3.13 ± 0.6 3.45 ± 0.7 2.87 ± 0.6 0.51 ± 0.3
Primary 3.37 ± 0.7 3.42 ± 0.6 3.64 ± 0.6 3.15 ± 0.6 0.62 ± 0.3
Secondary 3.50 ± 0.6 3.58 ± 0.6 3.72 ± 0.7 3.28 ± 0.6 0.68 ± 0.2
Tertiary 3.69 ± 0.6 3.62 ± 0.6 3.74 ± 0.6 3.28 ± 0.6 0.67 ± 0.2
∗C-Cough = Chronic Cough; DiB = Breathing Difficulties
status, symptoms, and level of educational attainment. The average score of the
WHOQOL’s domains ranges between 1 (i.e. worst HRQOL) and 5 (best HRQOL).
When looking at the different WHOQOL domains for all patients, we determined a
minimum average score of 2.95 in the environmental domain and a maximum aver-
age score of 3.50 in the social domain. This could indicate that social relations do
not change much when an individual falls sick. Similarly, the mean EQ-5D score
is 0.55 for all patients, with the range of the EQ-5D score lying between –0.59 to 1
(best health).
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Using the results in Table 3.2, we found higher mean scores (between 0.08 and
0.14) among males for all domains, the difference in all domains being statistically
significant with a P-value < 0.001 in the physical, psychological, and environmen-
tal domains, and a P-value < 0.01 in the social domain. The same holds true for
the average EQ-5D score of 0.03, with a P-value < 0.05. As expected, we found a
higher HRQOL level among younger patients with a consistent decline (ANOVA:
P-value < .001) in the mean scores among higher age groups in all WHOQOL do-
mains and in EQ-5D (with the exception of the last age group for psychological,
social domains, and for EQ-5D). The difference between the age groups (0.72) was
highest in the physical domain and lowest (0.24) in the environmental domain. The
largest divergence was at 0.31 in the EQ-5D between the age groups 65–74 and
15–24.
Next, we found higher HRQOL scores among patients who were single, fol-
lowed by those who were married, and by the remainder (widowed, separated, or
divorced) (see Table 3.2) (ANOVA: P-value < 0.001). As expected, patients who
were either widowed, separated or divorced had a lower HRQOL level. However,
as singles are most likely to be of younger age than members of the other groups,
the effect of age must be taken into account before making any inferences. The
largest disparity between married couples, singles, and the remainder was at 0.77
in the WHOQOL’s physical domain and the lowest level of divergence was at 0.41
in the environmental domain. The difference in the EQ-5D score was 0.32.
Regarding the patients’ education, as anticipated, we found that patients with
a higher level of educational attainment also had significantly higher (ANOVA:
P-value < 0.001) mean HRQOL scores in all domains and in the EQ-5D than pa-
tients with lower educational attainment levels. Between the different educational
groups, the highest disparity was at 0.67 in the WHOQOL’s physical domain with
the lowest level of divergence being in the social domain. The difference in the
EQ-5D score was 0.17.
Average HRQOL scores varied significantly (ANOVA: P-value < 0.001) be-
tween patients with different symptoms (individual or combined symptoms). The
disparity in the average HRQOL between patients from different symptom groups
was highest in the WHOQOL’s social and psychological domains (0.55 each), and
lowest in the social domain (0.21). The highest value in all domains was found
among patients who only had either a cough, a chronic cough, or fever. The lowest
value was established predominantly among patients with a chronic cough, fever,
or breathing difficulties. EQ-5D had a similar pattern with a divergence of 0.37 be-
tween patients with only a chronic cough and patients with a chronic cough, fever,
and breathing difficulties. Below we will present the results of the multivariate re-
gression analyses of the HRQOL scores on the different symptoms controlling for
sex, age-group, marital status, and patients’ level of educational attainment. Prior
43
Table 3.3. Spearman’s correlation (r) coefficients between the EQ-5D score and
the average WHOQOL domain scores
Physical Psychological Social Environmental EQ-5D
Physical 1.000 0.544 0.249 0.419 0.533
Psychological 0.544 1.000 0.331 0.503 0.393
Social 0.249 0.331 1.000 0.354 0.146
Environmental 0.419 0.503 0.354 1.000 0.283
EQ-5D 0.533 0.393 0.146 0.283 1.000
to presenting the results of the regression analysis, the results of EQ-5D’s validity
test in the Nepalese context are introduced.
The results (means) presented above point to an association between the aver-
age HRQOL scores in the different WHOQOL domains and the average EQ-5D
utility score. We could consider the above results a face validity of the EQ-5D for
measuring patients’ HRQOL as compared with the WHOQOL’s different domains,
which is considered a valid HRQOL measure in the Nepalese context (as described
earlier). Furthermore, the direction of change in the average EQ-5D utility score
is the same as the average WHOQOL domain scores in nearly all cases. In Ta-
ble 3.3, we present the results of the verification of EQ-5D’s construct validity with
reference to the WHOQOL’s different domains by estimating the correlation coef-
ficients as being located between the average EQ-5D utility score and the average
WHOQOL domain scores.
Based on the the results presented in Table 3.3, we determined that the EQ-5D
score has the highest degree of correlation with the physical domain of the WHO-
QOL (r = 0.533) and the lowest degree of correlation with the WHOQOL’s social
domain (r = 0.146). As stated earlier, the quantitative significance of the corre-
lation coefficient is based on Burnand et al.’s recommendation [17], therefore, the
association of EQ-5D scores with the WHOQOL’s social and environmental dimen-
sion (r = 0.283) is considered insignificant. While the degree of association with
the WHOQOL’s psychological domain (r = 0.393) is considered to be moderate,
the association with the physical domain is regarded as being substantial. These
results are as expected; as mentioned earlier, the EQ-5D dimensions are mostly
related to physical health (four questions out of five in the EQ-5D) and one is re-
lated to the WHOQOL’s psychological domain. Hence, we consider the EQ-5D
to be a valid instrument for measuring the HRQOL of Nepalese patients with lung
diseases, and proceed to the next step of describing the HRQOL in patients with
respiratory symptoms, using the EQ-5D and WHOQOL. We acknowledge that the
statement on validity would be stronger if the values of r were higher.
After having accepted EQ-5D as a valid tool to measure HRQOL, the next task
was to describe the variation in HRQOL impairment as measured by the EQ-5D and
the different domains of the WHOQOL with respect to respiratory symptoms and
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Table 3.4. Multivariate regression model describing EQ-5D and four dimensions
of the WHOQOL by symptoms, age, sex, marital status, and level of education
Regression coefficients (P-values) of EQ-5D utility scores on variables
EQ-5D Physical Psychological Social Environmental
Constant 0.75 (0.000) 3.51 (0.000) 3.54 (0.000) 3.40 (0.000) 2.90 (0.000)
Breathing Difficulties –0.16 (0.000) –0.29 (0.000) –0.26 (0.000) –0.07 (0.031) –0.11 (0.000)
Fever –0.12 (0.000) –0.12 (0.000) –0.08 (0.009) – –
Chronic Cough –0.03 (0.058) –0.14 (0.000) –0.12 (0.000) – –
Age Groups (10-year) –0.02 (0.000) –0.04 (0.000) –0.04 (0.000) – –
Sex (female) –0.03 (0.091) – –0.10 (0.000) – –
Married – –0.13 (0.013) – 0.13 (0.006) –
Divorced/Widowed/
Separated –0.13 (0.000) –0.36 (0.000) –0.21 (0.000) –0.32 (0.000) –
At Least Secondary
Education 0.09 (0.000) 0.33 (0.000) 0.29 (0.000) 0.25 (0.000) 0.40 (0.000)
Primary Education 0.05 (0.018) 0.23 (0.000) 0.16 (0.000) 0.16 (0.000) 0.27 (0.000)
R-Square 0.127 0.14 0.14 0.057 0.055
various demographic and socio-economic variables. We performed multivariate re-
gression analyses of different WHOQOL domains and EQ-5D scores on symptoms,
controlling for age, sex, level of educational attainment, and marital status. We built
on the notion of symptoms as independent variables in the regression model. Other
variables were gradually introduced and only those which were statistically signif-
icant (P-value < 0.10) were included in the final model. The results of the final
model are presented in Table 3.4.
The results of the regression analysis show that for all health-related quality of
life measurements compared to the results of the patient group with non-chronic
coughs (reference group), breathing difficulties reduced the HRQOL scores signif-
icantly compared to fever and chronic cough. For example, breathing difficulties
reduce the EQ-5D’s utility score (range: –0.59 to 1) by –0.16, which can be con-
sidered significant. We also found that patients with a higher level of educational
attainment had better HRQOL levels than patients with lower levels of education.
The advantage of having at least a secondary education was higher in all HRQOL
measurements than having only a primary level education. The HRQOL scores for
the EQ-5D and for the physical, psychological, and social domains of the WHO-
QOL were lower for patients who were either separated, divorced, or widowed. The
patients’ sex did not affect the HRQOL score except in the WHOQOL’s psycholog-
ical domain, where females demonstrated a slightly lower HRQOL. Older people
generally had lower levels of HRQOL. However, the effect of age is not evident
in the case of the WHOQOL’s social and environmental domains. Marital status
also did not influence the HRQOL scores in the environmental domain, but was the
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most significant factor in the social domain. The effect of breathing difficulties was
also smaller in these two dimensions.
In Table 3.5 we present the results of a similar exercise with the dependent
variable being the change in HRQOL score between the first visit to the health care
facility and the follow-up for the two groups of patients, i.e. patients with a chronic
cough who were followed-up after 2 months, and patients without a chronic cough
who were followed-up after 2 weeks.
Among the patients who were followed-up 2 weeks after the initial interview
(shown in the first block in Table 3.5), breathing difficulties, age, and patients’
marital status (being separated/divorced/widowed) were found to be significant ex-
planatory covariates of variation in the change in EQ-5D score. In the WHOQOL
domains, the variations in the change in the physical and psychological domains
were explained by breathing difficulties, age, and sex (being female), in addition
to the cough in the psychological domain. Similarly, the change in HRQOL score
in the WHOQOL’s social dimension depended on marital status only (being sepa-
rated/divorced/widowed), and for the environmental domain, age was the only ex-
planatory variable. The associations between the explanatory variables and depen-
dent variables were negative as indicated by the negative values of the regression
coefficients.
Among the patients with a chronic cough (second block in Table 3.5), breathing
difficulties and age were explanatory variables for the change in HRQOL scores as
measured by the EQ-5D, and the physical and psychological domains of the WHO-
QOL. Moreover, we found that being married was an explanatory variable (with
a positive association) for the change in the HRQOL score in the WHOQOL’s so-
cial domain. Finally, in the environmental domain, breathing difficulties, fever, and
level of educational attainment (with a minimum of secondary education indicating
a positive association) were found to be explanatory variables. All the associations
are negative, except where indicated otherwise.
Among all patients, the initial HRQOL score affects the change in the HRQOL
score with a higher degree of change among patients with lower levels of initial
HRQOL scores, as indicated by negative coefficients. To explain the coefficients,
let us consider a married male patient, aged 40, with secondary education, who
has breathing difficulties accompanied by a fever (no cough), and with an initial
EQ-5D score of 0.65. For comparative purposes, a second patient with similar
attributes has an initial EQ-5D score of 0.50. Both patients visit one of the study
facilities. Since neither has a chronic cough, our regression model can predict the
EQ-5D score of the patients after two weeks, using the coefficients from the first
block. For the patient with the 0.65 EQ-5D score, the predicted increase in his/her
HRQOL in two weeks is 0.18, while it is 0.29 for the second patient. The overall
picture based on Table 3.5 indicates that it is much more difficult for older patients
who have breathing difficulties to recover.
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Table 3.5. Multivariate regression model explaining the change in EQ-5D and in
the four dimensions of the WHOQOL with reference to symptoms, health care
facility type, age, sex, marital status, and level of education
Regression coefficients (P-values) of Change in EQ-5D utility score
and in the WHOQOL domains on variables
EQ-5D Physical Psychological Social Environmental
Without Chronic Cough (follow-up in 2 months)
Constant 0.84 (0.000) 3.31 (0.000) 2.27 (0.000) 2.38 (0.000) 1.76 (0.000)
Initial HRQOL –0.76 (0.000) –0.80 (0.000) –0.64 (0.000) –0.63 (0.000) –0.51 (0.000)
Breathing Difficulties –0.08 (0.000) –0.24 (0.000) –0.09 (0.073) – –
Cough – – 0.20 (0.087) – –
Age Group (5-year) –0.03 (0.000) –0.10 (0.000) –0.05 (0.000) –0.02 (0.124) –0.03 (0.006)
Sex – –0.13 (0.019) –0.09 (0.036) – –
Separated/Divorced/
Widowed –0.10 (0.011) – – –0.35 (0.000) –
R-Square 0.56 0.45 0.36 0.37 0.29
With Chronic Cough (follow-up in 2 months)
Constant 0.83 (0.000) 3.34 (0.000) 3.00 (0.000) 2.05 (0.000) 2.16 (0.000)
Initial HRQOL –0.77 (0.000) –0.80 (0.000) –0.79 (0.000) –0.65 (0.000) –0.65 (0.000)
Breathing Difficulties –0.04 (0.169) –0.14 (0.051) –0.09 (0.175) – –0.12 (0.052)
Fever – – – – –0.13 (0.022)
Age Group (5-year) –0.05 (0.000) –0.15 (0.000) –0.09 (0.000) – –
Married – – – 0.24 (0.000) –
At least Secondary
Education – – – – 0.24 (0.041)
R-Square 0.44 0.42 0.39 0.34 0.33
3.5 Discussion
In this chapter we presented the results on the health-related quality of life of indi-
vidual patients with respiratory symptoms at the time of their visit to a health care
facility, as well as at the time following their approximated recovery period. We
analyzed and explained the variations in the HRQOL by key socio-demographic
factors, as well as by different respiratory symptoms. We found that breathing dif-
ficulties are the most significant respiratory symptom that reduces patients’ health-
related quality of life considerably. Fever and a chronic cough also contribute to
the reduction of a patient’s HRQOL, however, to a lesser extent than breathing dif-
ficulties. We determined that younger patients have better HRQOLs; patients with
higher levels of educational attainment also have better HRQOLs; while patients
who are either separated, divorced, or widowed have lower HRQOL levels. Sex
was found to have an insignificant effect on the level of HRQOL.
It is crucial to test the validity of a measurement instrument in a new con-
text. Since we considered the WHOQOL as being a valid instrument to measure
HRQOL in the South Asia region, we tested the validity of the EQ-5D scores with
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regard to different WHOQOL domains. We have already shown that EQ-5D scores
are extensively associated with the WHOQOL’s physical domain and only moder-
ately with its psychological domain. We did not discover a significant association
between EQ-5D scores with the social and environmental domains of the WHO-
QOL. Based on these results, we concluded that the EQ-5D is a valid instrument
to measure the HRQOL among Nepalese patients, and that the description above
of the HRQOL of patients with respiratory symptoms in Nepal to be valid. In the
next section, we will discuss these results with regard to each studied explanatory
variable.
The symptom breathing difficulties was identified in approximately 30% of the
patients included in our study. Breathing difficulties are a common symptom during
exacerbations in patients with asthma and chronic obstructive pulmonary disease.
In many cases of exacerbation, urgent health care is required, since the patient’s
health deteriorates quite rapidly. For this reason, patients’ HRQOL is generally
lowest during episodes of exacerbations. Associating exacerbations with breath-
ing difficulties may explain the higher impact of this symptom on the reduction of
patients’ HRQOL. Table 3.5 shows that patients with breathing difficulties had sig-
nificantly lower HRQOL scores even after the approximate recovery period. There
might be two explanations for this: first, patients with breathing difficulties have
longer recovery periods, indicating the symptom’s longer-lasting impact on the pa-
tient’s health. Alternatively, these patients could be individuals who suffer from
asthma or chronic obstructive pulmonary disease, and due to the chronic nature of
these diseases, the affected patients have lower levels of HRQOL than the general
population. As a period of two weeks (in cases of non-chronic coughs) and two
months (in the case of a chronic cough) is a sufficient recovery period, the second
explanation seems more plausible.
Next, we found age to be an important factor, a well-known fact in HRQOL
studies in general. We did not find a significant effect of sex on patients’ level of
HRQOL. The most important demographic factor affecting the HRQOL level (in
the EQ-5D model) was found to be the patient’s marital status. Single and married
patients had a higher level of HRQOL compared to those who were separated, di-
vorced, or widowed. The results are based on a regression model including age,
gender, marital status, level of educational attainment, and symptom(s). The ex-
planation, therefore, lies mainly in the social and situational consequence of being
‘single’ (following the death of a spouse or a separation or divorce) within the
patient’s context. Among this group of patients, most are widowed (86%), older
(mean age around 60 years), and primarily female (close to 75%). That is, the
patients in this group are mostly dependent on their children and have very little
income of their own (especially the women), since most of the people in the re-
gion are farmers. The economic situation is better for men in this group than for
women, however, men who have lost their wife are more likely to receive lower
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quality of care at home than they did prior to their wife’s death. Hence, loneliness
and poverty may also lead to a lower HRQOL level in general, a level that may
reduce even more during illness.
Another important factor we found is the positive effect of a higher level of
educational attainment on patients’ HRQOL. Our results indicate that patients with
a higher educational level also have higher levels of HRQOL. Education here can
be seen as a proxy for socio-economic status. In a rural community people with a
higher education have a higher social status, as they are more likely to have been
born into a higher class/caste. In rural Nepalese villages education is usually fol-
lowed by good fortune rather than the other way around. In any case, people with
a higher educational level can make informed decisions quicker than those who are
uneducated. In particular, more educated people are more likely to choose the best
opportunities available to them and subsequently prefer to visit modern health care
facilities over the traditional ones.
Our study has some limitations. These are mostly related to the first time appli-
cation of the HRQOL questionnaire in the Nepalese context. Both the WHOQOL
and EQ-5D were used in a study in Nepal for the first time. We took the validity
of the WHOQOL to measure the HRQOL of Nepalese patients for granted, based
on the verification of validity of the WHOQOL in the Indian context. Though the
socio-cultural situations in India and Nepal are similar, our study would have been
reinforced had we validated the WHOQOL in the Nepalese context as prescribed
by the WHOQOL group. However, it was not within the scope of the PAL re-
search study to carry out the WHOQOL’s validity and hence, we acknowledge it as
a weakness of our study.
Secondly, we also acknowledge a similar caveat in the calculation of the EQ-
5D score where we used the utility score as defined for the UK’s population. Due
to the sizable difference between Nepal and the UK in terms of value-system and
utilities, the loss of utility attached to various levels of disability might significantly
differ. At the onset of our study, we searched for a community with an already es-
tablished EQ-5D utility score that was geographically closer to Nepal than the UK.
We found Japan to be the closest match, and in terms of Japan being an Asian coun-
try, we could have used Japan’s utility score. However, after careful consideration
of the differences between the two countries’ value-systems and the different levels
of socio-economic development, Japan was found to not be a more suitable alterna-
tive. The main reason for choosing the UK’s utility measurements over Japan’s was
that the EQ-5D was initially developed in the UK and holds greater credibility in
terms of quality and diligence in the research to estimate the utility measurements.
The limitation of our study is the lack of an objective generic measurement
of health in at least an ordinal scale, to facilitate the validity of the EQ-5D other
than using the WHOQOL. The nature of the PAL guidelines, which limited us
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to mostly recording the symptoms of patients, and the limitation of available re-
sources in terms of manpower (i.e. more trained health care professionals) and
medical equipment at the interview location compelled us to include such objective
measurements. Finally, the data on the HRQOL was not available for the general
population, which limited us from making any inference regarding the patients’
HRQOL relative to the general population’s.
We end this chapter with a recommendation for future research; additional
studies to validate generic health-related quality of life questionnaires, as well as
disease-specific HRQOL in Nepal should be conducted. Since many such question-
naires already exist, we recommend choosing those which are proven most suitable
in other countries and to carry out the validity of these questionnaires for future
use, especially for economic evaluations.
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4
Practical Approach to Lung Health in
Nepal: Improving Prescription Behavior
and Reducing Costs
This chapter assesses the impact of the Practical Approach to Lung Health (PAL)
guidelines in terms of prescription behavior and the total costs of prescriptions for
patients with asthma, chronic obstructive pulmonary disease, and pneumonia.
The study is a pre-post intervention comparison in a cluster-randomized trial
of primary health care facilities. Forty health care facilities (7 health posts and
33 sub-health posts) in Nepal were stratified by type and subsequently randomized
into intervention and control groups. Health care providers from the intervention
facilities participated in a five-day training program to familiarize themselves with
the adapted PAL guidelines and to learn how to apply them. Carbon-copy pre-
scription pads were used to collect prescription details from both groups. Two
sets of indicators were applied to measure the PAL guidelines’ impact in a multi-
variate regression analysis: the World Health Organization’s rational-use-of-drug
indicators and drug cost indicators.
The PAL guidelines were linked to a reduction in poly-pharmacy and to an
increase in the prescription of generic drugs, as well as prescriptions from the
essential drug list. The PAL guidelines were also associated with a decrease in
the average prescription and wastage costs for the diseases under consideration
here, except for COPD; however, these correlations were not statistically signif-
icant. Similarly, the PAL guidelines’ effect was also linked to an increase in the
prescription of antibiotics and adherence to the prescription guidelines, though it
was statistically insignificant.
There is evidence that the PAL guidelines’ implementation is effective in pro-
moting the rational use of drugs for certain respiratory diseases. Furthermore, a
cost-effectiveness analysis should be carried out to compare the PAL guidelines’ ex-
pected health effects with the actual implementation costs before continuing similar
forms of lung health training. In addition, the development of further managerial
strategies to guarantee the guidelines’ sustainability is encouraged.
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4.1 Introduction
Increasing drug costs are a burden for many health care delivery systems in both
developed and developing countries. Only operational costs, such as the salaries of
health care providers, are higher than the expenditure on drugs, a significant impact
on the already scarce resources [1]. Drug costs could be reduced if the prescrip-
tion behavior of health care workers improved. The non-rational prescription of
drugs promotes multi-drug resistance [2] and was estimated to increase drug costs
by 33% in India [3] and by 20–52% in rural Nepal [4]. Increasing drug prescription
costs influences patients’ purchasing decisions where out-of-pocket costs are com-
mon [5]. Various educational, managerial, as well as financial strategies have been
introduced to alter the prescription behavior of health care providers in developing
countries [6], including Nepal [7, 8], to promote ‘value for money’ in the health
sector. Providing training on the standard treatment guidelines (STG) is one of the
educational strategies being implemented in many countries to reduce non-rational
prescription behavior.
Nepal is one of the poorest countries in the world and spends 5.4% of its gross
domestic product (GDP) on health. Of this, only 23.5% is financed by the public
sector with the private sector, and especially consumers financing the rest on their
own (i.e. 72.4% is paid out-of-pocket) [9]. Thus, rising drug costs directly affect
patients’ decisions to purchase drugs, which ultimately influences access to health
care.
Based on encouraging experiences with the Integrated Management of Child-
hood Illness program (IMCI), the World Health Organization (WHO) recently de-
veloped generic clinical practice guidelines to improve the management of respi-
ratory diseases in adults, the Practical Approach to Lung Health (PAL) [10]. In
Nepal, the Ministry of Health (MoH) introduced the generic PAL guidelines in one
district, adapting them to the national setting [11]. Primary health care providers
from select pilot health facilities were trained in applying the PAL guidelines. One
of the aims of the PAL guidelines’ implementation is to enhance efficient prescrip-
tion behavior and to thus promote rational drug use for certain respiratory diseases.
This chapter assesses the impact of the PAL guidelines on prescription behavior
and prescription costs of PAL-targeted diseases, i.e. asthma, chronic obstructive
pulmonary disease (COPD), and pneumonia.
4.2 Methods and Materials
4.2.1 Design
This study was part of the international pre-post evaluation program “Assessing the
cost effectiveness of integrated respiratory care guidelines in Nepal” [12] which in-
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cluded a stratified cluster randomized trial [13] in the Nepalese lowland district of
Nawalparasi. The Nawalparasi district was selected because it met two prerequi-
sites for launching a pilot PAL program, namely a district in which both IMCI and
DOTS is implemented. The program included both locally adapted guidelines and
subsequent training.
Health care facilities
Of the 76 health care facilities in the Nawalparasi district, 40 were included in our
study based on highest patient turnout. The selected health care facilities included
7 health posts (HPs) and 33 sub-health posts (SHPs). These 40 facilities were strat-
ified by type and subsequently randomized into PAL intervention (21) and standard
practice control (19) groups. Both groups received a copy of the Standard Treat-
ment Schedule (STS) [14] prior to the PAL intervention. Each health care facility
in both groups employed a Community Drug Program (CDP) to ensure the avail-
ability of drugs throughout the year, and had received CDP training prior to the
program’s implementation. Rational drug prescription is one of the components of
CDP training [15].
Description of the intervention
The WHO’s generic PAL guidelines were developed in an international context
[16]. To complement its successful tuberculosis control program, Nepal was se-
lected as one of the countries that would benefit from the implementation of the
PAL guidelines. The implementation involved a number of steps. First, the generic
guidelines were adapted to the national Nepalese setting. Together with the Na-
tional Tuberculosis Centre (NTC), the WHO took the initiative to facilitate the
adaptation of the guidelines and the implementation process. Several professionals
and different organizations, along with health care providers from a pilot project
being carried out in a Nepalese district participated in the process and reached a
consensus on the content of the PAL-Nepal guidelines [17]. The guidelines target
health care workers at HPs and SHPs and follow the same format as the IMCI first-
level facility guidelines. Secondly, the NTC developed training materials and con-
ducted the training of health care providers from the selected intervention facilities
on the application of PAL-Nepal guidelines. At least one health care provider from
each facility participated in the training. The NTC organized a training of trainers
(ToT) with the assistance of WHO consultants in June 2002. Respiratory physi-
cians, trainers from the District Health Office (DHO) and the NTC participated
in the ToT. The five-day training program of health care workers was conducted
at the district level in July/August 2002, with the support of the ToT participants.
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Trainings were conducted in three small groups at the local hospital. Thirdly, fol-
lowing the completion of the training program, NTC supplied all PAL intervention
facilities with examination formats and wall posters.
4.2.2 Indicators and Coding
Indicators
We used the WHO’s Rational-Use-of-Drugs (RUD) indicators [18] to measure the
prescription behavior of health care providers in both groups before and after the
PAL intervention. These include the average number of drugs prescribed per pa-
tient encounter, prescription of generic drugs (in %), prescription of drugs from the
Essential Drug List (EDL) (in %) [19], prescription of an antibiotic (in %), and
adherence to the prescription guidelines (in %). We used three types of cost in-
dicators, i.e. expected costs, actual costs, and wastage costs, to assess the impact
of the PAL guidelines on overall prescription costs. We were not able to calculate
the costs for a full course of treatment because the available information on pre-
scriptions was incomplete. Instead, we calculated the drug costs on the basis of the
Defined Daily Doses (DDD) for solid oral preparations. For liquid oral and topical
preparations we used the unit costs of the product available in the local setting. Ac-
tual costs were calculated as the unit price of drugs prescribed, multiplied by each
drug’s DDD. Expected costs were calculated as the unit price of drugs for a par-
ticular disease as recommended by the PAL guidelines and multiplied by the DDD
of the proposed drugs. Wastage costs were calculated by subtracting the expected
costs from the actual costs.
Carbon-Copy Prescription Pads (CCPPs) were used to collect information on
prescription patterns. Many studies on drug use apply this method of data collec-
tion since its format does not differ from existing prescription pads, except for the
additional carbon-copy sheet. CCPPs had been in use in the 40 Nawalparasi pilot
facilities since the beginning of 2002, with the approval of the MoH. A one-day ori-
entation program for health care providers was organized prior to the introduction
of the CCPPs to explain their purpose and demonstrate their use. Field assistants
distributed and collected the CCPPs, including the prescription data. We collected
all disease-specific prescriptions made at each facility during each phase of the
study from February to May 2002, prior to the implementation of the PAL (base-
line) guidelines. Similarly, to assess post-intervention prescription behavior, we
collected all disease-specific prescriptions made at each facility during every phase
of the study from October 2002 to January 2003. The total number of prescriptions
(407) by groups is illustrated in Figure 4.1. In addition, field assistants collected
the individual drug prices at local health care facilities, as well as from nearby drug
retailers between July and October 2003.
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19 control group 21 intervention group
Stratification and randomisation of 40 health facilities 
Pre
84 prescriptions 
Post
67 prescriptions
PAL diseases
Asthma = 47
COPD = 35
Pneumonia = 2
PAL diseases
Asthma = 32
COPD = 29
Pneumonia = 6
PAL diseases
Asthma = 122
COPD = 24
Pneumonia = 9
PAL diseases
Asthma = 35
COPD = 15
Pneumonia = 51
Pre
155 prescriptions 
Post
101 prescriptions 
Figure 4.1. Number of prescriptions stratified by study group and diseases.
Coding
For the comparison to be feasible, we used two sets of disease-specific indicators
to determine appropriate prescription behavior: one set for selected lung diseases
that were to be treated according to the PAL-Nepal guidelines within the PAL in-
tervention group, and one set for selected lung diseases to be treated according to
the STS guidelines [14] in a standard practice control group. In the PAL interven-
tion group, asthma was coded as having been correctly treated when it was treated
according to the PAL guidelines, i.e. when the health care provider prescribed
salbutamol tablets or an inhaler; COPD was coded as having been correctly treated
when the health care worker prescribed either salbutamol tablets or an inhaler; and
pneumonia was coded as correctly having been treated when either cotrimoxazole,
amoxicillin, chloramphenicol, or penicillin VK with or without paracetamol was
prescribed. Similarly, in the standard practice control group, asthma was coded as
having been correctly treated when it was treated according to the STS guidelines,
i.e. when the health care provider prescribed salbutamol or aminophylline tablets;
COPD was correctly treated if the health care worker prescribed salbutamol or
aminophylline tablets; and pneumonia when cotrimoxazole or amoxicillin with or
without paracetamol was prescribed. Treatment was only classified as being ap-
propriate if the health care provider had prescribed the correct drug in accordance
with the PAL or STS guidelines. We coded all diseases into one aggregate group,
since our aim was to measure and evaluate whether the PAL guidelines promote
rational drug prescription for lung disease in general. Using regression analysis,
we accounted for the low number of prescriptions for individual diseases.
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4.2.3 Data Analysis
Data were entered using the software SPSS-Data Entry 3.0, SPSS, Inc. and ana-
lyzed using SPSS 11.0, SPSS Inc., and STATA 8.2, Stata Corp. The median price
per unit for each drug was calculated by pooling the price of the particular drug
at different health care facilities and retailers, and by pooling together the price of
the drug under its traded and its generic name. Separate prices were calculated for
different modes of administration. To compute the total drug costs for the entire
prescription dataset, the costs datasets were merged using a unique identifier for
each combination of a drug’s generic name drug and its mode of administration.
We used multiple linear regression models to explain the variation in each of the
outcome variables, namely the total costs of a prescription, total number of drugs
prescribed for each prescription, number of drugs prescribed from the essential
drugs list per prescription, and the number of generic drugs prescribed for each
prescription [20, 21]. We grouped the prescriptions by time period (pre- and post-
intervention), PAL facility status (PAL facility and non-PAL or control facility),
and existence of an intervention (PAL post-intervention). We used the pre- and
post-independent variable labeled ‘Non-PAL’ and ‘PAL’ to measure the changes in
relation to time trends. Next, we used the ‘PAL post’ parameter to measure the real
changes attributable to the PAL intervention, hence controlling for a secular trend.
In all regression analyses, we also controlled for other variables such as health care
facility level (HP and SHP), diagnosis, i.e. asthma, COPD, and pneumonia, as well
as for patient characteristics (age and sex). The distribution of total costs was found
to be skewed, and, therefore, a log-transformation on the total costs was used in the
regression model, as is common in cost studies. In total, we dropped three extreme
observations as outliers, which were possibly a result of an error in data entry.
In a second regression analysis, we calculated the odds of prescription guideline
adherence (as a yes/no criterion) and prescription of antibiotics (also as a yes/no
criterion) using logistic regression. The independent variables used in the model
were the same as in the multiple linear regression models. To account for clustering
of patients visiting a specific health care facility, we used the random-effect model
Huber-White, a solid method for calculating standard errors in cluster effects, as
part of the STATA 8.2 version [21, 22].
4.3 Results
4.3.1 Patients’ Characteristics
There was a slightly higher percentage of male patients in both groups throughout
the different phases of data collection. The median age of patients was similar
in both the control and intervention groups (during the pre- and post-intervention
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Table 4.1. Age and sex distribution of patients
Control Intervention
Prescriptions Pre Post Pre Post
Male (%) 49 (58.3) 41 (61.2) 88 (56.8) 55 (54.5)
Female (%) 35 (41.7) 26 (38.8) 67 (43.2) 46 (45.5)
Median age (IQR) 60 (49–65) 60 (41–70) 60 (45–69) 52 (34–62)
IQR = Inter-Quartile Range
period); the median age was slightly lower for the intervention group during the
post-intervention period (see Table 4.1).
4.3.2 Prescription Behavior and Prescription Costs
We calculated the mean and standard deviations of the specific indicators for ratio-
nal prescription behavior (Table 4.2). The average number of drugs per prescription
increased in both groups following the PAL intervention, but was far more evident
in the control group. The pre-post difference with reference to generic drug pre-
scriptions increased in both groups, but was slightly higher for the control group.
The percentage of drugs prescribed from the EDL declined in the control group
but increased in the intervention group. The percentage of prescriptions including
at least one antibiotic per patient encounter increased in both groups, whereas the
percentage of patient encounters indicating prescription guideline adherence de-
creased in the control group. Concomitantly, the aggregate average and aggregate
wastage costs for all lung diseases combined increased in both groups.
In the PAL intervention group a shift in diagnoses toward more pneumonia
cases and fewer chronic lung diseases was apparent. As such a shift was not
observed in the control group, it could be attributable to the PAL intervention.
Changes in absolute turnout were not analyzed, since they are subject to a number
of influences both at the district and local levels, e.g. seasonal changes, availability
of health care staff and of drugs. All these influences were accounted for in the
randomization process.
We used a linear regression to examine the PAL guidelines’ effect and to control
for a variation in case-mix, patients’ characteristics, as well as facility features.
Table 4.3 presents a summary of the linear regression models by different outcome
parameters for prescription behavior and prescription costs. The PAL guidelines
were particularly effective in reducing the average number of drugs prescribed per
prescription at PAL facilities, by six drugs for every 10 prescriptions. Generic
drug prescription and the prescription of drugs from the EDL also increased by 6%
and 10%, respectively, but this effect was not statistically significant. The average
amount of drug prescriptions reduced by 34% and wastage costs per prescription
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Table 4.2. Pre-post and intervention-control values of selected indicators for all diseases, expressed in mean (standard devia-
tions)
Percentage Percentage Percentage
of drugs of at least one of encounters Wastage
Percentage prescribed from prescribed indicating Cost per cost per
Pre-Post Drugs per of generic the Essential antibiotic adherence prescription prescription
Indicators prescriptions (n) prescriptions prescriptions Drug List per encounter to guidelines (NRs.)∗ (NRs.)∗
Control Pre (84) 2.56 ± 1.13 51.3 ± 35.9 71.3 ± 26.2 42.9 ± 49.5 21.4 ± 41.3 11.2 ± 16.0 9.8 ± 16.1
Post (67) 3.10 ± 1.22 56.3 ± 31.8 62.4 ± 28.8 62.7 ± 48.7 11.9 ± 32.7 17.0 ± 18.1 15.4 ± 18.2
a. Pre-Post
change 0.54 5.0 –8.9 19.8 –9.5 5.8 5.6
Intervention Pre (155) 2.52 ± 0.98 55.8 ± 31.5 64.1 ± 27.5 41.9 ± 49.5 14.8 ± 35.7 8.41 ± 11.4 6.94 ± 11.4
Post (101) 2.58 ± 0.97 56.8 ± 38.9 69.1 ± 28.5 66.3 ± 47.5 19.8 ± 40.0 17.9 ± 26.9 15.2 ± 27.0
b. Pre-Post
change 0.06 0.06 1.0 5.0 24.4 5.0 9.5 8.3
Relative
change (a–b) –0.48 –4.0 13.9 4.6 14.5 3.7 2.7
∗US$ 1 = NPR 75.
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Table 4.3. Linear regression models for indicators of rational prescription behavior
and beta coefficients (standard error) for various explanatory parameters†
Percentage
of drug Wastage
Percentage prescriptions Cost per cost per
Drugs per of generic from Essential prescription∗∗∗ prescription
prescription prescriptions Drug List (NPR) (NPR)
Indicators (n = 407) (n = 407) (n = 407) (n = 407) (n = 407)
Constant 2.69 (0.3) 38.15 (7.6) 78.21 (8.6) 2.09 (0.3) 5.92 (3.6)
Post vs. Pre 0.45 (0.2)∗ 6.79 (7.5) –6.98 (4.6) 0.51 (0.3) 4.63 (3.6)
PAL vs. Non-PAL 0.1 (0.2) 3.36 (7.1) –7.64 (4.6) 0.11 (0.2) –0.93 (2.9)
PAL post –0.65 (0.2)∗∗ 6.22 (9.4) 9.89 (6.0) –0.41 (0.3) –2.46 (4.1)
Asthma –0.58 (0.2)∗∗ 7.32 (4.5) 1.69 (4.0) –0.94 (0.2)∗∗ –4.34 (2.8)
COPD Dropped Dropped Dropped –0.34 (0.2) 2.49 (3.0)
Pneumonia –0.07 (0.2) –17.24 (6.1)∗∗ 9.07 (6.4) Dropped Dropped
Health care
facility level 0.3 (0.2) –0.9 (6.6) –10.99 (2.9)∗∗ 0.34 (0.2) 4.47 (3.1)
Age 0.004 (0.003) 0.15 (0.1) –0.1 (0.1) 0.002 (0.003) 0.08 (0.1)
Gender –0.2 (0.1) 2.6 (3.6) –0.18 (0.1) –0.09 (0.1) –1.13 (1.8)
R2 11% 7.5% 6% 15.92% 9.2%
†Selected indicators = constant + b1 (post) + b2 (PAL) + b3 (PAL Post) + b4 (Asthma) + b5 (COPD) +
B6 (Pneumonia) + b7 (Health Post) + b8 (Age) + b9 (male) + residual error. Between brackets: Huber-
White robust standard error accounting for potential cluster-effects (Williams, 2000; Ukoumunne et
al., 1999).
∗P-value = < 0.05;∗∗P-value = < 0.01;∗∗∗Log transforms
fell by NPR 2.46 (US$ 1 = NPR 73.15), but these findings were also not statistically
significant.
We performed another logistic regression for two specific indicators to examine
prescriptions including antibiotics and adherence to the prescription guidelines, and
to control for variation in the case-mix, patients’ characteristics, as well as health
care facility level. Table 4.4 indicates the summary of the logistic regression model.
We determined a low odd ratio1 in the prescription of antibiotics and a high odd
ratio in the adherence to prescription guidelines (2.29)2 as an effect attributable to
the PAL guidelines, but these findings were not statistically significant.
4.4 Discussion
There is evidence that implementation of the PAL guidelines is effective in pro-
moting the rational use of drugs for select respiratory diseases. The PAL guidelines
1Calculated as: e−1.0 = 0.37
2Calculated as e−0.83 = 2.29
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Table 4.4. Logistic regression model for specific bi-nominal indicators for rational
prescription behavior and beta-coefficients (standard error) for various explanatory
parameters
Antibiotics per encounter Adherence to guidelines
(n = 407) (n = 407)
Constant 0.33 (0.42) –1.68 (0.62)
Pre vs. Post 0.72 (0.45) –0.72 (0.43)
PAL vs. Non-PAL 0.14 (0.41) –0.63 (0.44)
PAL Post –1.00 (0.67) 0.83 (0.64)
Asthma –1.00 (0.48)∗ 0.67 (0.49)
COPD Dropped∗∗∗ Dropped∗∗∗
Pneumonia 3.31 (0.95)∗∗ 1.2 (0.6)∗
Health care facility level –0.01 (0.19) –0.19 (0.39)
Sex –0.2 (0.29) –0.03 (0.39)
R2 19.33% 19.2%
∗P-value = < 0.05; ∗∗P-value = < 0.01; ∗∗∗Due to co-linearity
Between brackets: Huber-White robust standard error accounting for cluster-effects (Williams, 2000;
Ukoumunne et al., 1999).
were associated with a reduction in poly-pharmacy, as well as an increase in the pre-
scription of generic drugs and drugs from the EDL. The PAL guidelines were also
linked to a decrease in average prescription and wastage costs, although these links
were not statistically significant. Similarly, there is a positive but not significant
effect of the PAL guidelines on the prescription of antibiotics and the adherence
to prescription guidelines. The fact that only one outcome variable, out of seven
being regressed, was found to be statistically significant might raise the suspicion
that the significance occurred by chance. However, the high level of significance
of the P-value of less than 1% can be taken as a strong reason for stating such a
chance is very unlikely.
The study reveals an increase in the number of drug prescriptions over time.
This may be the result of the community drugs program that was introduced in 2000
to ensure year-round availability of essential drugs. The program may also have led
to some supplier-induced demand, since health care providers can prescribe more
(yet unnecessary) drugs to increase drug revenues at the health care facilities.
Health care workers’ adherence to drug prescription guidelines was very low,
around 10–20%. The reason for this result may have been that the study selection
criteria only included patients in which one particular disease had been diagnosed,
although in reality patients may have suffered from a comorbid condition which
required the prescription of other drugs. This reduced the number of prescriptions
that indicated an adherence to the prescription guidelines.
Our study has several limitations. First, the monitoring of health care providers
by field assistants and the use of CCPPs may have influenced their prescription
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behavior. Secondly, the number of overlooked cases may have been high if the
health care provider did not mention the diagnosis or syndrome in the patients’
prescriptions. Third, drug prescription costs were calculated based on DDD and
not on actual costs. Actual costs may differ from our result on drug prescription
costs if the prescribed dosage is different from the DDD. Fourth, because of a low
patient inclusion in our study, drug prescription patterns were not analyzed with
reference to conditions, and important disease-specific findings may have therefore
been missed.
The PAL guidelines’ ultimate aim is to deliver more effective and efficient
health care services. Our study indicates that the guidelines do indeed promote
rational prescription behavior, although a reduction in treatment costs was not ap-
parent. When the costs of guideline implementation and supervision are considered
as well, the question is whether the additional costs related to the implementation
of PAL guidelines are worth the benefits. We recommend further analysis on cost-
effectiveness to compare the final costs and derived benefits. Furthermore, training
alone on the application of guidelines may not be a sufficient form of intervention to
ensure a modified prescription behavior in the long-term. Further training to bring
the staff at health care facilities up to date, as well as other managerial strategies
may be needed to foster permanent effects [23].
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Part II
PAL: MODELING POPULATION
LUNG HEALTH

5
Multistate Models to Study Lung
Diseases: A Review
Multistate models are useful for studying life histories in terms of events such as
disease incidence, progression, and mortality. Multistate models are widely used
in the study of medical prognosis, as well as in model-based economic evaluation
and medical decision making. For our study we reviewed journal articles on the
implementation of multistate models for lung health.
5.1 Introduction
A disease process is inherently a multistate process. At any point in time, individ-
uals are either in good or in poor health. In terms of a specific disease, individuals
are either diseased or non-diseased. In the course of time, the disease process con-
tinues up until death. In health care, the purpose of preventive intervention is to
prevent people shifting from a state of good health to one of poor health, or from
a non-diseased state to a diseased state. Likewise, curative interventions are aimed
toward increasing the rate of transition from a diseased to a non-diseased state, or
from poor to good health. The effect of such interventions on the process of change
in health-related states is studied by using multistate models. The models are esti-
mated through longitudinal data that record health status changes or the health state
of an individual at various points in time.
Multistate models are useful for studying life history events such as disease
incidence, progression, and mortality [1, 2]. Markov models are an example of
multistate models and are widely used in the study of medical prognosis [3], as well
as in the study of model-based economic evaluation and medical decision making
[4–6]. In this study, we review the use of multistate models to study lung health.
This chapter is part of a research study aimed at developing a multistate model
to evaluate the cost-effectiveness of the implementation of the Practical Approach
to Lung Health (PAL) guidelines in Nepal [7]. The guidelines initiated by the World
Health Organization (WHO) aim to improve the syndromic management of lung
diseases in youths (over 5 years of age) and adults in middle and low-income coun-
tries. The guidelines target four main respiratory diseases: tuberculosis, asthma,
chronic obstructive pulmonary diseases, and pneumonia, collectively referred to
as PAL-diseases. In Nepal, PAL has been adapted to local contexts and a pilot
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implementation of the nationally adapted package, PAL-Nepal, was tested in pri-
mary health care centers, health posts, and sub health posts in Nawalparasi, a rural
lowland district [8].
This chapter consists of two main sections. The first section presents a brief
description of PAL diseases and the relevant publications identified. The second
section addresses conceptual and measurement issues in intervention studies. One
measurement issue is the definition of the state-space, i.e. the disease states to be
distinguished. A second issue is the measurement of transitions from available data
which are often incomplete.
The definition of disease states is sometimes difficult to establish, mostly due
to the lack of proper knowledge of the disease processes and, even if the disease
states are well defined, it is sometimes difficult to measure them on account of lack
of resources in terms of human capital, infrastructure, and medical equipment. For
example the lack of properly trained doctors in rural Nepal makes it difficult to
assess the severity of a disease condition. Even in the presence of a doctor, the
lack of diagnostic equipment often makes the task of determining the severity of a
disease virtually impossible.
Once the state-space is defined, transitions between different states of health are
measured. For this, patients are continued to be monitored and data are collected
at certain intervals. We focus on the questions about when and what should be
measured. Based on the measurement, transition rates or transition probabilities are
calculated. In some cases, transition rates are needed for shorter periods. In others,
transition rates need to first be modeled and the effects of various covariates studied.
The uncertainty in the measurements’ estimation process must be reported. Failing
to do so makes the description of the disease process incomplete, and reduces the
usefulness of the measurement for future statistical inferences.
A literature review on the use of multistate models to study lung health con-
tributed to the establishment of a multistate model that could be used in our eval-
uative study. In Section 2, we briefly describe the PAL diseases and the articles
included in the review. We included eleven articles published between 1995 and
2005. Subsequently, in Section 3, we consider each aspect individually and de-
scribe and assess the current state of the art. In Section 4, we discuss how the
findings in this chapter contribute to the development of a multistate model for
PAL and, finally, draw some conclusions.
5.2 PAL Diseases
The next section briefly describes PAL diseases, namely asthma, chronic obstruc-
tive pulmonary disease, tuberculosis, and pneumonia.
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5.2.1 Asthma
Asthma is a chronic disorder of the airways that leads to recurrent episodes of
wheezing, breathlessness, chest tightness, and coughing, particularly at night or
in the early morning. These episodes are usually associated with widespread but
variable airflow obstruction that is often reversible either spontaneously or with
treatment. Based on the level of airflow limitation and its variability, asthma has
broadly been classified in a progressive level of severity as intermittent, mild per-
sistent, moderate persistent or severe persistent [9]. In addition, episodes triggered
by asthma exacerbations (attacks or worsening of asthma symptoms and lung func-
tion) can be classified in different levels of asthma control, such that a mild level
on a severity basis may become a severe acute exacerbation. The chronic-episodic
nature of asthma makes the disease a good candidate for a multistate modeling
framework. The disease can develop at any age, though childhood asthma, espe-
cially in boys, may disappear during puberty, but reappear again at a later stage
[9]. The prevalence of asthma is quite high; for example, the prevalence of asthma
among children in Nepal is up to 30% [9]. Deaths linked to asthma are mostly
attributable to failed disease management. Morbidity linked to asthma is usually
caused by increased severity, under-treatment of patients with anti-inflammatory
therapy, over-reliance on bronchodilators, and a delay in medical help during an
exacerbation.
We found eight papers of which we chose five for inclusion in this review. An
article by Boudemaghe was in French and was thus excluded on the grounds of the
language barrier. The first article by Soriano et al. [10] is based on cross-sectional
data and, hence, we will limit the review to the definitions of state, as longitudinal
data required to carry out transitional measures was not collected. Among the
remaining four publications, the multistate model was applied to examine the long-
term evolution of asthma in two papers by Combescure et al. and by Saint Pierre
et al. [11, 12]. In the last two articles by Paltiel et al. and Price and Briggs, the
multistate model was used to assess the cost-effectiveness of different interventions
[13, 14].
5.2.2 Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease is a chronic disease characterized by a de-
cline in lung function over time. The Global Initiative for Chronic Obstructive
Lung Disease (GOLD) [15] defined chronic obstructive pulmonary disease as “. . .
a disease state characterized by airflow limitation that is not fully reversible. The
airflow limitation is usually both progressive and associated with an abnormal in-
flammatory response of the lungs to noxious particles or gases”. According to the
GOLD, a diagnosis of chronic obstructive pulmonary disease should be considered
70
in any patient with a cough, sputum production, dyspnoea, and/or a history of ex-
posure to the disease [15]. The diagnosis is confirmed by spirometry. Based on the
spirometry, the GOLD defines four levels of chronic obstructive pulmonary dis-
ease: mild, moderate, severe, and very severe. The prevalence of chronic obstruc-
tive pulmonary disease is highest in countries where cigarette smoking has been,
or still is, very common [15]. The morbidity and mortality rate linked to chronic
obstructive pulmonary disease is among the highest in the world, ranked 12th in the
WHO’s Global Burden of Disease Study in the year 2002 with 1.9% of the Disabil-
ity Adjusted Life Years (DALYs) lost worldwide [15]. Dyspnoea and exacerbation
of chronic obstructive pulmonary disease are the main reason for seeking medical
attention [15].
We also included three articles that applied a multistate modeling framework
to study chronic obstructive pulmonary disease [16–18]. Sin et al. use the Markov
model in a cost effectiveness analysis in patients with varying severities of chronic
obstructive pulmonary disease defining state by level of severity [16]. Borg et al.
describe chronic obstructive pulmonary disease by means of a two-dimensional
Markov model [17]. The model consists of several primary states which refer to
the disease’s severity and several secondary states relating to exacerbation. They
tested their model in an evaluation of two hypothetical interventions treating dif-
ferent mechanisms of the disease, namely irreversible lung function decline and
exacerbation frequency [17]. Similarly, Oostenbrink et al. use a Markov model
to study the cost effectiveness of different treatments for chronic obstructive pul-
monary disease. The states are defined by levels of severity and of exacerbation
[18].
5.2.3 Tuberculosis
Tuberculosis is an infectious disease which appears as a progressive primary dis-
ease in persons who have been newly infected, or through endogenous reactivation
(post-primary disease), or exogenous re-infection in individuals with remote (la-
tent) infections [19]. Cases of tuberculosis can be infectious or non-infectious.
An infection with tuberculosis begins with the transmission of Mycobacterium tu-
berculosis. Infected persons either develop active tuberculosis or become latently
infected and may develop active tuberculosis at a future stage. Active tuberculosis
can develop more than once. Some crucial points in time in the tuberculosis pro-
cess are time of infection, onset of disease, case detection, duration of treatment,
relapse, smear conversion, and endogenous reactivation.
We have also included three articles by Blower et al., Vynnycky and Fine,
and Dye, in which a multistate approach was used in the analysis of tuberculosis
[20–22]. Blower et al. present two models of the transmission dynamics of M.
Tuberculosis. The first model distinguishes between three and the second between
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five states [20]. The models were applied to determine the reasons for the sud-
den rise and drastic decline of major epidemics in developed countries prior to the
availability of an effective therapy.
Vynnycky and Fine employed a compartmental model to assess the relative
contribution of different disease mechanisms in the decline of tuberculosis in Eng-
land and Wales in 1900. The model is an extension of the one introduced by Suther-
land et al. [23]. It distinguishes between eight active states and estimates the age-
specific risks for developing primary, endogenous, and exogenous tuberculosis.
Dye et al. extended and merged the models by Blower et al. and Vynnycky and
Fine to produce an age-structured compartmental tuberculosis model. The model
was applied to assess the potential effect of DOTS in developing countries with a
high prevalence of tuberculosis.
5.2.4 Pneumonia
Pneumonia is an acute infectious disease that is reversible, and has a short incu-
bation period. A multistate model of three states applies characterized by short
time-steps: healthy-diseased-deceased. We did not find any multistate or Markov
model that has been applied specifically to pneumonia.
5.3 Review
In this review our focus is on multistate modeling. We consider the state-space,
model assumptions, measurement of transitions, and the reporting of uncertainties.
5.3.1 State-Space
A multistate model is specified by a state structure and a set of rates or probabili-
ties of transition from one state to another [24]. The state-space consists of every
distinct health state [2]. Therefore, the first step in building a multistate model is
the enumeration of all distinct states of health that should correspond to standard
or literature-based notions of the disease [3]. An individual can display various
states of health at different points in time. The states distinguished in multistate
modeling, i.e. the choice of the state-space, depend on the research question. For
example, if the research question is to assess the impact of treatment on the duration
of hospital stay, the states may be defined as: healthy, diseased – not in hospital,
diseased – in hospital. If instead the research question is about the impact of the
treatment on health-related quality of life (HRQOL), the states could be defined as
‘with-good-HRQOL’ and ‘with-bad-HRQOL’.
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Asthma
The state-spaces for asthma in all but one study included in this review were based
on asthma control programs focused on short-term change. The level of asthma
severity, which only changes very slowly, is used to categorize patients into three
main groups: mild, moderate, and severe. The severity of asthma is measured by
both the level of airflow limitation and its variability [9]. Most studies use asthma
severity as a criterion for the inclusion of patients in the studies. To study the
change in severity, a longer study period is required and not much data on the
transition between severity groups are available.
Soriano et al. define states of asthma control as good, moderate, and poor
control. Soriano et al. determine these states on how many of the GINA goals
(goals set by Global Initiative for Asthma) are not achieved [9]. Achieving all
goals means that the patient does not experience any asthma-related symptoms that
carry any significance. The patients’ responses to straightforward questions are
recorded. These concern their experiences at different times: present day (5th),
past week (1st and 2nd), past month (3rd), and past year (4th). In a multistate mod-
eling framework, the incidents that are of particular interest are those that occurred
between two points in time, typically the time-steps between the last and the present
interview. Therefore, the state-space of asthma control based on the GINA goals is
problematic.
Combescure et al. and Saint Pierre et al. define state-space through three “con-
trol” states [11, 12]. These states are defined based on a list of asthma-related
incidents and ‘activities’. Combescure et al. and Saint Pierre et al. used data from
ARIA (Association pour la Recherche en Intelligence Artificelle) and the definitions
of a state-space in both cases are the same. Data were collected over a four year pe-
riod (1997–2001) from several French chest physicians reflecting a hospital’s real
life activity. At each visit, patients were categorized into one of three asthma con-
trol states, namely optimal, sub-optimal, and unacceptable, based on the frequency
of symptoms, their duration, the degree of bronchial obstruction, and the need for
rescue medications. For the multistate analysis, data were collected from visits that
were at least four weeks apart. Visits that took place less than four weeks following
the preceding visit were not included in the study. Most of the variables used to de-
fine the states were measured by posing questions on past experience, practice, and
incidents, as well as a measurement of FEV1 (Force Expiratory Volume in 1 sec-
ond). In poor medical settings, for example in rural parts of developing countries,
FEV1 measurement may not be possible; however, other variables can be used to
assess the state of the patient’s asthma control. Hence, the overall definition of the
states of asthma control can be considered an important contribution made by this
dissertation to the study of asthma control over time in different settings.
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Paltiel et al. [13] define four states of exacerbation based on the patient’s ex-
acerbation experience in the preceding month, such as chronic/stable (no exacer-
bation), exacerbation involving urgent-care, exacerbation involving the emergency
department, and exacerbation involving hospitalization. Twelve strata are formed
based on a combination of lung function (mild, moderate), prior hospitalization
(none, once, or more than once), and age groups (18–35, >35). Each stratum then
has a state-space comprising four exacerbation states. Patients who are over 35
years move to the subsequent age strata in which new rates of transition apply.
Transitions between the four states are all possible. Two deceased states (asthma-
related and others) are included in the state-space. The state-space used for the
cost-effectiveness analysis consists of 48 active states comprising twelve strata with
four exacerbation states each. The time-steps is one month and the model runs for
ten years. The model is data intensive (which is acknowledged by the authors who
consequently did not include additional dimensions, e.g. socio-demographics, risk
factors, and environmental exposure) [13], and all data are obtained from published
sources, except for the data for quality of life. At the core of the model lie four ex-
acerbation states and two deceased states which are similar to the asthma control
states of other studies. Death is rare in asthma studies hence, general death rates
can be applied which lead to a single deceased state. The authors included two
asthma-related death rates for the two age groups. The strata can be included in the
model as covariates following Saint-Pierre et al. [12]. This states structure is easy
to apply, convenient for data collection, and does not require much resources, like
a doctor or medical equipment.
In Price and Briggs [14], the different states of asthma control are based on the
patient’s exacerbation experience in the past week. They define five states: suc-
cessful control, sub-optimal control, primary care managed exacerbation, hospital-
managed exacerbation, and treatment failure exacerbation. The time-step between
space-states is one week, the reason for this being the chronic episodic nature of
asthma, with patients typically deteriorating within a relatively short period of time,
but also improving very quickly.
To summarize, asthma is modeled by multistate models with a state-space based
on asthma control. Asthma control is acute in nature and defined in accordance with
the severity of exacerbation and resources used to treat the exacerbation, and not
based on asthma severity, which is chronic in nature. The severity of exacerbation is
usually measured in 3–4 states and can easily be estimated by using a questionnaire
that focuses on resources needed to treat the exacerbations, thus facilitating data
collection. In addition, trained doctors and medial instruments are used in some
cases to define states in asthma. A deceased state is not included in most of the
models, since asthma-related deaths are rare, but also because the timesteps of the
clinical trials are short. The time-step is usually one month, except in Price and
Briggs’ model (2002), where the time-step is one week. Since all incidents and
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durations are important for such research studies, the time-step should be such
that the likelihood of more than two incidents occurring during the period of a
given time-step is minimal. This argument is made by Price and Briggs and is an
important factor to consider when planning the data collection process.
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease is a progressive, irreversible disease with an
increasing degree of airflow limitation and periods of acute worsening of the dis-
ease, also referred to as exacerbations [17]. The chronic-episodic nature of chronic
obstructive pulmonary disease is similar to asthma and hence, we would expect the
disease to have a similar state-space as is the case for asthma.
Sin et al. present a model to study the natural history of chronic obstruc-
tive pulmonary disease with a long-term severity of the disease measured by the
FEV1, as recommended by the American Thoracic Society [25]. Three severity
states (stages) are defined: stage 1, 2, and 3 (FEV1: >=50% predicted, <50 but
>=30% predicted, and <30% predicted). Data are mostly obtained through pub-
lished sources and surveys. The simulation runs for three years with twelve tri-
monthly time-steps. Patients often move to either higher stages of the disease or
die. The transition to higher stages, as is similar to the aging process in a life table,
is associated with a decline in FEV1 at a constant rate of decline of 47 mL per pa-
tient per year. Hence, with this steady decline in FEV1, a patient in stage 1 (FEV1
>=50% predicted) will reach stage 2 (30% =< FEV1 <50% predicted) within a
few years. During each time-step, the number of different exacerbation types is
derived from a given rate of exacerbations. Exacerbations are then classified into
three mutually exclusive categories, namely, mild, moderate, and severe, depend-
ing on the type of intervention required. The mean durations are 1, 2, and 4 weeks,
respectively. However, they are not defined as states, but rather as events. This can
be translated as each stage having 4 sub-states, namely stable, mild, moderate, and
severe exacerbation. Following incidents of exacerbation, patients move about be-
tween these states for some time before arriving at a stable state again. This model
is similar to the Asthma Policy Model by Paltiel et al., which is suitable for a life
course analysis of chronic diseases with acute episodes occurring at various time-
steps. In this model, the possibility of moving to higher stages does not depend
on the occurrence and type of exacerbation as cited by Borg et al. [17]. In Sin
et al., exacerbations are not treated as sub-states and the effect of exacerbation on
lung function decline has not been considered. Borg et al. address these issues in
their two-dimensional Markov chain to represent disease severity and exacerbation
status.
In their multistate model, Borg et al. cover four states of severity: I, IIA, IIB,
and III based on the GOLD definition using FEV1 [15, 17]. States IIA and IIB are
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further sub-divided into two states each, as IIA1, IIA2, IIB1, and IIB2, amounting
to a total number of severity states of six. Unlike in Sin et al., a patient can regress
one step to a milder severity state (within half a year). However, a patient who has
regressed one step cannot regress any further, so in order to differentiate between
patients who regressed to a milder severity state, two additional states IIA2 and
IIB2 were introduced. A deceased state is also included in the model. Each of the
six severity states has four exacerbation states, namely none, mild, moderate, and
severe. The definition of exacerbation is based on the symptom-driven definition
of exacerbations in accordance with Seemungal et al. (cited by the authors on page
156) [17]. The states of exacerbation are defined based on Rodriguez-Roisin’s
resource-driven staging development (cited by the authors on page 156) [17]. The
time-step is one week.
Oostenbrink et al. defined four severity states (mild, moderate, severe, and
very severe) based on the GOLD definition [18]. However, they do not include
the mild state in their study. The study period consist of only one year, hence
the state ‘deceased’ is also excluded. The time-step for the first cycle is eight
days and, thereafter, one month. In each cycle, a patient can have none, or one
exacerbation which is either non-severe or severe. The data used derived from five
clinical trials. The change in severity states as observed in eight days and one
month is too insufficient to conclude that change occurs at the severity level of
chronic obstructive pulmonary disease. Instead, only the change in FEV1 due to an
alteration of an acute condition, i.e. exacerbation, is taken into account.
In conclusion, due to the chronic-episodic nature of both asthma and chronic
obstructive pulmonary disease, both diseases can have a similar state structure.
The number of severity states is clearly defined by GOLD, namely mild, moderate,
severe, and very severe states. In most cases the number of exacerbation states are
defined by the type of resource needed to control the exacerbation, which ranges
from 3 to 4.
It would be helpful to have a two-dimensional definition of a patient’s state
(severity state, exacerbation state) at every phase. Severity-based models are not
useful in short-term studies. The time-step for severity is obviously longer than
that for exacerbation; since the change in severity level is a very slow process, the
time-step for severity should be a multiplication of the exacerbation dimension’s
time-step so that at the end of a severity episode, the transition between the states
of both dimensions can be examined. The time-steps of severity-based multistate
models comprise three months in Sin et al.’s study [16], six months in Borg et al.’s
[17] and one month in Oostenbrink et al.’s studies [18]. Similarly, the time-steps
of exacerbation-based multistate models range from one week in Borg et al. to
one month in Oostenbrink et al. Though Sin et al. assert that the average duration
of exacerbation is either one, two, or four weeks, depending on severity, it is not
considered a time-step per se. As stated earlier in the case of asthma, the decision
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on which time-step to use should be such that the probability of occurrences of
multiple incidents is minimized.
Tuberculosis
Unlike asthma and chronic obstructive pulmonary disease, tuberculosis is not a
chronic disease. Once a person is infected by m. tuberculosis, individuals become
diseased by either direct progression (the disease develops shortly after infection)
or endogenous reactivation (disease develops many years after infection) or never
develop active tuberculosis. A simple three-state tuberculosis model (also called
SLT model) is presented by Blower et al. [20] with the following states: suscep-
tible (no tuberculosis, S), latently infected by tuberculosis (no clinical illness and
non-infectious, L), and actively infected by tuberculosis (infectious tuberculosis,
T ). A deceased state (D) is added to the model. Individuals shift from the state
susceptible to either latent or to actively infected by tuberculosis. Once an individ-
ual is infected by tuberculosis, he/she remains infected for his/her entire life (and
is hence less likely to be infected again for immune-related reasons). Hence, there
is no transition back to the state susceptible. Transitions from the state latent to ac-
tively infected by tuberculosis are possible as a result of an endogenous reactivation
at a later stage and vice versa, following recovery from active tuberculosis. Indi-
viduals in a state of active tuberculosis can die from tuberculosis-related or other
causes, while individuals in other disease states die only from other causes. This is
a simple “SLT” model of tuberculosis. It is suitable for a quick analysis, since the
data needed for the SLT model is readily available in most countries of the world.
To study complexities in the tuberculosis disease process, the SLT model is fur-
ther modified to become a detailed model of tuberculosis transmission. The model
is then expanded with three refinements, with the state active tuberculosis being
divided into two sub-states: active non-infectious tuberculosis and active infectious
tuberculosis. Instead of allowing the (either with or without treatment) recovered
individual to return to a separate latent state, a recovered state is added to differenti-
ate between infected people who never developed active tuberculosis (i.e. remained
in a latent state) and those who developed active tuberculosis and eventually recov-
ered. Those who recovered can have a relapse and develop active tuberculosis or die
from other related causes. Models are then run with a set of differential equations
using secondary equations to study the transmission dynamics of tuberculosis.
Vynnycky and Fine [21] developed a tuberculosis model which is similar to
that of Blower et al.’s detailed tuberculosis transmission model. It distinguishes
between the intermediate state infected, which people enter after being infected by
tuberculosis. Individuals shift from the state infected either by developing primary
tuberculosis within five years of getting infected, or by moving to the state latent
when they do not develop active tuberculosis. The difference of Blower et al.’s
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detailed model is that infected individuals move to a latent state if they do not de-
velop primary tuberculosis shortly after infection. In Vynncky and Fine, those who
recovered from a primary infection episode moved to the latent state. In Vynncky
and Fine’s model, no distinction is made between infectious and non-infectious tu-
berculosis. Instead, exogenous and endogenous tuberculosis are differentiated from
the latent state and a state of re-infection is included, which follows the same course
before reaching the latent state within a timeframe of five years, complicating data
collection. The state re-infected is not included in Blower et al.’s model, since their
model addresses an immunocompetent population, implying that individuals who
were infected with tuberculosis are less likely to be infected again. Hence, these
individuals do not have an exogenous disease state. Lastly, in Vynncky and Fine’s
model, those who are infected but not diseased, as well as those who recover after
being diseased, will eventually arrive at the latent state unlike Blower et al.’s state
recovered. The time-step in Vynncky and Fine’s model is one year.
Dye et al. [22] aimed to assess the potential effect of DOTS in those developing
countries in which the disease is most prevalent. They developed an age-structured
tuberculosis model based on the two models discussed above. Their model includes
two active tuberculosis states like Blower et al.’s model, namely infectious tubercu-
losis and non-infectious tuberculosis, but only one latent state for those who never
develop tuberculosis and for those who recover from active tuberculosis. Individu-
als who are in a non-infectious tuberculosis state can move to infectious tuberculo-
sis with smear conversion. In addition, individuals in active tuberculosis states and
poor treatment can move to the state treatment failure (classified in cohort analy-
sis as failed, defaulted or transferred out). Similarly, individuals can be self-cured
and move from an active tuberculosis state to the natural cure state. The states
treatment failure and natural cure each have two separate sub-states for infectious
and non-infectious tuberculosis. Among the susceptible, those who are immunized
move to an immunized state but can potentially revert back to the state suscepti-
ble after the effect of immunization wears off. The time-step is one year and the
simulation runs with different equations from 1998 until 2020.
Based on these studies it is clear that tuberculosis models involve a range of
states, from a simple three-state SLT model (Blower et al.) to a more complex
model including nine states (Dye et al.). More states can be added or removed,
depending on the research question and availability or feasibility of data. For ex-
ample, states for those who are sensitive to a single or to multiple tuberculosis
drug(s) can be added, and could, for example, be referred to as drug-sensitive state
or multi-drug sensitive state [26]. More states could also be included by adding an
HIV/AIDS dimension.
In the PAL studies, patients were interviewed twice in a time-step of two weeks
or two months (depending on the duration of their cough). The first interview took
place directly at the health center during the patients’ first visit, while the second
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interview was (for the most part) conducted at the patient’s home two months later.
Patients were generally in an acute condition during the first interview. The effect
of treatment and follow-ups (either at the same health facility or at higher level
facilities) following the initial visit were recorded in the second interview. As our
aim was to test the effectiveness of the PAL guidelines’ implementation at the local
rural level, we were particularly interested in how acute cases are treated. Hence, a
longer time-step, commonly of one year, is too long for most clinical studies, such
as ours, where the effectiveness has to be visible within a short period of time, e.g.
within two weeks time.
The states that apply for tuberculosis generally include three different states in
addition to the state deceased, depending on the availability of data and the purpose
of the research. Additional sub-states can be added to the three main states in the
general model (Susceptible-Latent-Active). The time-step is usually one year. Un-
like asthma and chronic obstructive pulmonary disease, where the aim of medical
treatment is typically to alleviate the disability caused by recurrent exacerbations,
the aim in cases of tuberculosis is to treat the actual disease and ensure that it re-
mains latent. In other words, tuberculosis is similar to the cases of asthma and
chronic obstructive pulmonary disease with the difference being the number of in-
cidents. These are less frequent in active tuberculosis cases than the exacerbations,
but the duration of active tuberculosis lasts longer than the states of exacerbation,
though the acute phase is normally not very long.
5.3.2 Estimation of Transition Rates and Their Standard Error
In this section, we review the assumptions with regard to transitions between differ-
ent states and how the transition rates and probabilities are related in the modeling
process. We are interested in the data sources being used and how measurements
are taken, whether transition parameters are based on incidents measured during
a given period (incidents of exacerbation, the onset of symptoms, etc) or status
measured at a given point in time (lung function, sick or healthy, etc). To estimate
transition rates, the timing of the incident needs to be determined. If the timing of
the incidents is unknown, what assumptions can be made? Does the length of time
spent in a given state actually matter? We examined how transition rates and prob-
abilities are related and calculated. Not all models reviewed here are referred to as
multistate models by the authors, e.g., the compartmental model in the case of tu-
berculosis. Different methods are used for the transitions in the different multistate
models including the compartmental models including matrix equations, differen-
tial equations, and difference equations. In this review, we focus on the multistate
model aspects of the articles and on specific issues related to lung diseases.
Next, we review the model’s uncertainties. Uncertainties related to the esti-
mates are often addressed in studies, and we have therefore included a synopsis of
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the related uncertainties in this section, along with a review of the transition param-
eters. Uncertainties with reference to the sampling method in the multistate model
are considered and, consequently, point estimates, along with the standard error,
for example of initial distribution and the transition rates/probabilities, should be
included in the description of these parameters, and when providing details on the
results. With regard to forecasting, uncertainty is also associated with assumptions
about the future. These uncertainties could be random in nature due to sampling
errors, or they could be systematic owing to different model assumptions such as
the choice of time-step and the timing of incidents, the use of different methods for
calculating the flow in the model, and assumptions about the future for forecasting
purposes. Next, we review different methods used for the reporting of uncertainties.
Asthma
State-space in asthma models are either based on the severity of asthma measured
by lung function or on the control of asthma measured by the incidents of exacer-
bation. The change in the severity dimension is a slow (continuous) process and
it takes years for patients to move into states of higher severity. Asthma severity
can be measured at any point in time, and therefore, is best measured as a sta-
tus variable at the beginning and at the end of a time-step. On the contrary, the
control of asthma is measured by different (discrete) incidents experienced by the
patients. For example, an exacerbation incident requiring hospitalization leads to
a transition from a state that is better controlled to one in which control worsens.
In many instances, the severity of exacerbation is determined by the type of health
care required to effectively treat the exacerbation. The exacerbation’s timing and
incident can easily be measured, and the change in status within a given time-step
can largely be determined through the use of self-reporting, either at the time of
the interview or through a patient’s diary. Depending on the research question, the
measurement of various covariates, time-dependent and independent are taken as
well. These data can then be used in a regression analysis, as well as to explain
uncertainties. Below we review some of the important covariates and assumptions
related to the Markov processes in the multistate models.
Combescure et al. [11] and Saint Pierre et al. [12] studied the long-term evo-
lution of patients with asthma in asthma controlled states. The authors assessed
the transition between the asthma controlled states in a time-step of four weeks.
The actual durations of exposure were used as denominator to obtain the transition
rates (referred to as ‘forces’ by the authors). Six transition rates – expressed as
transitions per day – are estimated for the various transition possibilities between
the three states in terms of their maximum likelihood of occurring. The transition
forces are presented for the entire population, as well as for two severity-based
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strata individually. The transition forces are assumed to follow a continuous homo-
geneous Markov model, which implies that the transition rates are independent of
time (period, age or since last transition). In addition, Saint Pierre et al. incorpo-
rated in their study the effect of covariates on the transition forces. The covariates
included are Body Mass Index (BMI), severity index, and number of exacerbations.
A time-dependent covariate (duration of a state) is also incorporated, assuming a
piecewise but ongoing intensification. The probabilities of transitions are derived
from the transition rates and are presented as results in the evolution of transi-
tion probabilities over time. The main outputs of the model are a series of graphs
exhibiting the evolution of point estimates of the transition probabilities.
In both articles, authors reported on the standard errors of the transition forces
estimates by inverting the empirical information matrix (for further details, the
reader is referred to the relevant literature). No uncertainties are reported for the
transition probabilities, the output of the model. Combescure et al. present a stan-
dard deviation of the mean time spent in each state as an outcome of the model,
using the Delta method which is a method for deriving an approximate probabil-
ity distribution, when knowledge of the estimator’s variance is limited. No details
are provided, however. Saint-Pierre et al. describe the regression coefficients of
the covariates on the transition forces, along with the standard errors. In addition,
Saint-Pierre et al. carried out a sensitivity analysis to test the assumption of time
homogeneity in terms of a state’s duration applying log-likelihood tests between a
homogeneous model and a piecewise-constant model.
Paltiel et al. [13] developed an asthma policy model and, for demonstration pur-
poses, mostly used data from literature sources. Exacerbation rates are estimated
by establishing a relationship between the rate and the FEV1-predicted, using the
results from various studies. These rates are then adjusted to the distinct (origin)
states which differ by prior hospitalization status, again using a secondary source.
The number of patients requiring different types of urgent care is estimated us-
ing a secondary database, and the transition rates to the various (destination) states
which differ by urgent care types are determined. These dimensions are calculated
for different age groups and severity states. The effect of different interventions on
transition rates were also derived from the literature and adjusted. Likewise, data
on mortality rates were collected from the literature. All transition rates were then
transformed to the monthly probability transition matrix (without, however, men-
tioning which transformation method was used). The modeling time is 10 years
and all rates are assumed to be homogenous during this time period and within
each state (no more covariates).
Price and Briggs [14] noted the incidents of exacerbation within one week at
the end of each week using data from a total period of 12 weeks. The exacerbation
incident can occur at any time during any week. In the event of an exacerbation
incident during a given week, an asthma control status based on the subsequent
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intervention required (Primary care managed exacerbation or Hospital managed
exacerbation) is defined for each patient. When no exacerbation incident occurs, an
asthma control status (Successfully controlled or Sub-optimal controlled) is defined
for the patient based on his/her experiences, which are recorded in the daily diary
card. Next, based on the patients’ asthma control status, transition probabilities are
estimated between any two states. According to the authors, when no transition
is recorded between any two states, a zero transition rate between any two states
is theoretically not possible and, hence, Bayesian methods are applied to arrive at
non-zero transition probabilities. A set of transition probabilities is then calculated
based on the change in states during each of the 12 weeks. This indicates that the
model is a time-homogenous Markov model. The authors did not consider any
other covariates in their model – the Markov model is applied repeatedly using the
set of weekly transition probabilities for the entire 12 week period. Each week is
assigned a cost, depending on the control status of the given week.
Uncertainty in the transition probabilities was dealt with by assuming that the
transition probabilities, considered input to the model, follow the Dirichlet distri-
bution, which is a multinomial equivalent of the beta distribution. The authors
employed Probabilistic Sensitivity Analysis to analyze the uncertainty in the out-
puts of the model. A second-order Monte Carlo simulation technique was used,
in which for each simulation the transition probabilities and other variables (e.g.
unit costs of primary care consultations, costs of an in-patient day and length of
hospital stay, etc.) are randomly drawn from both the Dirichlet and the normal dis-
tribution, respectively. The distribution for the former is obtained empirically, and
from published sources for the latter. The simulation is repeated 1000 times and
the outputs (e.g. number of successfully controlled weeks, costs, cost-effectiveness
ratios) are recorded and later used to report the distribution in a scatter diagram,
and in 95% uncertainty intervals. Hence, the study can be considered complete in
terms of addressing the issues of uncertainty at the input, as well as at the output
level.
Among the articles reviewed, Paltiel et al. [13] include the severity dimension
in their multistate model in addition to the control dimension. Events of exacer-
bation are measured and transition rates and probabilities estimated. Exacerbation
incidents are, therefore, an important measure of effectiveness in the analysis of
the asthma disease process. In the PAL study, Juniper’s Asthma Control Question-
naire [27] was used for each interview with patients who had breathing difficulties
to collect information on the incidents of exacerbation in the last week and, hence,
can be used to define control states as was done in the reviewed papers. Finally,
uncertainties regarding the transition rates and probabilities were presented.
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Chronic obstructive pulmonary disease
Similar to asthma, the state-space in chronic obstructive pulmonary disease models
are also centered on severity and exacerbations. The change in the severity dimen-
sion is – like for asthma – a slow (continuous) process and it takes years for patients
to move into states of higher severity. Similarly, acute episodes are caused by an
exacerbation incident and a patient’s health status may change thereafter.
In Sin et al.’s multistate model [16], the initial compilation of patients accord-
ing to their states of severity defined by their levels of lung function (FEV1) were
taken from a large health and nutrition survey. The mean rates of transition from a
severity state to a state of higher severity (within three months) were estimated by
a mean decline in lung function based on data from another large lung health study.
The probability of transition was calculated based on these rates. Individual data
on FEV1 at the baseline could have been used as well and the transitions generated
by applying the mean decline in lung function. In any case, the lung function for all
patients was estimated as declining with a constant rate of 47 mL per year, in other
words, the transition rate is constant, irrespective of any other variable. Hence, the
model becomes a deterministic model. Furthermore, the assumption that the mean
rate of decline is constant for patients within and between different severity states
seems unconvincing, considering that the authors do not cite any other studies.
Incidents of exacerbation (mild, moderate or severe) can occur in every severity
state (stage). The rates of different exacerbation incidents in various severity states
were derived from the literature and are expressed in percentages over a 30-day pe-
riod. Patients in severe states suffered more in terms of the number of exacerbation
incidents, as well as in terms of the number of severe exacerbations. The authors
assumed the duration of each exacerbation type to last one, two and four weeks for
mild, moderate, and severe exacerbation, respectively. This is equivalent to hav-
ing four exacerbation-related states (with fixed durations), i.e. an individual is, at
any given point of time, either in a state of no exacerbation or in one of the three
exacerbation states varying in degree. As soon as an exacerbation occurs, a time
period depending on the type of exacerbation is weighted by a certain degree of
utility, irrespective of when the exacerbation occurred. For example, a person who
experiences an exacerbation at the end of a given time period will not spend his/her
days with a reduced quality of life until the next period; however, in the model, the
days in which the patient experiences a reduced quality of life arise in the period
in which the incident actually occurred. By modifying the model to define exac-
erbation states in line with those used in other studies, and by reducing the cycle
lengths for transitions between the exacerbation states, would greatly enhance this
model.
The effect of an intervention is introduced in the model as a reduction of the
exacerbation rate by 30%, with a 95% confidence limit derived from published
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literature. All transition and incident rates are presented with a 95% confidence
interval and with reference to published literature. However, the distributions these
rates follow are not mentioned, and the uncertainty on the initial distribution is
not mentioned. A Monte Carlo simulation with 100,000 sample sets is described
in which the rates from its distribution were randomly selected. The uncertainty
regarding the duration of an exacerbation state is not included, since fixed durations
are used (one, two, and four weeks for mild, moderate, and severe exacerbations).
Unlike Sin et al., Borg et al. [17] based the calculation of their data on a sin-
gle follow-up study and defined the exacerbation states within each severity state.
Data from a 10-year follow-up study was used to calculate the 10-year transition
probability between the severity states of chronic obstructive pulmonary disease.
The multistate model has a one-year time step. In the Appendix of their publica-
tion, Borg et al. explain how a one-year transition probability matrix is obtained
by calculating the 10th root of a 10 year transition probability matrix. The authors
claim that the root is unique given the matrix’s large number of constraints (and
numerous transitions not being possible). A similar process was used to arrive at
yearly rates of all-cause mortality. This process assumed homogeneity of transi-
tion probabilities throughout the entire 10 year period, ignoring any time and age
effects. The data used comprised three broad age groups. Simple linear interpola-
tion was carried out to obtain the transition probability matrix for the different age
groups. Nonetheless, the assumption is too simplistic and the authors acknowledge
the question of validity of such a method.
Exacerbation transition rates were based on data from a follow-up study and
estimated at the end of the week by assessing the incidents of different types of ex-
acerbation during a given week and the mean duration of these exacerbations. The
distribution of patients in different states is assumed to follow a stationary distribu-
tion, given that the severity does not change. The aspect of a stationary population
distribution was then used to estimate the stationary distribution of patients in vari-
ous exacerbation-related states. The mean duration of exacerbations was calculated
using the available data. The rate of transition out of the various exacerbation states
were then calculated as the inverse of the mean duration of exacerbations (1 / mean
exposure). The model does not include a deceased state, which is correct when
the cycle length (time-step) is small. However, in the long-term perspective in a
given cohort, the severity level of patients within a severity state is increasing, and
since the authors also emphasize the relationship between severity and the rate of
exacerbation, the stationary distribution assumptions may not hold true.
Borg et al. assume that the exacerbation process could affect both the progres-
sion toward severity and the mortality rates, and hence, proposed a simple mecha-
nism by introducing two variables, alpha and beta, which denote a value between
0 (no effect) and 1 (completely dependent). Authors report a limitation of the data
on the extent of the effect and hence, the mechanism was used in the sensitivity
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analysis only. The authors use bootstrapping to estimate the standard error of the
transition rates by re-sampling the data on the incidents and duration of the exacer-
bations numerous times.
Oostenbrink et al. [18] estimated the transition probabilities between severity
states using primary data. The severity states are assessed at the beginning and
at the end of each period. The transitions are assumed to occur mid-way in each
cycle. Since the durations between the follow-ups are not identical in the different
databases, the empirical transition probability matrices are converted for a period
of eight days (first cycle) and one month (12 subsequent cycles) using a Taylor
series expansion, which is explained in the Appendix of the paper. The transition
probability matrix for the first cycle is based on data from the patient’s first visit and
the first follow-up. The transition probability matrix for subsequent cycles is based
on data from the first and last follow-up visits. The assumption of a homogeneous
Markov process was made for the subsequent periods.
Two sets of probabilities of exacerbation by severity state were calculated as
the ratio of the number of exacerbations within a month and the number of patients
(in a given severity state) at the beginning of the month. The number of exacerba-
tions during each cycle was used in the model analysis and it was assumed that only
one exacerbation per patient could occur in each cycle. Unlike in Borg et al., the
durations in exacerbation were not used. Instead, when an exacerbation occurred
within a given cycle, the entire cycle was considered to be in a state of exacer-
bation, irrespective of the severity of the exacerbation, since the utility value was
assumed to reduce by 15% for non-severe and by 50% for severe exacerbations,
which were derived from the literature. However, the duration of exacerbations is
usually shorter in non-severe cases and it may be possible that the 15% reduction
in utility value only applies for a short period rather than for the entire month. In
conclusion, the model can be seen as a two-dimensional multistate model (as in
Borg et. al.) using the same time-step for both dimensions.
Oostenbrink et al. present standard errors together with the point estimates for
the transition probabilities and the probabilities of exacerbation. To calculate stan-
dard errors of exacerbation probabilities, a simple simulation with 5000 iterations
was performed. It is not clear how the simulation was carried out; most probably, a
bootstrap method was used. To account for uncertainty in the results, a Monte Carlo
simulation was conducted assuming transition probabilities following the Dirichlet
distribution, similar to Price and Briggs in their article on asthma.
We found that all articles included the transitions between states based on sever-
ity. However, not all models reviewed explicitly defined states based on exacerba-
tion. The rates and probabilities of exacerbation differ for varying severity levels.
The purpose of the interventions is to reduce the rates of exacerbation. Hence,
the modification of the models to include states that are based on exacerbation as
an individual dimension would be more suitable for the modeling of the chronic
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episodic nature of chronic obstructive pulmonary disease. Uncertainties in the in-
puts – transition rates – were included in the analysis of some of the authors, who
presumed that the transition rates followed a Dirichlet distribution, as was the case
in the asthma models. Monte Carlo simulations were used to estimate uncertainty
in the results. In conclusion, a multistate model for asthma and chronic obstructive
pulmonary disease can be identical with the states defined for both the chronic and
acute dimension.
Tuberculosis
Tuberculosis is not a chronic disease and it is possible to completely cure the dis-
ease. However, once a person is infected with tuberculosis he/she can remain in-
fected for his/her entire life with or without an incidence of the disease. The most
important incidents in the tuberculosis disease process are infection with the dis-
ease, the incidence of disease, being cured, relapsing, etc. In terms of tuberculosis
management, disease detection and the completion of a therapy are the most crucial
elements. Although the tuberculosis models included in this review are not explic-
itly referred to as multistate models, they are all in fact multistate models, with
state-space and transition rates being clearly defined. Unlike in standard multistate
models, transition probabilities and matrix algebra are not used, instead, a set of
differential equations and difference equations are applied.
Blower et al. [20] describe the transition rates between the different states using
various tuberculosis-related rates, proportions, coefficients, and probabilities from
the literature. The rate of change in the number of people in the given states is
established through ordinary differential equations. These rates of change are then
applied over time to obtain various tuberculosis-related outcomes. A set of model
parameters, along with the assumed distribution (triangular or uniform), are used
as input to the model.
The uncertainties in the results are dealt with by distributing 1000 points for
each outcome. Each point is a result of a set of values of parameters randomly
drawn without replacement from the parameters’ distributions, using a Latin Hy-
percube (LHS) sampling method. In this method, each probability density function
(pdf) is divided into equi-probable parts by n (1000 in this case) points. The LHS
method then takes a random sample without replacement from each pdf to create a
set of values of parameters. The sampling is repeated 1000 times, resulting in 1000
sets of parameter values. the authors acknowledge that the transition rates are time-
homogenous and there is no mention of any covariates. Once a patient is (newly)
infected by tuberculosis, the waiting period before he/she moves to the latent state
is not included in the model. The model seems to be carried out in a yearly time-
step. In that case, the waiting period for moving to the latent state would be one
year.
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Vynncky and Fine’s model [21] comprises many transition rates. Infection and
re-infection rates change over time (derived from the literature). Following infec-
tion (or re-infection), the rate of developing tuberculosis is high in the first year but
diminishes in later years, and is age-dependent (also based on the literature). The
rate of recovery depends on age, time, and the time since the onset of disease. The
fatality rates are also drawn from various studies. Hence, in terms of a multistate
Markov model, the model is non-homogeneous with reference to time. The time it
takes to transition from an infected state to a latent one is exactly five years. State-
specific mortality rates were also derived from various studies. A system of partial
differential equations is reduced to one of ordinary differential equations, which
are then solved using time-steps of one year and by applying the Euler method.
Using the model and the tuberculosis notification database from national surveys in
England and Wales, the age- and period-specific rates of developing active tuber-
culosis were estimated through different mechanisms. These mechanisms included
primary tuberculosis (shortly after the initial infection – during the first five years
of being infected), by endogenous reactivation (after five years), and by exogenous
re-infection (also after five years).
The uncertainties in the inputs were estimated by calculating the standard er-
rors of the estimates of these transition rates in the assumption that all forms of
tuberculosis notifications follow a Poisson distribution. Fifty sets of tuberculosis
notification rates were drawn, resulting in 50 notification data sets. Rates of de-
veloping tuberculosis were then matched to each dataset, and a 95% range of the
resulting distribution was reported to represent the uncertainties around the point
estimates calculated from the original dataset. Other inputs in the model were point
estimates.
Dye et al. [22] prepared a set of difference equations for the flow (one year
time-step) in the age-structured tuberculosis model. They estimated key indica-
tors and variables based on the literature. As in Vynncky and Fine, the estimated
rates of active tuberculosis was obtained through different mechanisms by match-
ing the three states (Susceptible-Latent-Tuberculosis) to the ‘compartmental’ model
on age- and period-specific data on tuberculosis incidents in The Netherlands. The
incidence rates were assumed to be age-specific (defining two age groups, children
<=15 and adults). These rates and other estimates (some region-specific) were
used in the model to make a projection for six WHO regions, beginning in 1910
for Europe and 1950 for the remaining regions (depending on when the incidents
of tuberculosis began to decline). The annual incidence rates and the proportion of
tuberculosis cases or deaths prevented by the Directly Observed Treatment Short
course (DOTS, a WHO recommended tuberculosis control strategy) were used as
measures for the effectiveness of tuberculosis control. The rates and proportions are
allowed to change over time based on historical facts, the model used, and future
assumptions.
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The ranges for all inputs and the standard deviations for the estimated rates
of active tuberculosis were reported. Uncertainty in the results was dealt with by
using Latin Hypercube Sampling and drawing 100 sets of parameters. All param-
eters were assumed to follow a rectangular distribution between their ranges. The
result of the simulation was presented as a 90% uncertainty interval. The authors
acknowledged that the uncertainty analysis was far from being complete, and hence
reported only on comparative indicators in relative terms.
All tuberculosis models reviewed focus on the macro level and apply a time-
step of one year. The transition rates between the different states are mostly drawn
from country-level data. In terms of micro analysis to analyze the effects at the
individual level, these models are not really useful in the context of PAL, since
the models do not incorporate the acute episodes when patients suffer from active
tuberculosis and seek health care. PAL aims to increase the case-detection rate of
tuberculosis by filtering the suspected tuberculosis cases from the pool of patients
with respiratory symptoms attributable to other diseases. States defined by inci-
dents of case-detection, start of treatment, or completion of treatment, can be use-
ful to determine the effectiveness of interventions. Regarding uncertainties, similar
methods were used in the case of asthma and chronic obstructive pulmonary dis-
ease. Instead of a Monte Carlo simulation, the Latin Hypercube sampling method
seems to be quite popular.
5.4 Conclusion and Inference for PAL
The review’s main message is that the existing multistate lung health models can
help us identify the states in the disease process with regard to disease manage-
ment. In the case of asthma and chronic obstructive pulmonary disease, states can
be defined by two dimensions, namely acute and chronic. Patients suffering from
both diseases in the chronic dimension only experience a very gradual change in the
course of the disease, with chronic states mainly being distinguished by the level
of the patient’s lung function. The acute dimension, in which a patient’s health
status changes more rapidly to poorer health states, is more critical but with proper
care a transition to a better health status can be achieved in a short period of time.
Without medical intervention, patients may seriously suffer and, in the worst case,
die. We found that acute states of asthma or chronic obstructive pulmonary disease
mostly depend on the level of medical intervention required to treat the exacerba-
tions, in other words, are resource-driven. Many interventions and strategies are
developed to improve patients’ health in the acute dimension, with PAL being one
such example.
Tuberculosis, on the other hand, is not a chronic disease. However, it is charac-
terized by an acute phase in which patients’ health states deteriorate considerably
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once the person develops active tuberculosis. With proper treatment, the acute
phase can be overcome in a short period of time. The patient has to take medi-
cation for a longer period of time, even though the patient feels as though he/she
is in perfect health. However, if the patient does not complete the full course of
treatment, the disease may potentially reappear and then in an even more serious
form. Unfortunately, we did not find any article that captured this micro aspect of
the disease process, as most of the tuberculosis models are studied at the macro
level. Therefore, the knowledge derived from the review of tuberculosis models is
useful for modeling tuberculosis at the macro level, but not suitable for studying
the effect of interventions such as PAL.
The second message is that multistate models are gradually being applied to
study the disease process of asthma, chronic obstructive pulmonary disease, and
tuberculosis. Various methods to estimate transition rates are either developed or
borrowed from other fields and are used quite effectively. Uncertainties in the esti-
mation of transition rates are reported in many cases, making it easier to establish
statistical inferences regarding the transition rates, as well as the multistate model’s
output. The review has revealed that the multistate model is, and can be, an impor-
tant tool for studying the lung disease process.
This review was conducted to critically examine how multistate models are be-
ing used in lung health. We now have some insight on how multistate models can be
applied to study individual disease processes, namely asthma, chronic obstructive
pulmonary disease, and tuberculosis. However, we did not find any articles in-
volving a multidisease model, i.e. modeling more than one disease simultaneously.
Secondly, the data used in most articles was collected from developed countries,
where human capital and medical resources are adequate. The different states are
defined on measurements that are reliable, valid, and most importantly, disease-
specific. In similar settings and in a single disease study, the knowledge gained
from this review can be highly useful. However, the use of this knowledge is not so
straightforward for PAL studies.
Based on the knowledge we acquired from this review, we developed two mul-
tistate models to study the cost-effectiveness of PAL in Nepal. In the following sec-
tion, we discuss the inference we made for PAL. First, the PAL guidelines represent
an integrated strategy for four lung diseases including pneumonia, asthma, chronic
obstructive pulmonary disease, and tuberculosis. Secondly, PAL was implemented
in rural health care settings in Nepal and the PAL guidelines were adapted in such
a way that health care providers with lower levels of training could understand and
implement them when treating patients. The health care providers are often the
only persons working at the health facilities and have a minimal level of resources
available to them in terms of infrastructure and other medical health care resources.
Both of these ‘constraints’ demand a model that is generic and non-disease specific
such that a single health dimension can detect the changes in the health status of
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the ‘lung’ patients, which can be achieved when implementing the PAL guidelines,
while the treatment of patients with respiratory symptoms does not always result in
a diagnosis of a disease. At the same time, the generic measurement should be such
that it can be easily implemented at low cost, and that the patients who are usually
poor and less educated, can understand the measurement. Based on this review
and the above discussion, we will briefly introduce how we went about to solve
the above-mentioned problem. In the PAL system, patients are managed (treatment
and/or referral to higher level health facilities) on the basis of their symptoms, un-
less the diagnosis is known in advance. The common symptoms of different respi-
ratory diseases make it difficult to make a diagnosis when health care providers are
not adequately trained and resources are limited. The PAL guidelines aim to reduce
erroneous diagnoses by assessing the patient’s condition with algorithms that fol-
low a syndromic approach to disease. Health care providers are guided through the
assessment of a patient step-by-step to determine a specific disease classification
resulting in either explicit disease management or, if necessary, in the treatment of
the disease [8]. To test the effectiveness of such guidelines, the different states of
the diseases have to be based on the symptoms or a general health status. States
based on a generic measure of respiratory condition would be the ideal dimension.
A simple two-state model (acute and chronic-stable states) can be used to model
the patients in PAL. More states can be included in the acute dimension based on a
generic measurement of (respiratory) health. Patients who suffer from chronic ob-
structive pulmonary disease or asthma (known or unknown) would suit this model,
since exacerbation would lead to the acute state (or, one of the acute states), forcing
patients to visit a health center. If followed-up, patients could recover and return
to a better health state, or completely recover in the chronic state. The same could
apply to tuberculosis – patients only visit the health center when the disease has
reached an acute state. At the follow-up visit, a patient’s condition would either
deteriorate to a worsening of the acute state (even death) or with case detection and
the start of a therapy (DOTS) return to an improved state of health.
In the following two chapters, additional details are presented on the actual
analysis of the effectiveness of implementing the PAL guidelines using a multistate
model.
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6
Defining Disease States in Health
Modeling Based on Quality of Life:
An Alternative for Modeling Disease
States Based on Prognostic Variables
The categorization of health states leads to the definition of distinct health states,
which can be used in the study of disease evolution. The new classifications of
health states are typically carried out on the basis of categorizing prognostic vari-
ables of diseases. Remarkably, despite its frequent use as an outcome variable,
hardly any classification is performed on the basis of variables measuring quality
of life. In this study, we propose several methods for the categorization of health
states on the basis of Health-Related Quality Of Life (HRQOL).
6.1 Introduction
Researchers have been working on methods to classify heath states for modeling
purposes for quite some time [1, 2]. In his paper “Note on grouping”, Cox in 1957
proposed classifying individuals’ health as “poor”, “average”, or “good”, based on
a variable X representing a property linked to the individual’s health [1]. The cat-
egorization of health states leads to the definition of distinct health states, which
can be used in the study of disease evolution. A common approach to the modeling
of disease processes is the multistate approach, which includes the Markov process
[3, 4]. The issue of categorizing health states continuously re-emerges in research,
as new measures of health state are being used in epidemiological and health eco-
nomic models. The new classifications of health states are typically performed on
the basis of categorizing prognostic variables of diseases by first determining the
variables that predict the outcomes of patients with distinct characteristics and then
by categorizing the prognostic variable [5]. Prognostic variables could be an ab-
sence or presence (and level) of signs and symptoms, for example a cough, fever,
etc. or diagnostic tests like level of blood sugar, blood pressure, etc.. For example,
in patients with chronic obstructive pulmonary disease or asthma, the lung function
measured by spirometry as FEV1 (forced expiratory volume in one second) is used
to categorize the severity of the disease.
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Health-Related Quality Of Life (HRQOL) is a recommended outcome variable
in health economics and epidemiology to measure individuals’ health status [6, 7].
Especially when we are not able to measure the prognostic variables, HRQOL can
be helpful in measuring a patient’s state of health, though it might not necessarily
identify the disease as such, for which a more disease-specific HRQOL would be
required, but it certainly reveals the overall state of a person’s health at the given
point in time. The HRQOL measures are used in economic evaluations to measure
the utility of patients (in terms of time trade-off, explained later), to estimate qual-
ity adjusted life years (QALYs) gained or lost, and the measurement of effect in the
cost-effectiveness analysis used to calculate the cost per QALYs gained/lost. The
general HRQOL measures can be used as a single instrument to measure the general
population’s health in multi-disease studies. Despite HRQOL’s widespread use, the
categorization of individuals’ health based on HRQOL has not yet been taken up,
except in a study on obesity [8]. In most cases, HRQOL functions as a continuous
variable and the mean value or the changes in mean values are assessed. How-
ever, a good HRQOL instrument should be interpretable (for further details, see the
introduction in Chapter 1) [9], in order to compare HRQOL impairment between
patients (e.g., to determine whether an individual has a normal, mild, moderate, or
severe impairment of HRQOL) [9]. Defining meaningful categories of HRQOL can
make this possible. When measuring the change in HRQOL impairment of individ-
ual patients over time, the interpretability of the HRQOL measure reveals whether,
for example, change is trivial, small but important, important, or very important,
etc. [9]. Hence, two issues are essential, namely the definition of HRQOL states
for discriminative usage and the definition of the scope of the changes for evalua-
tive purposes. Defining such categories facilitates the use of multistate models – in
which the state variables are generally discrete variables – to study the evolution of
health in different HRQOL states. Indeed, when the determination of HRQOL is an
outcome of a modeling exercise, its value is attributed to the categorized prognostic
variables of a disease, meaning HRQOL is treated as an outcome or an indication
of being in a particular disease state with a given value, for example, level of blood
pressure, temperature, etc. specifying the state [10–13]. In that respect it could be
claimed that HRQOL is always modeled indirectly. If HRQOL is really considered
an important outcome of health, direct modeling of HRQOL is warranted and a
categorization of health states on the basis of HRQOL should be explored.
The main objective of this chapter is to explore and develop methods for defin-
ing discrete health states based on HRQOL, which can then be used in multistate
models, for example, to study the evolution of general or specific populations’
HRQOL states. We propose several methods of categorization of health states on
the basis of HRQOL and apply these methods on lung diseases, namely pneumo-
nia, tuberculosis (TB), chronic obstructive pulmonary disease (COPD), and asthma
in the context of the Practical Approach to Lung health (PAL) study in Nepal.
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6.2 Methods
The EuroQol EQ-5D questionnaire [14] is a commonly used tool to measure health-
related quality of life. It contains five dimensions of health (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression) with three levels of re-
sponse (1 for “no problem”; 2 for “some problem”; 3 for “severe problem”), which
define 243 (35) health states. A unique feature of the EQ-5D is that former val-
idation research allows attributing a measure of severity to the 243 health states
[15]. This measure of severity is often referred to as “utility”. The utility score that
corresponds to a condition a patient is in can be understood as the amount of per-
fect quality time a patient is willing to trade for one unit of his/her (lower) quality
time. For example, if a person suffering from asthma is willing to trade 10 years
of his/her life in his/her current state with 8 years of a perfectly healthy life, the
utility of the patient’s current state is said to be 0.8. In EQ-5D, the utility score
has a value of 1.00 when morbidity is absent (person is healthy) (11111) and 0.00
when the person is dead. Very severe health states, like 33333, get negative values
(–0.59). For details see Chapter 3, section 2.
The main issue here is that utility scores are available (a continuous variable)
and we want to divide them into meaningful categories so the utility scores can
be used as a discriminative measure, as well as an evaluative measure [9]. The
question then is how the state of a person with a utility score of, say, 0.65 should be
referred to – for example, in a good, bad, or worst health state – and how to refer
to a change in the utility score from 0.65 to 0.85 – for example a trivial, small but
important, or very important change in health status [9].
6.2.1 Categorization on the Basis of the Description of the 243 EQ-5D
Health States
The unique feature of the uni-dimensional severity score of the multidimensional
EQ-5D becomes apparent when we try to classify health states on the basis of the
five-dimensional descriptive system. To begin, we could divide the 243-EQ-5D into
two groups of health states: full-health and poor-health. A full-health state can be
defined as a state in which there is “no problem” in all dimensions i.e., a score
of 11111, and the poor-health state as one with at least “some problems” in one
or more of the dimensions – in total, 242 states. This procedure can be extended
to more than two states and the change in an individual’s health over time can
be studied by using multistate models with the state definitions described above.
However, even with such a simple classification rule we are faced with the problem
that we do not know what the distinctive contribution of different dimensions and
levels on the overall HRQOL is. Indeed, 31111 must logically represent a more
severe health state than 21111, but without additional assumptions or information,
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there is no way of telling whether a score of 31111 is worse than, say, 12111.
Fortunately, we have additional information on health state severity in the form of
the utilities of the EQ-5D health states as valued in former research [15].
6.2.2 Categorization on the Basis of the Utility of the EQ-5D Health
States
If we want to categorize health states on the basis of their utility score, we have
to define cut-points. Before doing so, we should first determine the optimal num-
ber of categories. This will depend on the characteristics of the epidemiological
models involved. In asthma [16] and chronic obstructive pulmonary disease [17],
it is most common to model the disease using three or four categories of health.
Therefore, we explored the effect of having three or four states as final outcomes.
Secondly, the cut-points have to be defined. This is a research problem with only a
metric solution. To facilitate the interpretation of the modeling results, the clinical
relevance of the cut-points should be considered as well. We tried to include both
considerations by taking the following steps:
Defining states by visual exploration of utility distribution
First, we began with an exploratory analysis by visualizing the distribution of the
utility score. Figure 6.1 illustrates the distribution of EQ-5D utility scores among
2164 patients with respiratory symptoms who visited health facilities in the rural
Nepalese district of Nawalparasi (a brief description of the data is provided at the
end of the methods section). The bar with utility score 1 (full health) is distinct. The
distribution reveals a clustering of patients in three states: full-health (utility score
of 1), moderate-health (utility score of 0.5 to 0.9), and low-health (utility score of
less than 0.5), with low-health corresponding to the poorest health state. The three
states are distinct in Figure 6.1; however, defining four states is not straightforward
or even possible by just looking at the figure. This visual definition of states serves
as a starting point in the process of defining utility-based HRQOL states.
Defining states using the concept of minimal important difference
The next step is to arrive at a metric definition of cut-points. First, we define a
Minimal Important Difference (MID) in the EQ-5D, which serves as the minimum
change in the EQ-5D utility score over time and is perceived by individuals as be-
ing important. There is no universally accepted MID for the EQ-5D utility score,
although a change of 0.05 is considered reasonable [18]. However, in this analy-
sis we define the MID as a difference of 0.10 in the utility score, in view of the
fact that the decline in health from full-health (EQ-5D state “11111” with a utility
96
score of 1) as a result of an altered state of health in the EQ-5D’s third dimen-
sion (pain/discomfort), leads to a state of health (EQ-5D state “11211”) that has a
smaller value (smaller than 1) and a utility score of 0.882, which is a decline of a
little over 0.10.
For cross-sectional data on the EQ-5D, we can illustrate a metric method of cat-
egorization using Dalenius and Hodges’ method (1959) [2]. We used this method
for the sake of illustrating an existing method and to compare the result with those
from other definitions of states in this chapter.
Dalenius and Hodges assert that a frequency table in ascending or descending
order of the outcome variable’s variable must first be prepared (example utility in
our case). The square roots of the frequency are then calculated and a cumulative
of the square root of the frequency determined. For a given number of states, the
next step is to choose cut-points to create equal intervals on the cumulative scale
established in advance. In our case, the outcome variable is the patients’ utility
score. We applied this rule for all 2164 utility scores and arrived at the following
results: (i) three strata: full health (score 1), moderate health (score 0.5 to 0.89),
and low health (score lower than 0.5); (ii) four strata: full health (score 1), mild
health (score 0.6 to 0.89), moderate health (score 0.2 to 0.59), and low health (score
lower than 0.2). This is a quick approximation of categories of a static variable in
cross-sectional data. However, if longitudinal data is available for the variable to
be categorized, changes in the score over time might be taken into consideration to
determine the cut-points. This is important because our ultimate objective is to use
the utility categories to define a multistate model, in which individuals’ transitions
between the different states will be modeled.
Defining states of health using Cox’s method
According to Cox, the best system of grouping is the one that retains as much infor-
mation as possible [1]. In our context of modeling the progress of a disease, we are
interested in capturing the occurrence of incidents that trigger a change in the states
of health or a transition, and the non-occurrence of incidents that do not cause any
change in the states of health or to non-transition within a set of health states over
a period of time, using a multistate model. Using a multistate model for a given
state-structure defined by a set of cut-points, a loss of information over a period of
time develops when actual incidents trigger transition (defined by certain criteria,
for instance, the minimum change in the EQ-5D utilities) but are not recognized as
having initiated a transition. Additionally, a loss of information may develop when
the non-occurrence of incidents that cause non-transitions are recorded as being
transitions, for example, if a cut-point is 0.60 and a patient has a value of 0.59
and 0.61 at two points in time, the definition of cut-point regards this change as a
transition, when in reality, a change of 0.02 might not be significant enough to be
97
EQ5D utility scores, UK weight
30
0
10
20
–5
1.00.0 0.5–0.5
N
um
be
r 
of
 p
at
ie
nt
s
EQ5D utility scores among patients with
respiratory symptoms in rural Nepal
Figure 6.1. Histogram of utility scores using EQ-5D in all patients (n = 2164) with
respiratory symptoms at their first visit to a health facility
considered an actual change. We refer to this as being a false transition. We pro-
pose a criterion for determining an optimum set of cut-points, one that maximizes
the measurement of the suitability to categorize a set of cut-points, defined as the
percentage of actual incidents (transition/non-transition) identified by the structure
of health states among the total population at risk at the beginning of the period.
The first step in the establishment of the criterion was to define the occurrence
of actual incidents that trigger transition, as well as the non-occurrence of incidents
that cause non-transition. For this purpose, we defined a Minimal Important Tran-
sition (MIT) as the minimum change in utility that patients consider a significant
change in their health status. Like for the MID, we chose this criterion to be at
least 0.10 in terms of EQ-5D utility scores. Based on the MIT, a true transition was
defined as a change of at least one MIT, while a true non-transition was defined as
no change or a change of less than one MIT being evident. Next, for each set of
states defined by a set of cut-points, incidents within these states were counted over
a specific time period and the measurement of the suitability of categorization for a
set of cut-points was calculated. We performed this exercise for three and for four
states, with all possible cut-points beginning with an initial cut-point of zero.
6.2.3 An Illustration of Modeling Health States Based on HRQOL
For a given state structure, individuals can be classified under one of the HRQOL-
based health states at any point in time. As time passes, individuals either move to
a better or worse health state or remain in the same state of health according to a set
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of probabilities for a given time interval known as a Transition Probability Matrix
(TPM, also called P-matrix). The TPM, along with the initial distribution of the
population into various states, provides the final distribution at the end of the given
interval.
The TPM can be estimated from the empirical data by capturing the state in-
dividuals are in at the beginning and at the end of the interval. The TPM can be
used to measure the effectiveness of health interventions by comparing two sets
of transition probabilities, one associated with an intervention group and the other
associated with a control group. At the same time, the health state probabilities,
which are a result of applying these TPMs on the initial state distribution, can also
be used as a measure of effectiveness. However, with regard to the PAL study,
the initial distribution of patients was not the same in the intervention and in the
control groups. The use of health state distribution as a measure of effectiveness is
difficult to compare and, hence, we used the TPMs as a measure of effectiveness.
Furthermore, the interpretation of the transition probabilities is easier and makes
more sense at the individual level than the health state distribution approach. We
compared the transition probabilities of two TPMs by defining a (positive) effect as
implicating a higher probability of transition to a better health state or as maintain-
ing the status quo, or displaying a lower probability of transition to a poorer health
state. Specific transition probabilities between two TPMs can be compared, for ex-
ample, if the probability of transition from, say, a low state of health to a moderate
one within a two week time period is 0.4 in the case of PAL and 0.3 in the case of
STS, then the PAL strategy can be considered as being more effective than the STS
strategy.
However, the comparison would remain vague unless the difference is quite
profound as the number of states increases. For each TPM, a unique distribution at
stability exists referring to the long-term distribution, given the TPM remains con-
stant. Analogous to a speedometer, this stable distribution can be used to compare
the effectiveness of various TPMs, hence reducing the number of factors to include
in a comparison.
Further, a single measurement of effectiveness can be derived from each TPM
by weighing the degree of stability in the different states of stability against the
average utility of time spent in the respective states. The average utility in each
state is estimated using the empirical HRQOL data. The single measurement thus
obtained is the commonly used average quality adjusted life years (QALYs) lived
every year by every person, in our case, the average QALYs lived by the stable
population, since the distribution at stability does not change to any further extent.
The average QALYs lived by the stable population ranges from a maximum value of
1 (entire population is in full health) to a minimum value of –0.59 (entire population
is in worst health).
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The uncertainty in the TPM due to sampling was addressed by using a bootstrap
method with a 95% confidence interval with 2.5th and 97.5th percentiles of boot-
strapped results. We drew 5000 bootstrapped samples repeatedly from the original
sample and used STATA 8.2 and Excel for our calculation.
6.2.4 Data Source
Data used in this study was derived from a facility-based, cluster randomized trial
conducted to study the cost-effectiveness of the implementation of the Practical
Approach to Lung health (PAL) guidelines as compared to the Standard Treatment
Schedule (STS) in the lowland district of Nawalparasi in Nepal. 42 health facilities
in the Nawalparasi district of Nepal were randomly categorized into PAL (n = 22)
and STS (n = 20) groups. At least one health care provider at each of the 22 health
facilities was trained during the period of June–July 2002. Data were collected
from 2243 patients who visited the 42 facilities throughout the period of September
2002 to September 2003 (see Table 6.1). Patients aged 15 years and above with at
least one of the following symptoms, fever, cough, and breathing difficulties were
included and interviewed at the health facility. Patients who only had a fever or
cough with a duration of less than 15 days were excluded for further follow-ups,
since the chances of actually having one of the target diseases (pneumonia, TB,
chronic obstructive pulmonary disease, and asthma) was rather low. Patients with a
chronic cough (chronic condition) that lasted more than 15 days were interviewed
two months later and the remainder (acute condition) were interviewed after two
weeks. All patients who completed the EQ-5D in both interviews were included in
our analysis (in total, 1167 patients).
6.3 Results
We used MIT criteria to determine best cut-points for the three and four states
model using data from the PAL-study (n = 1167). For the three state model, the
percentage of actual transitions (with the change in utility score being greater than
the MIT) and actual non-transitions (with the change in utility score being lower
than the MIT) was revealed among all patients in the range of 70.9% to 81.1%. The
highest value was obtained for the cut-points 0.6 and 0.9. For four states, the range
was from 75.0% to 87.7%, and the highest value was obtained for the cut-points
0.4, 0.7, and 0.9.
Table 6.1 presents the results of the comparison of the effectiveness of STS (1st
column) and PAL (2nd column) for two groups of patients, namely those ‘without a
chronic cough’ (1st row) and those ‘with a chronic cough’ (2nd row) (see Chapter 3
for details), by using the multistate model for determining transition probabilities.
In Table 6.1, the origin states are displayed in the rows and the destination states
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are found in the columns. In each of the blocks, the numbers in the first column
(in italics) represent the distribution of states at the beginning of a period, and the
numbers in the first row (in italics) indicate the distribution of states at the end of
the period as a result of the transition probabilities represented by the remaining
numbers in the block. The transition probabilities for patients without a chronic
cough are considered for a period of two weeks, and the transition probabilities
for patients with a chronic cough are considered for a period of two months (see
Chapter 3 for details). To illustrate, the transition probability that a patient without
a chronic cough and in a severe health state, will move to a state of full health within
a two week period, is 0.23 given that patients are visiting a STS health facility. The
transition probability is higher at 0.29 if the patient visits a PAL facility.
We determined that all the transitions between the two states of health are pos-
sible, except the transition from a full health to a severe health state. According to
the data, only few patients with respiratory symptoms at the time of their first visit
to a health facility enjoyed full health, but later regressed to poorer states (mild or
moderate health states), but not to a severe health state. Among patients with a
chronic cough, more patients stayed in or moved to full health states in PAL than
in STS.
Each transition probability matrix in the long-term leads to a unique stable
distribution shown in Table 6.2. Among patients without a chronic cough, STS’
performance was better than PAL’s, since more people stayed in healthier states,
while in the case of patients with a chronic condition, the PAL performed better
than the STS, since more people remained in healthier states. Since the results in
Table 6.2 represent the distribution in the long-term, it should be interpreted as a
theoretical consequence, since in reality a person who is cured does not stay in
the system, which is not affected by the transition probabilities. Its use should
be strictly limited to being implemented as a comparative tool, since the results
are independent of the initial state distribution. Another advantage of the stable
distribution is the interpretation of results in terms of time spent in each state by a
person at stability. For example, a patient with a chronic cough who visits an STS
facility will spend 38% of his/her time in a state of full health, compared to 61%
full health, if he/she had visited a PAL facility.
In order to obtain a single value associated with a transition probability matrix
of health states based on EQ-5D utility scores, we first estimated the utility weights
for time spent in each state, along with the mid-95% range of 5000 bootstrapped
samples, for comparative purposes (Table 6.3). The utility weight of spending time
in each of the four states was estimated by calculating the mean of the EQ-5D utility
scores at the time of the first visit to a health care facility for groups of patients in
each distinct state of health. The QALYs lived per year at stability associated with
each TPM in Table 6.1 were calculated by weighing the time spent in each state
(Table 6.2), by corresponding utility weights (Table 6.3), and finally, by adding the
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Table 6.1. Transition probabilities for patients without a chronic cough (two weeks) and with a chronic cough (two months) in
PAL and STS, with states defined on the utility cut-points 0.4, 0.7, and 0.9 with the state of origin displayed in rows and the
destination state in columns
STS PAL
Destination States
Origin States Full Mild Moderate Severe Full Mild Moderate Severe
Patients Without Chronic Cough
State State
Distribution 46% 27% 10% 6% Distribution 46% 31% 14% 9%
Full 8% 0.83 0.13 0.04 0.00 6% 0.74 0.26 0.00 0.00
Mild 39% 0.51 0.36 0.11 0.02 25% 0.58 0.30 0.10 0.02
Moderate 24% 0.53 0.31 0.13 0.04 35% 0.48 0.29 0.14 0.08
Severe 29% 0.23 0.39 0.18 0.20 34% 0.29 0.34 0.20 0.17
Patients With Chronic Cough
State State
Distribution 36% 32% 15% 18% Distribution 42% 23% 20% 14%
Full 6% 0.33 0.58 0.08 0.00 13% 0.68 0.24 0.08 0.00
Mild 31% 0.44 0.39 0.08 0.10 39% 0.60 0.22 0.10 0.08
Moderate 28% 0.44 0.29 0.15 0.13 50% 0.36 0.28 0.19 0.16
Severe 36% 0.24 0.23 0.21 0.32 53% 0.28 0.20 0.32 0.20
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Table 6.2. Distribution at stability: Consequence of P-matrix
EQ-5D utility cut-points
States STS PAL
Patients Without Chronic Cough
Full 74% 68%
Mild 19% 27%
Moderate 6% 3%
Severe 1% 1%
Patients With Chronic Cough
Full 38% 61%
Mild 44% 24%
Moderate 10% 11%
Severe 8% 4%
Table 6.3. Average EQ-5D utility weights (95% bootstrapped range) of time spent
in each state
States Average Utility Weights
Full 1.00 (–)
Mild 0.78 (0.77–0.78)
Moderate 0.62 (0.61–0.62)
Severe 0.03 (0.02–0.05)
weighted time. For example, for patients without a chronic cough who visited STS
facilities, the time spent in different states at stability is illustrated in Table 6.2 (74%
of time in full health, 19% of time in moderate health, etc.) and are weighted with
the state utility scores from Table 6.3 (1 for full health, 0.78 for moderate health,
etc.), to determine the QALYs lived per year of 0.93 years (0.74∗1 + 0.19∗ 0.78
+ 0.06∗0.62 + 0.01∗0.03). The final results are presented in Table 6.4 along with
the mid-95% range of 5000 bootstrapped samples. The results are similar for both
state-structures. PAL performed well among patients with a chronic condition, but
not among patients with an acute condition.
Table 6.4. QALYs lived per year per person at stability and 95% bootstrapped CI
Conditions STS PAL
Acute 0.93 (0.88–0.98) 0.92 (0.88–0.96)
Chronic 0.78 (0.73–0.85) 0.86 (0.81–0.93)
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6.4 Discussion and Conclusion
We have demonstrated the method of identifying optimum categories by determin-
ing cut-points that capture most of the true transitions and true non-transitions
based on individuals’ responses to an HRQOL questionnaire, by maximizing the
percentage of accurate identification of incidents over time. We have shown that
for a four states model, the optimum cut-points for the EQ-5D utility score in pa-
tients with lung disease are 0.4, 0.7, and 0.9. For the given state-structure, we pre-
sented an algorithm to arrive at a single measurement of effectiveness as QALYs
lived per year at stability, using multistate models, and compared PAL and STS’
effectiveness. We presented the results for a state-structure based on the EQ-5D
utility score. By modeling health states categorized on the basis of HRQOL, which
is a recommended outcome measurement tool in public health, we are the first to
model the evolution of patients in an HRQOL-based multistate model and used the
results to compare the effectiveness of an intervention with the help of a control.
In the methods section, we described several methods for categorizing a sin-
gle variable by exploring distribution and a method based on minimizing variance
within each group in line with Dalenius and Hodges (1959) [2]. For cross-sectional
data, these methods can be used to categorize the results of a variable (continuous
or discrete with many values) into smaller groups for descriptive purposes. How-
ever, if the objective is to study a process with additional data on the process or
available outcomes, the final results achieved following classification might be af-
fected by the different choices of classification. We aimed to determine the best set
of cut-points to stratify the EQ-5D-based utility. Hence, we proposed a criterion
that included measures of a process at two different points in time and defined a
measurement of suitability of the classification by determining true transitions and
true non-transitions, captured by the classification as a percentage of total transi-
tions. The true transition was defined as a change of 0.10 in EQ-5D utility scores.
The choice to use 0.10 corresponds to twice the minimal important difference of
0.05, mentioned by Dolan [18], and to the change in utility, when a person in full
health is confronted with ’some problem’.
The incidents considered were those that triggered transition to a different state,
as well as within the same state; the measure of the suitability of classification con-
sists of the sum of true transitions and true non-transitions. Here, we assume
that the value of identifying a true transition is similar to identifying a true non-
transition. Two state-structures might have the same number of identified true
transitions and true non-transitions, but may differ in how they capture the true
transitions and the true non-transitions. That is, if the relative significance of these
incidents can be expressed as a weight, the weighted measure would indicate the
improved state. In this study, we assumed the relative importance to be 1 for both
transition types identified.
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Lastly, the use of multistate models to model disease over time using different
outcomes is common, but we did not find any literature defining health states based
on health-related quality of life. In that sense, this is the first attempt to do so.
HRQOL is an established measurement of individuals’ health states. The defini-
tion of a few distinct states based on HRQOL will increase the use of analytical
techniques such as multistate models, including Markov models. It is also conve-
nient to scale individual’s HRQOL according to a few distinct states. In this study,
we have demonstrated the use of a multistate model with homogeneous Markov
assumptions, to compare the effectiveness of an intervention with a control. More-
over, we used the stable proportional distribution at stability as an outcome of an
intervention. Stable distribution is independent of initial distribution, which makes
it more appealing. However, care should be taken in the interpretation, since the
stable distribution is technically not possible in some case, and the results only im-
ply a theoretical consequence of a transition probability matrix and should be used
for comparative purposes only.
In conclusion, we presented a way to define states in lung health based on
HRQOL data. We demonstrated that a uni-dimensional utility measure is needed to
do so, like, for instance, the utilities attached to the EQ-5D health states. We defined
a measure of suitability for the classification by determining the occurrence of true
incidents or no incidents causing transitions and non-transitions and identified by
the classification as a percentage of the total transitions among patients with lung
disease. For a state structure with four states of EQ-5D, the best set of cut-points is
0.4, 0.7, and 0.9. Finally, using this best set of cut-points in a multistate model, we
found that the PAL intervention is as effective as the STS strategy among patients
without a chronic cough, whereas among patients with a chronic cough, the PAL
strategy could foster a better state of health state than the STS strategy.
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The Health Effects and Medical Costs of
the WHO’s Practical Approach to Lung
Health for the Nepalese Population –
A Model-Based Analysis Using Cluster-
Randomized Trial Data
Lung diseases are a leading cause of morbidity and mortality in developing coun-
tries. This study models the long-term cost-effectiveness of implementing the
WHO’s Practical Approach to Lung health (PAL) in adults in Nepal. The PAL
guidelines on symptomatic case management of tuberculosis, chronic obstructive
pulmonary disease, asthma, and pneumonia are compared to the current Standard
Treatment Schedule (STS).
A multi-disease, multi-state projection model was used to compute the PAL-
related lifetime change in the Nepalese population’s lung health. Parameters for
the model were largely drawn from a facility-based cluster-randomized trial involv-
ing 42 health care facilities and 2243 patients, and the impact of PAL and STS on
the health-related quality of life, and patient-level costs were collected in interviews
with patients with respiratory symptoms. Program level PAL implementation costs
were also estimated. Costs and effects were extrapolated to scale up PAL to the
whole of Nepal, with uncertainties presented on a bootstrapped cost-effectiveness
plane and in acceptability curves.
When keeping to the PAL guidelines, the treatment of a lung disease episode
costs US$4.40 and US$3.54 on the basis of the STS guidelines. Implementing the
PAL guidelines at all first level government health facilities in Nepal would cost
US$111 per quality-adjusted life years gained, compared to the STS guidelines. Us-
ing a threshold of US$150 per QALY gained, PAL’s probability to be cost-effective
is 54%.
For the government, the implementation of the PAL guidelines is more costly
than maintaining the current STS guidelines, but patients benefit in terms of the
reduction of their out-of-pocket expenses for their treatment and in terms of better
health of the population. The implementation of the PAL guidelines in Nepal is,
therefore, likely to be cost-effective.
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7.1 Introduction
Lung diseases are a leading cause of morbidity and mortality in developing coun-
tries. Lower respiratory infection, tuberculosis, chronic obstructive pulmonary dis-
ease (COPD), and asthma together amount to 15.4% of all disability-adjusted life
years (DALYs) lost in the South-East Asia Region [1, 2]. In Nepal, most people
live in rural areas with primary health care available through nurses who obtain
basic training in health care and some additional training on the job [3]. The com-
mon symptoms associated with various lung diseases often lead to misdiagnosis
and hence, the worsening of disease severity which may lead to death. With the
exception of the case management of tuberculosis, the Nepalese health system has
no standard strategy for dealing with the large number of lung diseases. This trans-
lates into a low quality of health care delivery and unnecessary expenses for both
the health system and the individual patient [2].
With the progress in the Integrated Management of Childhood Illness (IMCI)
[4], an integrated case management strategy, a number of countries throughout the
world together with the World Health Organization (WHO) have initiated a Practi-
cal Approach to Lung health (PAL), developing generic clinical practice guidelines
on integrated case management of pneumonia, tuberculosis, chronic obstructive
pulmonary disease, and asthma [2, 5]. The PAL strategy requires local adaptation
of the WHO guidelines for the specific epidemiology, formulary, and health man-
power of a country. So far, only few countries have undertaken local adaptations
of PAL including Peru, Morocco, Kazakhstan, and Nepal. In Nepal, the National
Tuberculosis Centre (NTC) together with the WHO convened Nepali profession-
als and organizations to adapt the PAL guidelines in 2000. The Nepal guidelines
were designed for implementation by health care providers at health posts and sub-
health posts and were accompanied by training materials. This initiative is intended
to promote better lung care among adult patients at first level health facilities [2].
It is important to assess PAL’s economic attractiveness to verify whether the
resulting health benefits merit the use of (scarce) health care resources. In a prior
study on the effectiveness of PAL, Shrestha et al. [6] found that the implementation
of PAL is effective in promoting the rational use of drugs in select respiratory dis-
eases. They also found that PAL was effective in patients with a chronic cough and
asthma [6]. To date, no economic evaluation of PAL has been performed. Because
the next decision regarding PAL would be whether to implement it in the entire
country we created a simulation model of the costs and effects resulting from such
a policy.
We used a multi-disease, multi-state projection model to model the changes in
lung health among Nepal’s adult population based on what was learned from the
Nawalparasi trial. We used cost data from the trial to evaluate the cost-effectiveness
of implementing PAL guidelines in all first level government health facilities in
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Nepal. Such a policy would cover around 30% of all adult patients seeking care for
lung diseases, with the remainder seeking care from traditional healers or private
health care providers.
7.2 Methods
7.2.1 Background on Design of Field Trial of PAL Nepal
A prospective trial of the PAL-Nepal program was conducted between 2001 and
2003 during which staff at 42 health care facilities were randomized into a control
group of 20 facilities, which applied the standard treatment schedule (STS) used in
community practices to treat lung disease, and an intervention group of 22 facilities
at which five days of training were offered by the NTC in the use of the PAL
guidelines.
At least one health care provider from each of the 22 health care facilities was
trained in the period of June to July 2002. Patients aged 15 years and up with
at least one of the symptoms fever, cough, or breathing difficulties were included
and interviewed at the health care facility. We obtained clearance from the local
Committee of Ethics and written consent from the patients included in the study.
Patients with only a fever or a cough lasting less than 15 days were excluded for
further follow-up interviews, since the likelihood of these patients having one of
the target diseases was quite low. Patients with a chronic cough lasting over 15
days were interviewed two months later, and the remainder two weeks later. A
maximum of three attempts were made to schedule a follow-up interview. Data
were collected from 2243 patients who visited the 42 facilities in the period from
September 2002 to September 2003. The translated version of the EuroQol EQ-5D
questionnaire [7, 8] was used to obtain a single preference-based utility score for
each patient on a scale in which 0 represented death and 1 represented full health
[9]. All patients who completed the EQ-5D during both interviews were included in
our analysis (a total of 1167 patients). It was assumed that all first level government
health facilities in Nepal treat around 30% of all adult patients seeking care for
lung diseases, with the remainder visiting traditional healers or private health care
providers.
7.2.2 A Multi-State Projection Approach
A multi-disease, multi-state projection model (Figure 7.1) was developed to study
the lifetime health experience of closed cohorts who had reached the age of 15
years before the projection period subject to the two interventions:
i. Continuation of current STS guidelines (STS scenario)
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ii. Implementation of PAL guidelines (PAL scenario)
Both interventions were implemented for 10 years following standardized
WHO methodology for modeling cost-effectiveness of health interventions [10].
The model integrates four different lung diseases, namely pneumonia, tuberculo-
sis, chronic obstructive pulmonary disease, and asthma, reflecting the nature of the
PAL-guidelines. All diseases include both an acute state represented by X-state and
a chronic state represented by C-state (with the exception of pneumonia which only
has an acute state). Individuals at any point in time can either be in a Susceptible
state (susceptible to different lung diseases) or in any one of the diseased states in
the X-states or C-states.
The model is evaluated in a time-step of two weeks. This time-step was chosen
based on the extensive review of studies on multi-state models of lungs diseases
(for details, see Chapter 5). The status of an individual at the beginning and at the
end of a time-step could differ due to a transition between health states. At the
beginning of a time-step, an individual in the Susceptible state can either remain
in that same state, die, or enter an acute state (X-states) as a result of an incidence
of either tuberculosis or pneumonia, or on account of a first incidence of either
asthma or chronic obstructive pulmonary disease. While in an acute state at the
beginning of a time-step, individuals at the end of one can either remain in the same
acute state (in the process of remission or due to the worsening of the condition)
or die (lack of proper treatment, no treatment, or failure of treatment) while the
patient can move to a chronic state (C-states) due to remission (treatment of an
acute state or natural remission) or recovery (natural or owing to proper treatment),
or, in case of pneumonia, to the Susceptible state after recovery. In our multi-state
model, patients in an acute or a chronic state of disease cannot make a transition to
another disease’s acute or chronic state. For example, a patient in a chronic state of
tuberculosis will not experience an asthma attack.
Within a time-step of two weeks, patients who are in a chronic state of tubercu-
losis can either move to the state Susceptible (after a complete recovery), die (from
tuberculosis or other causes), or remain in a chronic state during the process of
treatment, or because of unsuitable treatment. For example, patients not following
the treatment schedule (DOTS) can remain in a chronic state of tuberculosis for
extended periods and may in the worst case enter an acute state of tuberculosis due
to remission.
In the case of asthma and chronic obstructive pulmonary disease, patients re-
main in a stable chronic state within a time-step of two weeks due to good control
of asthma or appropriate management of chronic obstructive pulmonary disease.
Patients in chronic states do not die as a result of the disease since the transition
to the acute state precedes death-related asthma and chronic obstructive pulmonary
disease. However, death could occur during a time-step of two weeks when, for
110
X-state
Pneumonia
 
 
X-state
Tuberculosis
 
 
 
X-state
COPD
 
 
 
X-state
Asthma 
X-state
Asthma 
X-state
COPD 
X-state
Tuberculosis 
S-state no
lung disease
Exacerbation
Remission
Recovery
First incidences
Figure 7.1. Multi-disease, multi-state model
Note: Dashed lines represent deaths due to specific lung disease or due to other causes
example, a patient in a chronic state actually makes a transition to the acute state
and dies during that time period. We assume that the probability of such consec-
utive events is rather very low and, hence, do not include it in the model. This
implies that deaths in chronic states are attributed to other causes. Patients in a
chronic state of asthma or chronic obstructive pulmonary disease are always at risk
of exacerbation which will change the patient’s state from a chronic to an acute
state.
The change in an individual’s status within a state-space during a given time-
step is triggered by an incident or incidents that result in a transition from one state
to another. Information on transitions during a time-step can either be expressed
through transition rates or transition probabilities. Transition rates during a spe-
cific time-step from one state (say, state S) to another (say, state X) are estimated
by the ratio of observed number of incidents during the time-step in which the
transition from state S to state X takes place, and total time spent in state S by
those who already were in state S at the beginning of the given time-step. Whereas
transition probability from state S to another state X during a given time-step is
estimated as the proportion of individuals who were in state S at the beginning of
the time-step, but are in state X by the end of the time-step. Transition rates are not
duration-specific, however, transition probabilities are. In our multi-state model,
we modeled the status distribution of the population in an interval of two weeks
and hence, transition probabilities were easier to calculate and explain, since we
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were interested in the status of individuals at the beginning and at the end of each
time-step.
After defining the state-space, the next step was to fill the model with the data
collected. Firstly, the baseline distribution of the study population in 2001 in var-
ious states of the multi-state, multi-disease lung model (Figure 7.1) was prepared.
Secondly, the transition probabilities between the states were estimated and the
model tested for 10 years in a time-step of two weeks. The data for estimating
the initial distribution and the transition probabilities were obtained from various
sources, including the national census of Nepal [11], the WHO’s studies on burden
of disease [12], and literature [13–16].
The initial distribution of the population in various states is needed before pro-
jecting a population’s development using a multi-state model. The age-sex specific
distribution of the population derived from the 2001 census [11]. Since informa-
tion on the prevalence of pneumonia, tuberculosis, chronic obstructive pulmonary
disease and asthma was available through the Burden of Disease study for Nepal
(BoD) [12], we divided the population into five states, namely: susceptible and four
states for each disease.
However, in our multi-state model (Figure 7.1) as already mentioned, we have
more than one state of diseases for tuberculosis, chronic obstructive pulmonary dis-
ease, and asthma, namely X-states and C-states. In total, the model consists of eight
states, susceptible, four acute states (X), and three chronic states (C). Hence, we
had to divide the prevalence ratios of tuberculosis, chronic obstructive pulmonary
disease, and asthma into X-states and C-states, for which data was not available in
the BoD database. In Appendix A, we explain the method we developed to divide
the diseased population into either the acute or chronic states for the initial baseline
setting.
The procedure in Appendix A provides an approximation of the prevalence of
chronic states of tuberculosis, chronic obstructive pulmonary disease, and asthma,
and was calculated for each age and sex. Data on prevalence of disease (pri), rate
of new incidences (misx), mortality rates (case fatality, background mortality, and
all cause mortality) were obtained from the Burden of Disease study for Nepal [12];
the population numbers are based on the census of Nepal [11]; and the data on rate
of remission/exacerbation were calculated from the frequency of exacerbations and
remissions per year, obtained from various literature (see Table 7.1) [13–16].
In the next step, transition probabilities between the different states were cal-
culated by sex and one-year age group, reflecting the probability of moving from
one state to another or maintaining the status quo during a time-step of two weeks.
(for more details, see Appendix B) [17, 18]. The transition rates for estimating the
transition probabilities derived from various sources. The new incidence rates of
diseases, duration of diseases (pneumonia and tuberculosis), mortality rates (case
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Table 7.1. Inputs in the model for duration of disease episode and number of
exacerbations per year
Chronic
obstructive
pulmonary
Pneumonia Tuberculosis disease Asthma
Duration of disease episode (in state X) 10 daysa 28 daysb 7 daysc 13 daysd
Duration of disease (in states X and C) – 1.6 yrsa – –
Number of exacerbations per year – – 2.4c 1.3d
Source: aBurden of Disease study; bHansel(2004)[13] and Dion (2004)[14]; cWilkinson (2004)[15];
dDennis (2000)[16]
fatality, background mortality, and all-cause mortality), and recovery rate (tubercu-
losis) were obtained from the Burden of Disease estimates for Nepal [12]. Average
duration of disease in an acute state of tuberculosis, chronic obstructive pulmonary
disease, and asthma (see Table 7.1) [13–16] were used to calculate the transition
rates from acute states. Transition probability from an acute state to a chronic or
susceptible state is inversely proportional to the duration of the disease in an acute
state. For example, if the average duration in an acute state is, say, 10 days, and
assuming there are no deaths, then the rate of transition from the acute state can
be approximated by 1/10 = 0.01 transitions per day of exposure, or 36.5 transitions
per year of exposure. This procedure, as well as the deaths (case fatality, back-
ground mortality), are taken into consideration to estimate the transition rates from
acute states. Yearly transition rates were converted to a two-weekly transition rate,
reflecting a realistic timeframe for all four diseases to detect potential changes in
patients’ clinical status that may occur while in an acute state of health (see Chap-
ter 5 for more details) [19]. These two-weekly rates were used to determine the
two-weekly transition probabilities as explained in Appendix A [20].
The model was tested in a time-step of two weeks for 10 years, and we as-
sumed the transition probabilities to remain constant during the projection period.
Based on the two-weekly transition probabilities and the distribution of patients in
different states at the beginning of each two week time-step, the model estimates
the number of patients in acute and in chronic states of tuberculosis, chronic ob-
structive pulmonary disease, and asthma, and time spent in these states within each
two week time-step, by taking the average of the number of patients in different
states at the beginning and at the end of each time-step multiplied by two weeks.
This corresponds to the assumption of a uniform distribution of incidents within
a two week interval. Total time spent in various states weighted by health-related
quality of life weights for each state are used to estimate the quality adjusted life
years (QALYs) (explained below), which are then used in the calculation of cost-
effectiveness analysis as a measurement of effect.
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7.2.3 Utilities and QALYs
Utilities were calculated on the basis of the trial data. In the absence of disease
diagnosis, utilities were not estimated in accordance with disease category but dif-
ferentiated by acute and chronic state as an average across all patients. A baseline
utility was estimated by taking the mean of the utility scores across all patients
at the time of their first visit to a health care facility (n = 1167). Therefore, the
baseline utility score represents the utility score of patients shortly after entering
the acute state. Of the total number of patients (n = 1167), only those without a
chronic cough (n = 658) were followed-up after two weeks (see Section 7.2.1) and
the average change in utility within two weeks was estimated. Assuming that the
utility of a patient changes uniformly during the two week period of undergoing
treatment in an acute state, we estimated the average state utility of patients in the
acute state as the sum of all patients’ baseline utility and half the difference for
change in the utility during the first two weeks. This method is equivalent to es-
timating the state utility by taking an average of the utility at the time of entering
the state and at the time of exiting it. When we planned the data collection, two
weeks was considered representative of the average duration of all diseases under
study (ranging from seven days for pneumonia to 28 days for tuberculosis, see Ta-
ble 7.1). Since patients with a chronic cough were followed-up only two months
later, we do not have information on the utility score of these patients two weeks
after their first visit to the health care facility. We assumed that the average change
in utility within two weeks for patients with a chronic cough was the same as that
for patients without a chronic cough: for example, if the average utility of patients
without a chronic cough is 0.60 at the time of their first visit to a health care facility,
and if the average change in utility within two weeks is 0.20, then the final average
utility at the end of two weeks is 0.80. And if average utility of patients with a
chronic cough is 0.50 at the time of their first visit, and assuming that the average
change in utility is the same among both groups of patients, the final average utility
will be 0.70. The utility scores for the chronic state were assumed to be equal to
the average utility obtained from patients with a chronic cough two months later.
The two sets of utilities for the acute and chronic states were estimated for both
PAL and STS groups of patients. The utility score in a state without any of the four
diseases (S in Figure 7.1) was assumed to equal 1. Apart from the different sets of
utility scores for patients by type of facility visited, all the transition probabilities
were assumed to be same, due to the unavailability of the data.
With the output from the model, quality adjusted life years (QALYs) were cal-
culated by multiplying the total time spent in various states with the corresponding
utility scores. The difference in QALYs between the STS and PAL scenarios is
considered being the population’s health gain following the implementation of the
PAL guidelines.
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7.2.4 Costs
Costs were analyzed from the societal perspective and include patient-level costs
and program-level costs. Patient-level costs include the costs of facilities, person-
nel, equipment, materials, drugs, and laboratory investigations, and were based on
trial data [21]. Program-level costs include costs of meetings, training, logistics,
etc., and were calculated for the implementation of PAL in all first-level health care
facilities in Nepal, assuming an initial training of all health care providers took
place before the implementation of PAL and that a refresher training was offered
after five years. In addition, the operating costs of implementing PAL with the
assistance of a central- and district-level contact responsible for supervising the ap-
propriate implementation during the clinical trial was included in the program costs.
Data on these costs were gathered from the trial and extrapolated to the country as
a whole. All costs were discounted at 3%. Because of measurement problems, pro-
ductivity costs were not included. All costs are reported in the exchange rate from
January 1, 2003 with US$1 equivalent to NPR 73.15.
The total costs of the STS scenario were calculated by multiplying average
patient-level costs per episode and total number of incidences of acute episodes
obtained from the model. The same procedure was followed to estimate the costs
in the PAL scenario, but in addition, total program costs were added. The total
incremental cost is the cost difference between the PAL and STS scenarios.
7.2.5 Cost-Effectiveness Analysis
The Incremental Cost Effectiveness Ratio (ICER) was calculated by dividing the
difference in cost between the PAL and STS scenarios by their difference in the
population’s health. To deal with the uncertainty related to the costs and utilities
derived from the trial, patient-level data was bootstrapped 5000 times. To measure
the impact of choosing different time-steps, we ran the model with a time-step of
one, three, and four weeks.
7.3 Results
Patients treated in accordance with the PAL guidelines experience higher utility
weights in acute and chronic states than patients treated with the current STS (Ta-
ble 7.2). The utility weight of being in an acute state is slightly higher for patients
receiving treatment at PAL facilities than for those visiting STS facilities. We do
not have any means of knowing whether there is a difference in average recovery
time or rather, the average duration in an acute state between the PAL and STS
scenarios. Hence, our assumption is that, irrespective of facility type, patients will
spend the same amount of time in the acute state. The only difference there might
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be is in the health-related quality of life reflected by the difference in state utility.
The same is true for the chronic state; we do not know whether patients treated at
PAL facilities will have lower rates of exacerbation or remissions, and therefore,
we assumed that the outcome of the PAL and STS scenario is identical, except that
the health-related quality of life might differ. The model’s output indicates that in-
dividuals spent an average of 0.29% of their total lifetime in an acute state of lung
disease, and 4.26% in a chronic state of lung disease. Based on these estimates, the
total QALYs lived by the population is higher in the PAL scenario than in the STS
scenario.
Patient-level costs per lung disease episode were lower in PAL than in STS
(Table 7.2). Program costs did not apply to STS, and in PAL were largely related
to operating costs for supervision and coordination during the 10 year period. In
total, treatment of a lung disease episode costs US$6.40 in keeping to the PAL
guidelines, and US$5.74 on the basis of STS, including both patient costs (health-
related and non-health related) and program-level costs. Excluding non-health re-
lated costs, the treatment of lung disease is US$4.40 following the PAL guidelines,
and US$3.54 applying the STS. The total costs of implementing PAL in all govern-
mental first-level health care facilities would equal almost US$7 million, of which
the bulk would be spent on program costs. Compared to STS, implementing PAL
in all first-level government health care facilities in Nepal would cost US$111 per
QALY gained. Results for the implementation in all first-level governmental health
care facilities are presented in a cost-effectiveness plane [22] to illustrate the uncer-
tainty in the estimate of costs and effectiveness (Figure 7.2).
A cost-effectiveness acceptability curve [23] shows the probability of PAL be-
ing cost-effective, taking the study’s uncertainty and the maximum willingness to
pay for a QALY (threshold) into account. With a threshold of US$150 per QALY
gained [24], PAL has a 54% probability of being cost-effective. The maximum
probability of PAL’s cost-effectiveness is 69%, given the probability of occurrence
of negative health effects. Sensitivity analysis by changing the model’s time-step
to one, three, and four weeks resulted in no change in the ICER value.
7.4 Discussion
Implementing PAL in all governmental first-level health facilities is a relatively
cost-effective intervention, with a cost per QALY gained of around US$111. In
comparison, benchmarks that have been suggested for assessments of whether or
not a health sector intervention is cost-effective include a cost per DALY averted
or life year gained of per capita income [25] (Nepal having a per capita income of
around US$230 per year) [26], twice per capita income (US$460) [27], three times
per capita income (US$690) [28], and US$150 [24]. The cost per QALY gained
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Table 7.2. Results on Costs (US$), utilities, and cost-effectiveness
Health Outcomes STS PAL
Health state utility (EQ-5D utility scores)
Acute State: Baseline utility, mean (SD)†,i 0.49 (0.36) 0.49(0.36)
Acute State: Change in utility at follow-up, mean (SD)†,ii 0.27 (0.35) 0.31 (0.38)
Acute State: Utility at follow-up, mean†,iii 0.63 0.65
Chronic State: Utility, mean (SD)†,iv 0.71 (0.36) 0.73 (0.35)
Total time spent without lung disease over 10 years
(’000 years) 37,415 37,415
Total time spent in acute state over 10 years (’000 years)v 114 114
Total time spent in chronic state over 10 years (’000 years)vi 1,672 1,672
Total number of new/recurrent episodes over 10 years
(’000)vii 3,723 3,723
Total QALYS lived during 10 years (’000) 38,746 38,774
Cost
Non-health care costs per episode: food, travel and lodging,
mean (SD)† 2.20 (0.31) 2.00 (0.22)
Health care costs per episode 3.54 3.36
Health care costs: drugs, registrations and laboratory,
mean (SD)† 1.01 (1.09) 0.83 (1.00)
Health care costs: salary, rent, equipment, etc.† 2.53 2.53
Total program level costs – 5,960,022
Adaptation costs 8,985
Training and refresher training 1,875,075
Operating costs (national-, district-level supervision,
contact person) 4,075,962
Program-level costs per episode – 1.04
Cost-effectiveness results
Including non-health care costs
Difference in costs 2,459,181
Difference in QALYs 28,749
Incremental cost-effectiveness ratio 86
Excluding non-health care costs
Difference in costs 3,203,830.19
Difference in QALYs 28,749
Incremental cost-effectiveness ratio 11
†based on trial data;
i based on the baseline utility of all patients included in the analysis;
iifollow-up done after two weeks assumed to have endpoint utility of the acute episode;
iii(baseline utility score) + (change in utility)/2, assuming that change is gradual during the episode;
ivmeasured at two months after treatment, and assumed to be the utility weight during the
chronic/stable state of lung disease;
vpneumonia (27%), tuberculosis (6%), chronic obstructive pulmonary disease (14%), and asthma
(53%);
vituberculosis (10%), chronic obstructive pulmonary disease (15%), and asthma (75%);
viipneumonia (30%), tuberculosis (3%), chronic obstructive pulmonary disease (22%), asthma
(45%).
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Figure 7.2. Cost-effectiveness plane with 5000 bootstrap samples of the difference
in costs and QALYs generated between the PAL-scenario and the STS scenario
is less than most of these benchmarks, indicating that the PAL scenario is a cost-
effective intervention. However, considering the presence of uncertainties in the
study, this can only be said with a probability of around 54%. The variation in cost
and effectiveness shown in Figure 7.2 could have occurred due to the variation in
age, sex, marital status, or severity of the disease. These similar factors along with
the distance between a patient’s home and the healthcare center, which is directly
related to non-health care costs (travel, food and lodging), might have contributed
to the variation in the costs. Further, knowledge of the disease specific utility score
for acute and chronic states would have reduced the variation in both health effects
and costs. It was not possible in this study to diagnose the patient due to various
constraints. For optimum use of the multi-state model, the disease specific health
effects and costs would have contributed to a more detailed single disease analysis.
The model included the change in utility in acute states and the state utility of
chronic states (an approximate) to estimate the health effects of PAL, and can thus
be considered conservative. Other effects on, for example, case fatality, different
utilities while in the chronic state, incidences, and remissions were not taken into
account due to lack of data. The positive effect of the Integrated Management of
Childhood Illness (IMCI) (see Chapter 1, p. 6), an integrated case management
strategy, has been proven in many settings [29]. Similar expectations can be made
regarding PAL. With a longer follow-up period of PAL patients, more data on the
effect of PAL on mortality, incidences, and remission, and the state utility of the
chronic state (for example, with utility data collected after longer periods of time
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Figure 7.3. Cost-effectiveness acceptability curve based on 5000 bootstrap sam-
ples illustrating the probability of cost per QALY gained being cost-effective at
different values of ceiling ratios
when patients are more stable) would become available, and PAL could appear even
more cost-effective.
The implementation of PAL in all governmental first-level health facilities car-
ries with it high program costs. Program costs per episode would decrease if a
higher proportion of the population were reached. No extra health care facility
costs related to the implementation of PAL were included. In practice, additional
resources such as oxygen cylinders, inhalers, extra medicine, additional time, and
paper work may increase the cost per episode in the PAL scenario compared to the
STS scenario.
PAL guidelines target four lung diseases that are unique in their epidemiology,
with a single algorithmic approach through a training of health care providers at
first-level health care facilities in rural communities. Our model was specifically
developed keeping in mind the nature of these guidelines. Though many disease-
specific models exist for the diseases modeled here, a single model combining these
four diseases does not exist, i.e. we were the first to develop one for the purpose
of the economic evaluation of the PAL guidelines. This is a unique model for the
purpose stated. Depending on specific diseases, more states can be added to detect
transitions in disease sub-states resulting in better and more precise outcomes.
In conclusion, the implementation of PAL increases intervention costs com-
pared to the current care received for US$1.04 per episode. Patients, on the other
hand, benefit with regard to the reduction of their out-of-pocket expenses on direct
medical costs (by 18%) and on non-medical costs (by 9%). The health benefit,
on the other hand, is not substantive as demonstrated by the minor difference in
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utility’s average difference at the beginning and end of the observation period be-
tween patients receiving treatment under the PAL guidelines and those visiting STS.
In general, the study reveals that the probability of a PAL intervention to be suc-
cessful measured by its cost-effectiveness compared to the STS lies just over 50%.
Further evidence on the impact of PAL on incidences and duration of exacerbations
of lung diseases could render the intervention more cost-effective.
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Appendix A
For a specific population, let S(t), XP (t), XTB(t), XC(t), XA(t), CT (t), CC(t)
and CA(t) be the number of people in the state Susceptible and in the respective
states (P - Pneumonia, TB - Tuberculosis, C - Chronic obstructive pulmonary dis-
ease, and A - asthma) at time t, which is the sum N(t), the total population.
Let pri(t) represent the prevalence of respective diseases (i equal to P, TB, C,
and A) in the population at time t.
Then,
XP (t) = N(t) · prP (t) (7.1)
Xi(t) + Ci(t) = N(t) · pri(t); for i in {TB, C and A} (7.2)
S(t) = N(t) · (1 − sum(pri(t)); for i in {P, TB, C and A} (7.3)
Let, vi(t) be the proportion of a population with disease i in an acute state at
time t.
Then,
Xi(t) = N(t) · pri(t) · (1 − vi(t)) (7.4)
Ci(t) = N(t) · pri(t) · vi(t) (7.5)
Let di be the average duration of disease i in an acute state.
To approximate the value of vi, we go back in time with t − di. Assuming
that the prevalence of disease, pri(·), and the proportion of diseased (with/among
prevalence pri) in chronic states, vi(·), at time t and t− di are equal, the following
equations apply:
Xi(t − di) = N(t − di) · pri · (1 − vi) (7.6)
Ci(t − di) = N(t − di) · Pri · vi (7.7)
S(t − di) = N(t − di) · (1 − sum(pri)); for i in {P, TB, C and A} (7.8)
Assuming that the time spent in an acute state is equal to the average duration
of disease in an acute state at time t, all the patients who were initially in state Xi
at time t − di will either die or remit to state Ci from state Xi.
During time (t − di, t), due to new incidences of disease individuals move to
state Xi from state S and either die or remain in the state Xi at least until the end
of the period, the number of new incidences during (t − di, t) being:
sxi(t − di) = S(t − di) · pisx(t − d
i) (7.9)
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where pisx(t − di) is the probability of new incidences of disease during interval
(t − di, t) for those who are in state S at the beginning of the interval. For a given
incidence rate of new cases of disease (S to Xi), misx(t − di), the probability of
new incidences can be calculated as:
pisx(t − d
i) = [misx(t − d
i) · di]/[1 + misx(t − d
i) · di/2] (7.10)
In addition to new incidences of disease i, prevalent cases in state Ci at time t−
di move to state Xi in time (t−di, t), with incidences of remission or exacerbation,
and either die or remain in state Xi, the number of incidences from a chronic to an
acute state is described by:
cxi(t − di) = C(t − di) · picx(t − d
i) (7.11)
where picx(t−di) is the probability of remission or exacerbation of disease during a
time interval (t−di, t) for those who are in state Ci at the beginning of the interval.
For an incidence rate of remission or exacerbation of disease (C-state to X-state),
micx(t − d
i), the probability of remission or exacerbation can be calculated as:
picx(t − d
i) = [micx(t − d
i) · di]/[1 + micx(t − d
i) · di/2] (7.12)
From equations (7.9) and (7.11), the total number of patients in the X-state at
the end of the interval is defined as:
Xi(t) = [sxi(t − di) + cxi(t − di)] · cf i (7.13)
where cf i is the mortality correction factor. Assuming uniform distribution of
events during the interval, the correction factor is calculated as:
Cf i = [1 − (f i + f b) · di/2]/[1 + (f i + f b) · di/2] (7.14)
where f i is the case-fatality rate (per year) in state Xi due to disease i, and f b is
the background mortality rate (per year) due to disease other than the four diseases
studied here.
Hence, using the above equations, we can derive the proportion of people with
disease i in a chronic state (Ci) as:
vi = [(pri/cf i) · (N(t)/N(t − di)) − (1 − sum(pri(t))) · pisx(t − d
i)]/
[pri · pisx(t − d
i) + (pri/cf i) · (N(t)/N(t − di))] (7.15)
where N(t)/N(t − di) = (1 − f · di/2)/(1 + f · di/2), f is the cause for the
mortality rate.
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Appendix B
Obtaining a P-matrix from rates
Age and sex-specific transition probabilities are collected in a matrix known as a
P-matrix, with the initial state in the column and final state in the row. If transition
probabilities are known, the construction of the P-matrix is straightforward. How-
ever, epidemiological measures are often reported in rates and these rates have to
be transformed into probabilities. Assuming uniform transitions within a cycle, we
used a method suggested by Rogers et al. and Willekens et al. [17, 18] to obtain
a P-matrix from the rates using the formula P = [I + 1/2M]−1[I - 1/2M], where I
is a unit matrix and M represents a matrix – known as M-matrix – constructed of
rates. In our model, the rates depend on age and sex only. The model runs for 10
years, age-sex specific population experiences, the transition according to the age-
sex specific P-matrix in a cycle of 2 weeks, i.e., 26 times a year. After one year, the
population turns one year older and the P-matrix is also replaced accordingly.
Types of health care providers trained in PAL
The health care providers refer to auxiliary health care providers, ANMs, health as-
sistants and medical officers in the facility. Other lower level health care providers
are not PAL-trained.
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Conclusion and Discussion
8.1 Conclusion
In this study we have demonstrated that implementing the PAL guidelines increases
the Nepalese government’s expenditure, owing mainly to training and the supervi-
sion of health care providers. On the other hand, implementing the PAL guidelines
reduces patients’ out-of-pocket costs, mostly due to the lower average cost of drugs
prescribed. The PAL implementation is also found to be effective in improving
patients’ health-related quality of life, especially in non-chronic cough patients.
Finally, a multi-state integrated lung disease model was developed to analyze the
cost-effectiveness of the PAL guidelines compared to the standard practice. The
model outcomes show that the implementation of PAL is found to be cost-effective
given standard benchmarks. Uncertainty analysis shows that the probability of the
PAL program to be effective is only 54%. So, it is difficult to conclude that PAL is
effective. This is discussed in detail below.
The first objective of the evaluation study was to compare the costs of imple-
menting the PAL guidelines in governmental health care facilities with the costs
of maintaining the standard range of medical services. We demonstrated in Chap-
ter 7 that the costs for the government when implementing the PAL guidelines in
terms of program-level costs is about US$6 million (spread over ten years), which
comes to be an average of US$ 1.04 per episode, per patient. At the patient level,
patients visiting PAL facilities pay less per episode in terms of health care costs
(US$ 0.83 vs. US$ 1.01), as well as in terms of non-health care costs (US$ 2.00
vs. US$ 2.20). In Chapter 4, a reduction in patient-level cost in terms of reducing
wastage drug costs (due to the prescription of drugs not needed by the patients) by
NPR 2.46 (US$ 0.033) is found, however, to be statistically insignificant. Hence,
in terms of costs, PAL likely reduces patients’ out-of-pocket expenditures. On the
other hand, it is evident that implementing PAL will incur extra costs for the gov-
ernment. However, this cost can be reduced once PAL is integrated in the basic and
continuous training of health care providers. After PAL is adapted nationally, we
expect the costs of training health care providers on how to treat lung patients using
the standard schedule will cover some or all of the program costs of implementing
the PAL guidelines.
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The second objective of the PAL evaluation study was to compare the outcome
for patients treated at PAL facilities to the outcome of those treated at facilities
using the standard range of medical services. We began with a symptom-specific
outcome analysis in Chapter 2. We determined a higher effectiveness of treatment
at PAL facilities for patients with breathing difficulties and a non-chronic cough.
These patients were suspected to have asthma. Next, in Chapter 4, we demonstrated
an indirect positive health effect on patients through the change in prescription be-
havior of health care providers. Health care providers were more likely to adhere to
the guidelines, as well as increase the rational use of drugs which resulted in lower
antibiotic prescriptions, higher prescriptions of generic drugs, as well as drugs from
the essential drugs list. Similarly, the use of the PAL guidelines led to fewer pre-
scriptions of multiple drugs. These effects, though not all statistically significant,
are expected to lead to better health in patients. Next, the general health effects in
patients were analyzed using a generic health-related quality of life questionnaire.
We have shown that the patients treated at PAL facilities scored higher on the
health-related quality-of-life questionnaire than the patients treated at non-PAL fa-
cilities, albeit only in patients with a chronic cough. Based on a preference-based
utility measure, EuroQOL, the difference in the average utility gained during cer-
tain periods between those patients visiting PAL and those visiting non-PAL facili-
ties was insignificant among patients with a non-chronic cough, whereas the differ-
ence was significant among patients with a chronic cough, with a higher utility gain
being achieved among patients treated at the PAL facilities. In Chapter 6, we pro-
posed a multistate model approach to study the evolution of patients’ health-related
quality of life. This reported similar results. We have used multistate models in the
evaluation since they are expected to be useful for studying the evolution of dis-
eases as defined by different disease states. Multistate models are widely used in
studies on medical prognosis, as well as in studies of model-based economic eval-
uations and medical decision making, as the costs and effectiveness of treatment
can be properly analyzed by observing the changes in disease states over time. The
analysis in Chapter 6 shows that the implementation of PAL affords better health
for patients with a chronic cough, who are mostly likely to have COPD or TB.
Lastly, the third objective of the PAL evaluation study was to determine the
cost-effectiveness of the PAL guidelines strategy compared to other potential in-
vestments in a population’s health, as well as to the existing services being pro-
vided. In Chapter 7, we estimated the cost-effectiveness of the PAL guidelines
strategy as compared to the existing standard treatment schedule. Our results in-
dicate that the PAL guidelines strategy is more likely to be cost-effective com-
pared with the standard treatment schedule among patients other than those with a
chronic cough. Overall, the cost-effectiveness of PAL is not significant for all pa-
tient groups considered, as revealed by the uncertainty analysis which showed that
when the PAL implementation is likely to be (cost-)effective in little more than half
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of the cases. We used an integrated multistate life table model for all four diseases
to carry out the cost-effectiveness analysis of the implementation of PAL compared
to standard practice. Based on the results, we concluded that the implemented PAL
guidelines strategy as a whole is less likely to be cost-effective than assumed. Dur-
ing the follow-up we observed various problems in the implementation of PAL. We
will discuss these in the following section.
8.2 Discussion
Before a new intervention or already existing intervention within a new context
can be fully implemented, a pilot implementation is a necessary and an important
step to study the interaction between the intervention and the local context. The
pilot implementation process consists of various steps, and during each step, the
intervention is continuously modified in an iterative way. We discuss each step of
the pilot implementation of the PAL guidelines in Nepal.
The first step in the implementation process was to establish theoretical validity
of the intervention itself on ethical grounds, as well as on scientific grounds. A
well-documented, well-reviewed report on the process of the development of the
PAL guidelines with state-of-the-art knowledge of science was the basis to launch
the implementation process. The PAL guidelines passed this test as reported in
the various documents of the World Health Organization (WHO) available on its
Web site (http://www.who.int/tb/dots/pal/en/). Based on the initial face value of the
guidelines and discussions at various levels, the Nepal Tuberculosis Center (NTC)
under the Ministry of Health-Nepal (MoH-N), along with technical support from
the WHO, planned to carry out a pilot implementation of the PAL guidelines in
Nepal. The assessment of the process at this level is beyond the scope of this study
and reported by Ten Asbroek et al.
The training of health care providers in the use of the PAL guidelines was car-
ried out by trainers who had previously been trained by experts from the NTC
and the WHO. The training of the trainers and the actual training of the health
care workers by these trainers were the most important steps in the implementation
process. How well the training was conducted and how the trainees received the
knowledge was crucial for the success of the implementation of the PAL strategy.
As far as we can recall, the actual training process was not documented. This could
be important question as much of the success of the training depends on the knowl-
edge gained by the trainers and the trainees. If the training is ineffective, health care
providers will be more likely to adhere to their old ways. During the observation
of patients, we included some questions (observation points) to check whether the
health care providers were following the PAL guidelines but the results are inclu-
sive. Thus, it is highly recommended to place more emphasis on evaluation of the
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training of health care providers. In the case of PAL, we assumed the training to be
a black-box. We continued with the cost-effectiveness analysis on the assumption
that the training was successful.
Two months after the last training session was conducted, we sent out field
assistants (FAs) to each of the 42 health care facilities to collect data from individ-
ual patients with lung disease-related symptoms. We waited for two months before
examining the actual effect of the PAL guidelines, since we believed that the imme-
diate effect of the training would be misleading and wanted to measure the effect
in a real-life setting. An additional expectation was that the trained health care
providers shared their knowledge of PAL with their co-workers. Our analyses is
based on the assumption that patients treated at a PAL facility are not differentiated
based on whether or not the health care was provided by a PAL-trained health care
provider. In sub-health posts the same person who had received training in the use
of the PAL guidelines generally also treated patients. However, in health posts and
primary health care centers, non-PAL trained health care providers were included
in the intervention group as well. In a one case, a PAL-trained health care provider
at a sub-health post was replaced by another health care provider who had no PAL
training. These are the issues related to the real-life design of the experiment and
contributed to the (lower) effectiveness of the implementation of PAL as compared
to an efficacy study.
During the entire period of study, a few providers who had received training in
PAL were briefly monitored by higher level medical personnel with regard to the
implementation of the PAL guidelines. This can be considered a serious omission
on the part of implementation. In the general set-up, a series of regular monitoring
is conducted by supervisors from local, regional, national, and international levels.
PAL was not included in these regular supervisions in spite of the agreement with
the NTC. This is the second issue (the first being the quality of training) that we
observe a possible dilution of training effort and the quality of implementation.
Basically, a single training session was provided and the health care providers were
left to themselves to work for the rest of the period. This is a common practice,
yet we believe that additional supervision and managerial activities would have
contributed considerably to PAL’s effectiveness.
In the evaluation we need to measure effectiveness using valid instruments. As
explained in previous chapters, the remoteness and the lack of resources at the fa-
cilities restricted us using modern medical equipment to measure the health status
of patients. This is also the reason why the PAL intervention is a symptom-based
approach and not diagnosis-based. We could only afford to measure symptoms
whose descriptions could be obtained either from the patients reporting them di-
rectly, or by using inexpensive general medical equipment. The follow-up visits to
patients’ homes took place mostly in remote areas with no, or only partial, public
transport facilities, and it was not possible to bring along expensive equipment to
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these areas. Therefore, we used different questionnaires, as well as observations by
field staff, to measure the health status of patients.
The reliability and validity of the translated questionnaires was not tested in the
specific Nepalese settings. A first challenge was the language, as several languages
are spoken in the area. We prepared two sets of questionnaires, one in Nepali and
the other in Bhojpuri, a dialect spoken by people in the Terai region of Nawal-
parasi. Questionnaires were translated again backwards. They were developed to
make them simple and comprehensible. Still, some respondents had trouble un-
derstanding some of the questions. Many of the questions were used for the first
time in Nepal. In Chapter 3, we presented the results of the validation analysis,
using patient data. Apart from the questionnaire used in this analysis, additional
instruments are available. We recommend that more exploration of such tools is
conducted, and more validation exercises carried out in the future for these and
other instruments, considering that such questionnaires are very effective, cheap,
and easy to administer.
Based on the collected data, we performed an empirical analysis and developed
a PAL multi-state model to study the evolution of four PAL diseases in the Nepalese
population. During our review of existing models for lung diseases, we found
many disease-specific models for single diseases. In most cases, disease states were
defined based on measurements of health status assessed mostly in well-equipped
and well-manned environments. This was not possible for the new models. Because
these models are disease-specific, all disease models have different definitions. We
used generic measures of health status so the model could be used to study all PAL
diseases at the same time. This generic measure facilitates comparisons with other
diseases as well.
Based on a review of existing multi-state models for lung health, we proposed
a new multistate model in Chapter 6 for the modeling of generic health-related
quality of life data. We did not find any multistate model using the HRQOL and,
hence, this is the first effort to do so. Our model can be further developed to study
the evolution of HRQOL in other disease processes and in other national settings.
Finally, we used the PAL model along with our empirical analysis to estimate
the cost-effectiveness of PAL compared to the standard range of treatment. We did
not find PAL to be particularly cost-effective. Based on the field experience during
the pilot phase, we listed several reasons. We would like to emphasize that when
studying cost-effectiveness analysis in developing countries, one must seriously
plan the implementation of the intervention. Lack of dedication and capacity of
both national and international implementers profoundly affects the process.
In conclusion, the future implementation of the PAL strategy in the primary
health care facilities should consider the strengths and weaknesses at various levels
of implementation as reported here in this book, to achieve better results in terms
of better health returns given the budgets spent. We found that some patients at
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the individual level with specific respiratory symptoms who visited PAL facilities
are enjoying improved health, as well as a reduction in their out-of-pocket costs.
However, the overall cost-effectiveness of the PAL program is doubtful, possibly
due to either lack of real effect in the acute phase or to the small sample size of
disease sub-groups. Because of the partial positive results and the existing possi-
bilities to improve further implementation the next PAL phase should be flexible
and conditional to more evaluation and monitoring.
Longaandoeningen in ruraal Nepal
Modellering van gezondheidstatus en de economische eval-
uatie van richtlijnen voor een geı¨ntegreerde benadering van
longaandoeningen
Mensen lopen verschillende gezondheidsrisico’s. Ziekten kunnen worden voor-
komen, verzacht of genezen. In arme landen lijden mensen aan ziekten die in rijke
landen goed te voorkomen zijn. Kennisoverdracht van rijke naar arme landen en
investeringen in de gezondheidszorg kunnen bijdragen aan de vermindering van de
gezondheidsverschillen in de wereld. Om hierbij succesvol te zijn dienen interven-
ties te zijn aangepast aan lokale omstandigheden en vooraf te worden onderworpen
aan een kosten-baten analyse. Hierbij worden gezondheidseffecten gerelateerd aan
de kosten van de interventie.
Dit boek presenteert de resultaten van een kosteneffectiviteitsanalyse van een
door de Wereldgezondheidsorganisatie (WHO) ontwikkelde geı¨ntegreerde aanpak
van longaandoeningen, de zogenaamde Practical Approach to Lung Health (PAL).
De WHO-PAL aanpak werd toegepast in ruraal Nepal waar verschillende lon-
gaandoeningen zoals longontsteking, tuberculose (TBC), chronische obstructieve
longziekten (COPD) en asthma veel voorkomende kwalen zijn. Veelal ontbreken
er goed uitgeruste gezondheidsvoorzieningen en goed opgeleid personeel. De PAL
aanpak voor de eerstelijnsgezondheidszorg is ontwikkeld voor gezondheidswerkers
met een beperkte opleiding. In 22 willekeurig gekozen centra voor basisgezond-
heidszorg in een ruraal district (uit een totaal van 42 centra) werd ten minste e´e´n
gezondheidswerker opgeleid volgens het PAL richtlijnenprogramma. In hetzelfde
district werden de 20 andere centra als controle centra meegenomen. In een ver-
volgonderzoek werden de gegevens gedurende een periode van een jaar verzameld
van alle patie¨nten die deze 42 gezondheidscentra bezochten en die symptomen van
longziekten vertoonden i.c. koorts, hoesten en ademhalingsproblemen. In dit boek
worden de resultaten van de PAL benadering vergeleken met die van al bestaande
gezondheidszorg in de controle centra, in termen van kosten, gezondheidseffecten
en kosteneffectiviteit.
Het onderzoek laat zien dat introductie van PAL tot hogere kosten leidt, als
gevolg van de kosten van scholing en supervisie van gezondheidswerkers. Per
ziekte-episode nemen de kosten toe met US $1.04. Deze additionele kosten moeten
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worden gedragen door de overheid of de internationale gemeenschap. Indien een-
maal PAL op brede schaal is geı¨ntroduceerd en geı¨ntegreerd in de basis- en vervol-
gopleidingen van gezondheidswerkers, zullen deze extra kosten aanzienlijk dalen.
Voor patie¨nten vermindert PAL de zelfgemaakte kosten, vooral als gevolg van
de lagere kosten van medicijnen. De WHO-PAL aanpak bevordert rationeel gebruik
van medicijnen: vermindering van overbodig gebruik van medicijnen en antibiot-
ica, en toename van recepten voor generieke medicijnen en andere medicijnen van
de lijst van essentie¨le geneesmiddelen. Patie¨nten die gezondheidscentra bezoeken
waar de PAL aanpak wordt gevolgd, geven per ziekte-episode gemiddeld minder uit
aan gezondheidszorg (US$ 0.83 versus US$ 1.01) en overige indirecte kosten (US$
2.00 versus US$ 2.20). Dit is een belangrijk resultaat omdat de meeste patie¨nten die
gezondheidscentra bezoeken arm zijn en iedere substantiele besparing van uitgaven
een verschil maakt.
Patie¨nten met niet-chronische ademhalingsmoeilijkheden (met een duur van
minder dan twee weken) hebben baat bij PAL. De betere gezondheidseffecten van
een bezoek aan een PAL voorziening vergeleken met een bezoek aan een ander
centrum zijn het resultaat van een beter voorschrijfgedrag van gezondheidswerk-
ers, geringere kosten en een hogere effectiviteit van de behandeling. Deze effecten
zijn echter niet allemaal statistisch significant.
Bij een effectmeting is van belang hoe het resultaat wordt gemeten. In ruraal
Nepal kunnen de effecten van PAL interventies niet worden uitgedrukt in standaard
ziekte-specifieke uitkomsten omdat meting van de gezondheidstoestand van een
longpatie¨nt medische apparatuur vereist die in afgelegen gebieden niet beschikbaar
is. De WHO-PAL aanpak is daarom gebaseerd op symptomen en niet op diagnose.
In het onderzoek werden verschillende vragenlijsten gebruikt om de gezondheid-
stoestand van de patie¨nt te bepalen. De algemene gezondheidstoestand werd vast-
gesteld met generieke maten van kwaliteit van leven de zg. Quality-of-Life score
(QoL) die aan de specifieke context waren aangepast. Ons onderzoek toont aan
dat patie¨nten met chronische hoest die behandeld werden in gezondheidscentra die
werken volgens de WHO-PAL methode een betere QoL score hadden dan patie¨nten
die in andere centra waren behandeld.
Voor de studie van effecten van interventies is het van belang het ziektepatroon
te volgen in de tijd en men kan de veranderingen beschrijven aan de hand van een
ziektemodel voor longziekten. Voor het onderzoek werden twee rekenmodellen on-
twikkeld die voor een specifiek longaandoening een aantal toestanden onderschei-
den en het verloop van de aandoening beschrijven in termen van transities tussen
toestanden (multi-state modellen). Het eerste multi-state model is een generiek
model van kwaliteit-van-leven (QoL). Het tweede model geeft een geı¨ntegreerde
beschrijving van de vier longaandoeningen. Dit laatste model werd ontwikkeld
op basis van een uitgebreid literatuuronderzoek. Hierbij werd een groot aantal
modellen van longaandoeningen werden bestudeerd om een verantwoorde keuze te
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kunnen maken van de te onderscheiden toestanden en van de tijdseenheid voor de
beschrijving van het ziekteproces.
Het eerste multi-state model beschrijft de gemeten veranderingen bij patie¨nten
in het vervolgonderzoek in termen van generieke, gezondheidsgerelateerde
kwaliteit-van-leven (QoL). De gezondheidsmaten zijn gemeten met behulp van de
zogenaamde EuroQoL schaal. Dit model is te gebruiken wanneer een diagnose
onbekend is en men alleen de symptomen kan vaststellen en de verandering hierin
door behandeling. Dit model is ook te gebruiken wanneer de symptomen worden
veroorzaakt door verschillende aandoeningen zoals in het PAL onderzoek. Mod-
elberekeningen tonen aan dat de gezondheidsgerelateerde QoL van patie¨nten met
niet-chronische hoest meer verbeterde bij bezoek aan gezondheidscentra waar de
PAL methode werd gevolgd dan aan een bezoek aan de controle centra. Dit resul-
taat komt overeen met de andere empirische bevindingen.
Het tweede model is ontwikkeld om de kosteneffectiviteit van de PAL richtlij-
nen te bepalen ten opzichte van de standaard praktijk. Bij de longpatie¨nten zijn hi-
erbij de drie gezondheidstoestanden onderscheiden: gezond, ziek met acute symp-
tomen, en ziek met chronische symptomen. Aan de hand van het model werd
de verblijfsduur in iedere toestand geraamd en die verblijfsduur werd gewogen
voor de ernst van de gezondheidstoestand. Tevens werden de kosten uitgerekend
naar gezondheidstoestand in de acute en vervolg-fase. De modelberekeningen en
de diverse economische uitkomstenmaten tonen aan dat de PAL aanpak kostenef-
fectief kan zijn. De onzekerheidsanalyse toont dat de kans dat WHO-PAL effec-
tief niet hoger is dan 54 procent wanneer men alle patie¨ntengroepen gezamenlijk
beschouwt. De conclusie dat PAL kosteneffectief is, kan daarom niet zonder meer
worden getrokken omdat de kans op succes in de hele groep te gering is.
Op basis van de resultaten van dit onderzoek kan men de WHO-PAL benader-
ing het voordeel van de twijfel geven. De resultaten zijn gedeeltelijk positief. De
verdere uitbouw van het programma is reeds begonnen. De huidige studie geeft
verschillende opties om de aanpak verder verbeteren.
K.C. Samir
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